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Group B Streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis in 
developed countries. In the majority of cases, GBS is vertically transmitted from the mother 
during or preceding birth. Candida albicans is an opportunistic fungal pathogen of the female 
GU tract, causing vaginal thrush, for which pregnancy is a risk factor. As C. albicans is known to 
synergistically interact with Streptococcus bacteria within the oral cavity, it was hypothesised 
that C. albicans and GBS may interact within the vaginal tract. Using a vaginal epithelial cell 
association assay, it was shown that C. albicans significantly promoted GBS association with 
vaginal epithelial cells (VECs) and, likewise, GBS significantly promoted C. albicans. The AgI/II 
family surface-expressed adhesins of GBS, designated Bsp proteins, were found to contribute 
to GBS interactions with VECs and with C. albicans, while the C. albicans cell surface protein 
Als3 was pivotal for the coassociation between these species. Investigations into the VEC 
response to GBS and C. albicans implied that coassociation may reduce neutrophil chemotaxis, 
despite enhanced transcription of proinflammatory cytokine genes. Proteomics studies 
revealed that extracellular matrix (ECM) components, or proteins that modulate ECM 
components, were significantly elevated in dual-species-infected VECs, while apoptosis-
related proteins and proteins involved in MAPK signalling were largely downregulated. Taken 
together, these data suggest that GBS and C. albicans synergistically interact in a manner that 
could promote GU tract colonisation and persistence, and that this coassociation is dependent 
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Chapter 1 Introduction 
1.1 Vaginal epithelium overview 
The vagina is made up of non-keratinised squamous epithelium and can be split into a 
number of sections. Above the basement membrane is the basal layer, followed by the 
parabasal layer, then the intermediate cells (stratum spinosum), with the superficial 
layer exposed at the surface (Figure 1-1). The superficial layer of cells is continuously 
exfoliated and replaced by cells from the basal layer of the epithelium. Basal cells flatten 
and differentiate as they travel through the layers of the vaginal epithelium to the 
superficial layer, with this process directed by hormones. As levels of oestrogen increase 
throughout the menstrual cycle, the volume of vaginal secretions increases, alongside 
the maturation and thickness of the epithelial layer, stimulating accretion of glycogen 
(Nunn and Forney, 2016;Sjoberg et al., 1988).  
 
Figure 1-1 Vaginal epithelium structure.  
Reproduced from (Farage and Maibach, 2006). 
 
The female genitourinary (GU) tract undergoes changes throughout a woman’s lifetime 
due to a number of factors, including hormones. For example, changes occur during the 
monthly menstrual cycle, at the onset of puberty or menopause (Farage and Maibach, 
2006). At the start of the menstrual cycle, vaginal pH is typically higher than when in the 




middle of the menstrual cycle (pH 6.6 on day 2 vs. pH 4.2 on day 14) (Wagner and 
Ottesen, 1982). Mid-cycle is also when the vaginal mucosa is at its thickest, with the 
highest level of intracellular glycogen (Farage and Maibach, 2006). Changes in the 
vaginal mucosa during menstruation are due to changes in hormone cycling, and this 
response is due to the oestrogen level gradually increasing up to mid-cycle. Decreasing 
oestrogen from this point influences exfoliation of the surface cells and thinning of the 
epithelium (Farage and Maibach, 2006). Levels of oestrogen are low (<50 pg/mL) during 
menstruation, achieving a first peak during ovulation (200-250 pg/mL) before decreasing 
and then building to a second, lesser peak around day 21 (150 pg/mL) (Gajer et al., 
2012). These changes in oestrogen levels correlate with glycogen content within the 
vaginal tissues (Sjoberg et al., 1988). 
The vaginal mucosal layer also provides receptors for microbial attachment. Vaginal 
epithelial cell (VEC) surface-expressed receptors facilitate microbial adhesion. For 
example, mannose receptor has been shown to enable binding of HIV protein gp120 
(Fanibunda et al., 2011). Extracellular matrix (ECM) components, such as collagen, 
fibronectin and laminin are further adhesion targets for GU tract microorganisms, 
including Trichomonas vaginalis, Chlamydia trachomatis, Lactobacillus crispatus, 
Lactobacillus brevis, Candida albicans and Group B Streptococcus (GBS) (Singh et al., 
2012;Skerl et al., 1984). Pre-incubation of C. albicans with fibronectin significantly 
reduced C. albicans binding of VECs, intimating a role for fibronectin in adhesion of C. 
albicans (Skerl et al., 1984). Additionally, one study found that all clinical isolates of GBS 
expressed laminin-binding protein Lmb and fibronectin-binding protein ScpB, indicating 
that binding these ECM components may be important for initiation of colonisation (Al 
Safadi et al., 2010). Lactobacillus iners binds to vaginal fibronectin more strongly than 
other species of lactobacilli, and this was suggested to contribute towards persistence of 
the microorganism (McMillan et al., 2013). Vaginal pH plays a role in adhesion of 
microbes, as many lactobacilli lose the ability to adhere to fibronectin as pH approaches 
neutral (Nagy et al., 1992). This may explain dysbiosis resulting from vaginal infections 
such as bacterial vaginosis (BV), during which the vaginal pH rises. Adhesion of 
Gardnerella vaginalis, a causative organism ofBV, is also pH dependent, with optimal pH 
being between 5 and 6 (Peeters and Piot, 1985). 
  




1.2 Genitourinary tract in health and pregnancy 
There are a variety of determinants within the GU tract that can influence its health 
status. These include the constituents of the cervico-vaginal fluid (CVF), along with the 
resident microbiota. These aspects can, in turn, be altered by factors such as age and 
hormone status (Huggins and Preti, 1981). 
 
1.2.1 Cervico-vaginal fluid 
CVF contains transudate fluid and secretions from the Bartholin’s glands (Huggins and 
Preti, 1981). Furthermore, CVF is composed of cervical mucus, endometrial and 
oviductal fluids and exfoliated cells, all of which vary in response to levels of hormones 
(Huggins and Preti, 1981). CVF has a role in the GU tract innate immune response to 
infection. A key role of CVF is to prevent access of microbes to the underlying 
cervicovaginal tissue. This is achieved by regularly discarding the mucus, along with 
sloughing of the superficial epithelial layer (Venkataraman et al., 2005). CVF also 
contains antimicrobials such as lysozyme and complement, alongside having a low pH 
and the presence of lactic acids (Valore et al., 2002;Cohen et al., 1984;Zegels et al., 
2009). A number of cationic antimicrobial peptides have been isolated from CVF, 
including human beta-defensin 2 and cathelicidin. In total, 18 proteins have been 
isolated from CVF and identified as host defence proteins (Venkataraman et al., 2005). 
One study found that CVF collected from a small sample of donors allowed growth of C. 
albicans, but not GBS, in 3 of the 5 donors (Valore et al., 2002). 
 
1.2.2 Resident microbiota 
There are an estimated 108 bacteria for every gram of CVF (Delaney and Onderdonk, 
2001). The resident microbiota can afford protection through colonisation resistance 
against incoming microbes. The dominant commensal microbes of the healthy vagina 
are Lactobacillus species, four of which predominate: L. iners, L. crispatus, L. jensenii, L. 
gasseri (Zhou et al., 2007;Ravel et al., 2011). Lactobacilli have been reported to use the 
glycogen harvested from routine sloughing of epithelial cells to generate lactic acid and 
maintain vaginal pH at 3.5-4.5. This serves to reduce the likelihood of colonisation by 




pathogenic microorganisms (Nasioudis et al., 2015;Mirmonsef et al., 2014;Boris and 
Barbes, 2000). However, a more recent study found that the lactobacilli that most 
routinely colonise vaginal surfaces are unable to metabolise glycogen. Instead, these 
species metabolise the breakdown products of α-amylase digestion of glycogen (Nunn 
and Forney, 2016). Although vaginal tract α-amylase was previously assumed to be 
secreted by the host, it has been implied to be derived, in part, from other vaginal 
microbes (Nunn and Forney, 2016). 
Oestrogen controls the rate of epithelial sloughing and hence the levels of free glycogen. 
As such, the vaginal microbiome is subject to change depending on ageing, the phase of 
the menstrual cycle or pregnancy (Farage and Maibach, 2006;Owen, 1975). There are 
reports of increasing Lactobacillus and decreasing non-Lactobacillus species as the 
menstrual cycle progresses, with highest levels of non-Lactobacillus species during 
menstruation (Eschenbach et al., 2000). This may be due to the microbial composition of 
the vaginal tract being most stable at peak oestrogen levels (Gajer et al., 2012). 
Alongside acidification of the GU tract, lactobacilli can outcompete pathogenic 
microorganisms for host targets such as epithelial cells, and can release antimicrobial 
peptides (bacteriocins) (Cohen et al., 1984;Boris and Barbes, 2000). Another compound 
released by lactobacilli is hydrogen peroxide, which can induce oxidative stress in 
pathogenic bacteria (Tramer, 1966;Reid and Burton, 2002). Similar antimicrobial 
mechanisms have been described for lactobacilli in the gastrointestinal (GI) tract (Servin, 
2004), which is important as the GI tract can act as a reservoir of microbes for GU tract 
colonisation. After lactobacilli, other frequent colonisers of the vaginal tract include 
Peptococcus species, Bacteroides species, Staphylococcus epidermidis, Corynebacterium 
species, Peptostreptococcus species, and Eubacterium species (Bartlett et al., 1977). Due 
to the continuity of the vaginal and cervical tracts, the cervical microbiome is largely 
homogenous to the vaginal microbiota (Smith et al., 2014;Huang et al., 2015). 
 
1.2.3 Effects of pregnancy on the GU tract 
During pregnancy, the mother undergoes a number of hormonal and metabolic changes 
to sustain the development of the foetus. In terms of metabolic changes, ghrelin, the 
‘hunger hormone’, has receptors which are located in the placenta and reproductive 




organs. Ghrelin levels increase up to the middle of a pregnancy, causing increased 
weight gain, high levels of fasting blood glucose and resistance to insulin (Fuglsang, 
2008). These symptoms are also impacted by the maternal GI microbiome. A distinct 
difference has been found in GI microbes in each of the three trimesters, and this has 
been shown to affect the metabolism of the mother. Microbes from the stool of women 
in the third trimester conferred increased levels of fat, insulin resistance and 
inflammatory response in mice (Koren et al., 2012). 
In terms of hormonal changes, high progesterone concentrations early in pregnancy 
favour secretion of Th2 rather than Th1 cytokines, and this is thought to be anti-
inflammatory in order to maintain pregnancy (Kumar and Magon, 2012). There is also a 
steep rise in oestrogen concentrations, due in part to additional oestrogen secretion 
from the placenta (Nunn and Forney, 2016). High concentrations of oestrogen during 
pregnancy increase the levels of glycogen within the GU tract. As mentioned, glycogen 
harvested from exfoliated epithelial cells is used as a carbon source by vaginal microbes, 
and thus is hypothesised to support establishment of a C. albicans infection (Ma et al., 
2012;Tarry et al., 2005;Dennerstein and Ellis, 2001).  
The vaginal microbiota is considered stable during pregnancy due to consistent levels of 
hormones, with a reduction in overall microbial diversity. Pregnant women have a 
higher quantity of vaginal lactobacilli when compared to non-pregnant women, which 
largely consists of L. crispatus and L. iners, with a corresponding decrease in carriage of 
bacteria associated with BV (MacIntyre et al., 2015;Romero et al., 2014;Walther-Antonio 
et al., 2014). Factors contributing to this besides hormones are the reduced vaginal pH 
during pregnancy and the increase in vaginal secretions (Prince et al., 2014). As 
oestrogen levels drop after birth, levels of lactobacilli begin to decrease, underlining an 
important role for oestrogen in control of the vaginal microbiota (Romero et al., 
2014;MacIntyre et al., 2015). Indeed, there is an increase in endometritis in postpartum 
women, correlating with a rise in BV-causing microorganisms, including G. vaginalis, 
Bacteroides spp. and GBS (Watts et al., 1989). 
 




1.3 Group B Streptococcus 
1.3.1 Genus Streptococcus 
The first evidence of streptococci came from the 1683 drawings by van Leeuwenhoek of 
magnified matter scraped from his teeth. In 1879, Louis Pasteur isolated and identified 
streptococci from women suffering from puerperal fever, a postpartum condition which 
was often fatal. When the isolated streptococci were proven to cause the disease, they 
became the first identified infectious agent. The bacteria were named from the Greek 
‘strepto’ meaning twisted chain; and ‘coccus’, due to the resemblance of their spherical 
appearance to berries. Streptococci are Gram positive (Figure 1-2) and facultatively 
anaerobic (Nobbs et al., 2009). 
 
Figure 1-2 Gram stain of GBS strain NEM316. 
 
Streptococci were traditionally classified, and in some cases named, due to Lancefield 
typing, whereby the composition of the streptococcal cell wall is used to categorise 
strains (Lancefield, 1933). In the case of groups A, B, C, E and G, this is based on 
polysaccharides, while for groups D and N this is based on teichoic acids, and group H is 
typed based on lipoteichoic acids (Rosan, 1973). Although this categorisation is effective 
for human pathogenic streptococci, the group antigens are in some species absent or 




shared by multiple taxa (Nobbs et al., 2009). Alongside Lancefield typing, streptococci 
were also traditionally divided into groups based on their capacity to lyse red blood 
cells, known as haemolysis. Three categories were described: α, β or γ (Xu et al., 2014a). 
Streptococci are classed as α-haemolytic if an aura of green is formed when the bacteria 
are grown on blood agar. This arises due to oxidation of haemoglobin by hydrogen 
peroxide produced by the streptococci. This green colouration also reflects why some 
oral-colonising streptococci are referred to as ‘viridans’ streptococci (i.e. ‘viridis’ = Latin 
for ‘green’). The pyogenic streptococci induce β-haemolysis on blood agar, which is 
characterised by a complete lysis of red blood cells and appears as a halo of yellow 
around bacterial colonies (Nobbs et al., 2009). The term γ-haemolysis is a bit of a 
misnomer as this is the category into which streptococci that are non-haemolytic are 
placed. 
An alternative, and more recent, method of classifying streptococcal species is based on 
the 16S rRNA gene sequence. This divides streptococcal species into six groups (Figure 
1-3). The pyogenic group includes known human and animal pathogens S. pyogenes, S. 
agalactiae, S. uberis and S. dysgalactiae. There is a wide range of diseases caused by 
pyogenic streptococci, including tonsillitis, toxic shock syndrome, necrotising fasciitis, 
neonatal sepsis and bovine mastitis (Edmond et al., 2012;Royster and Wagner, 
2015;Cunningham, 2000). The mitis group of streptococci is made up almost exclusively 
of species which colonise the oral and nasopharyngeal cavities, and many of these 
species have been implicated in infective endocarditis, which is an inflammation in the 
lining of the heart (Barrau et al., 2004). Bovis group streptococci have been isolated 
from cases of meningitis and endocarditis (Amado et al., 2015;van Samkar et al., 2015), 
while mutans group streptococci are oral cavity colonisers and are aetiological agents of 
tooth decay (Kutsch, 2014). Anginosus and salivarius group streptococci are typically oral 
colonisers of humans and other animals (Nobbs et al., 2009). 
 





Figure 1-3 Streptococcus taxonomic relationships.  
Classification of selected streptococcal species depending on 16S rRNA gene sequence. Taken from (Nobbs 
et al., 2009). 
 
1.3.2 GBS overview 
Streptococcus agalactiae is a group B, β-haemolytic Streptococcus; hence its alternate 
designation as Group B Streptococcus (GBS). GBS was first identified in 1887 as the 
causative agent of bovine mastitis (Bisharat et al., 2004;Lancefield and Hare, 1935). In 
1935, GBS was isolated from human vaginal swabs and identified as the cause of fatal 
post-partum maternal infections. This was significant because all other serious 
streptococcal infections at that time were assumed to be caused by S. pyogenes (Group 
A Streptococcus, GAS) (Fry, 1938;Lancefield and Hare, 1935). GBS was identified as the 
predominant cause of neonatal infection in the 1960s and remains the foremost cause 
of neonatal sepsis and meningitis in Western countries (Eickhoff et al., 1964;Bisharat et 
al., 2004;Edmond et al., 2012). GBS is also increasingly a causative agent of disease in 
immunocompromised adults, among whom the disease rate is 4.1-7.2/100,000 people 
(Farley, 2001). The median age of GBS disease in non-pregnant adults is 63 years, and 




the rate of disease among this population doubled between 1990 and 2007 (Skoff et al., 
2009). One reason for this may be that cell-mediated immunity typically decreases with 
age, increasing the chance of infection (Edwards and Baker, 2005). Colonisation rates 
among the elderly are approximately 25%, similar to that of pregnant women (Edwards 
and Baker, 2005). 
Alongside human infections, GBS causes disease in animals, particularly cattle and fish. 
Bovine mastitis, an inflammation of the mammary glands in cows, is a significant cause 
of disease affecting cattle. This costs the dairy industry in the US an estimated $2 billion 
annually (Wellenberg et al., 2002). The main causative organisms of bovine mastitis 
include E. coli, Staphylococcus aureus and GBS (Nair et al., 2005). GBS also causes 
disease in cats, dogs, aquatic mammals such as dolphins, crocodiles and even frogs 
(Brochet et al., 2006;Evans et al., 2008;Bishop et al., 2007;Amborski et al., 1983). A 
further area of particular concern is the incidence of GBS disease among fish farmed for 
human consumption, such as Nile tilapia. GBS is responsible for substantial morbidity 
and mortality, often causing meningoencephalitis (Evans et al., 2009;Pereira et al., 
2010). Furthermore, consumption of fish was described by one study as a risk factor for 
human GBS colonisation with capsular serotypes commonly found to infect fish (Foxman 
et al., 2007). 
 
1.3.3 GBS carriage and disease rate 
In healthy adults, GBS has been found in 15-30% of GI or GU tracts, and the main 
reservoir of GBS is the GI tract (Jiang and Wessels, 2014;Le Doare and Heath, 2013;Carey 
et al., 2014). The overall rate of neonatal GBS disease in the UK is 0.5/1000 live births, 
according to the Royal College of Obstetricians and Gynaecologists (Hughes et al., 2012). 
However, the risk of neonatal disease rises to 2.3/1000 live births in the UK where an 
expectant mother has vaginal swabs that test positive for GBS. Furthermore, chance of 
colonisation in a future pregnancy, when the mother has been colonised in a previous 
pregnancy, is 38% (Hughes et al., 2012). There is limited data available on the rate of 
GBS disease in low and middle income countries; however, what data is available 
suggests that the mortality rate of neonatal GBS disease may be up to three times 
higher outside high income countries (Le Doare and Heath, 2013). This is reinforced by 
reports that disease rates may be as high as 3.06/1000 live births in parts of Africa 




(Dagnew et al., 2012). Furthermore, an estimated 6-15% of all births are preterm, with 
the largest burden in Sub-Saharan Africa, leading to the deaths of approximately 4 
million newborns annually. Of these preterm births, between 25-40% are thought to be 
due to bacterial infection, including GBS (Vornhagen et al., 2016). 
Neonatal colonisation is 29 times more likely to occur if the mother is colonised (Boyer 
and Gotoff, 1985), and one study found that neonates had a three times higher chance 
of requiring intensive care if their mother was colonised compared to neonates born to 
un-colonised mothers, regardless of whether the neonates in question were culture-
positive for GBS themselves (Brigtsen et al., 2015). A correlation has also been found 
between maternal anti-GBS antibody titres and infant health. Babies born to colonised 
mothers with anti-GBS antibody titres of more than 2 µg/mL sera more commonly 
suffered no infectious symptoms when compared to babies born to mothers with lower 
levels of antibody (Baker et al., 1981). This underlies the importance of maternal 
immune health, and provides evidence that a GBS vaccine could be effective in 
preventing neonatal disease. 
 
1.3.4 Risk factors for GBS disease and colonisation  
Limited information is available to determine the risk factors of GI tract colonisation; 
however, one study found that risk factors included black race, marijuana use, and an 
age of over 21 years (Meyn et al., 2009). Vaginal colonisation may be affected by a 
number of factors, including local hygiene, sexual practices, ethnicity, tampon or IUD 
use, obesity, or composition of the vaginal microbiota (Le Doare and Heath, 
2013;Colbourn and Gilbert, 2007). Risk factors for vaginal carriage of GBS include a rise 
of vaginal pH above 4.5, experiencing vaginitis symptoms and unusual discharge (Leclair 
et al., 2010;Park et al., 2012). A number of microorganisms are thought to compete with 
GBS for colonisation in the vaginal niche. For example, Bifidobacterium exhibits 
antimicrobial activity against GBS in vitro, and Lactobacillus species can prevent the 
proliferation of GBS and subsequent adhesion to VECs (Ruiz et al., 2012;Zarate and 
Nader-Macias, 2006). Intravaginal challenge of mice with Lactobacillus reuteri prior to 
infection with GBS was found to influence the immune response generated against GBS. 
There was a reduction in influx of neutrophils, but a rise in activated macrophages and B 
cells, and this amounted to a protective effect on the host (De Gregorio et al., 2016). In 




fact, an inverse relationship has been described between the presence of lactobacilli in 
the vaginal tract and the presence of GBS (Ronnqvist et al., 2006;Kubota et al., 2002). 
Streptococcus salivarius given as a probiotic was also shown to impair GBS using a 
mouse model of vaginal colonisation (Patras et al., 2015b). 
  
1.3.5 GBS disease in neonates  
The first signs of GBS infection in neonates include a blue appearance of the skin 
(cyanosis), jaundice, lethargy, fever, respiratory distress and seizure (Dong et al., 2017). 
There are two forms of GBS neonatal disease, classified according to the onset of these 
symptoms. Early onset disease (EOD) is an infection which presents by 6 days old (Baker 
and Barrett, 1974;Weisner et al., 2004;Zaleznik et al., 2000) and this accounts for 60-
70% of all neonatal GBS disease in developed countries (Le Doare and Heath, 2013). EOD 
typically presents as pneumonia or sepsis (Heath et al., 2004). Sepsis results from 
prolonged survival of GBS in the blood and significant cytokine induction (Berner et al., 
2001), while pneumonia results from aspiration of GBS-infected material during birth, 
followed by subsequent invasion and damage of lung tissues (Doran et al., 2002). EOD 
requires the mother to be carrying GBS in the GU tract, leading to vertical transmission 
in utero or during parturition as the predominant mode of transmission (Baker and 
Barrett, 1974;Weisner et al., 2004;Colbourn and Gilbert, 2007). Approximately 20-30% 
of pregnant women carry GBS vaginally in Western countries, with 50% of their children 
becoming colonised, and 1% progressing to invasive disease (Le Doare and Heath, 
2013;Hughes et al., 2012). One study claimed that risk of transmission from the 
maternal GU tract to the neonate was as high as 70% (Bodaszewska-Lubas et al., 2013).  
Late onset disease (LOD) manifests 7-89 days after birth (Hughes et al., 2012;Weisner et 
al., 2004;Harrison et al., 1998). Infants may become infected nosocomially or from 
community sources; however, the mother may still be the primary source of 
transmission (Weisner et al., 2004;Edmond et al., 2012). Meningitis has been observed 
in over 40% of LOD cases (Heath et al., 2004;Weisner et al., 2004), and contributes to 
substantial neurological sequelae. Around half of children surviving GBS meningitis had 
some form of disability such as sight or hearing loss (Bedford et al., 2001;Libster et al., 
2012). Meningitis results from GBS first surviving within the bloodstream and then 
crossing the blood brain barrier (BBB), leading to induction of cerebral oedema, cerebral 




ischaemia, increased intercranial pressure and inflammation, predominantly mediated 
by neutrophils (Doran et al., 2016). 
 
1.3.6 GBS disease in adults 
GBS is capable of causing disease in immunocompromised adults, although the disease 
burden is largely among those suffering from a chronic illness, such as diabetes or 
cancer, and is often nosocomially acquired (Fujita et al., 2015;Farley, 2001). In fact, 20-
25% of GBS infections of non-pregnant adults are in patients with diabetes (Farley, 
2001). The adult form of disease typically presents as non-specific bacteraemia, or as 
infections of the skin and soft tissue, and only rarely presents as meningitis or 
endocarditis (Fujita et al., 2015;Scully et al., 1987a;Sambola et al., 2002;Ross, 1984).  
 
1.3.7 GBS classification and disease 
One major system used for the classification of GBS is based on expression of different 
types of capsular polysaccharide (CPS). There are ten serotypes of CPS (Ia, Ib and II-IX) 
that are antigenically and structurally distinct, and their distribution seems to be 
uniform worldwide (Alkuwaity et al., 2012;Edmond et al., 2012). Four CPS serotypes are 
associated with most disease: Ia, II, III and V (Zhang et al., 2006;Jiang et al., 2008;Farley, 
2001). Serotypes Ia, III and V are the cause of around 80% of EOD and 92% of LOD 
disease (Alkuwaity et al., 2012;Weisner et al., 2004;Zaleznik et al., 2000). CPS serotype III 
is associated with a higher incidence of infant meningitis (Baker and Barrett, 
1974;Weisner et al., 2004;Harrison et al., 1998). 
GBS strains can also be classified according to sequence type (ST); otherwise known as 
clonal complex (CC). Multilocus sequence typing comprises the sequencing of fragments 
around 500 bp in length of 7 housekeeping genes in order to group bacterial strains and 
investigate their population dynamics (Jones et al., 2003). Human pathogenic GBS 
strains belong to six CCs: CC-1, -10, -17, -19, -23, -26 (Jones et al., 2003;Da Cunha et al., 
2014), and one study found that just four CCs (CC-1, -17, -19, and -23) accounted for 
more than half of all isolated GBS (Jones et al., 2006). Of these, CC-17 was found to be 
significantly more associated with invasive neonatal disease than the others. All GBS 




isolates which were identified as CC-17 were also CPS III (Jones et al., 2006). EOD is 
significantly associated with CC-23 of CPS Ia, as well as CC-17 of CPS III (Bohnsack et al., 
2008;Martins et al., 2007;Martins et al., 2017). More than 80% of LOD cases are caused 
by CC-17 strains, which are also highly associated with meningitis (Poyart et al., 
2008;Martins et al., 2007;Tazi et al., 2010). CC-17 is responsible for a greater proportion 
of neonatal GBS disease than might be expected based on maternal colonisation by this 
CC (Jones et al., 2006;Martins et al., 2017).  
 
1.3.8 Molecular basis of GBS pathogenesis 
1.3.8.1 Adhesion to epithelial tissues 
Adhesion to host surfaces is an important first step in the pathogenesis of GBS disease. 
Consequently, GBS possesses many proteins at the cell surface which act as adhesins, 
facilitating attachment and colonisation of host mucosae (Figure 1-4). Some of these 
adhesins are able to target receptors directly expressed on the host cells, while many 
others seemingly utilise an ECM bridging molecule such as fibronectin, fibrinogen or 
laminin. 
 
Figure 1-4 Schematic of GBS cell surface proteins.  
Taken from (Shabayek and Spellerberg, 2018). 




Alpha C protein is a GBS cell surface protein which contains long tandem repeats. Alpha 
C protein of GBS has been shown to bind to and facilitate invasion of GBS into cervical 
epithelial cells in vitro (Bolduc et al., 2002). WT GBS invaded at 3-fold greater numbers 
than the null mutant, and was transcytosed across cervical cells at 5-fold greater 
numbers (Bolduc et al., 2002). A neonatal mouse model of infection showed that an 
alpha C protein null mutant was 7-fold reduced in virulence compared to WT, and led to 
increased host survival (Li et al., 1997). 
Pili are long, thin structures extending away from the bacterial cell surface and are 
important for adhesion to host cells. The protein subunits and enzymes required for 
pilus biogenesis are encoded by loci known as pilus islands (PI), which can be separated 
into variants PI-1 and PI-2, with PI-2 further subdivided into PI-2a and b (Rosini et al., 
2006). GBS pili are composed of three proteins: a major backbone subunit, an accessory 
anchor subunit and a tip-associated adhesin subunit. Both pilus types 1 and 2a mediate 
GBS adhesion to HeLa and A459 cells (Dramsi et al., 2006;Pezzicoli et al., 2008), and 
promote GBS survival in a mouse model of vaginal infection (Sheen et al., 2011). Pilus 
type 2a, but not other pili, is also involved in biofilm formation (Rinaudo et al., 2010).  
FbsC is a cell surface protein of GBS which binds to fibrinogen in a dose-dependent 
manner, with fibrinogen binding by GBS ablated by the deletion of FbsC (Buscetta et al., 
2014). Deletion of FbsC significantly decreased adherence of GBS to endothelial brain 
cells, intestinal and lung epithelial cell lines, as well as reducing biofilm formation 
(Buscetta et al., 2014). Mice were found to be protected from killing by GBS after 
inoculation with FbsC, and mice had an increased survival and decreased GBS burden 
when challenged with an FbsC null mutant (Buscetta et al., 2014). Similarly, adhesin 
BsaB has been shown to be important for GBS binding fibronectin, VECs and cervical 
epithelial cells in vitro. When constitutively expressed on the surface of Gram positive 
surrogate host Lactococcus lactis, BsaB conferred the ability to bind ECM components 
fibronectin and laminin, as well as VECs and cervical epithelial cells. BsaB also enabled 
biofilm formation in L. lactis (Jiang and Wessels, 2014).  
Serine-rich repeat (SRR) proteins are cell surface adhesins which are highly glycosylated, 
and are found in many Gram positive bacteria, where they have been described to 
contribute to adhesion to host cells (Stinson et al., 2003;Siboo et al., 2005). SRR protein-
1 (Srr-1) of GBS has been shown to bind fibrinogen and promote vaginal and cervical 




colonisation (Wang et al., 2014;Sheen et al., 2011). A mutant GBS strain deficient in Srr-1 
was significantly reduced in binding VECs, endocervical and ectocervical cells, with WT 
function restored by complementation (Sheen et al., 2011). In a mouse model of vaginal 
infection, GBS deficient in Srr-1 was impaired in persistence (Sheen et al., 2011). The 
only receptor-adhesin pair definitively described for GBS is that of Srr-1 and cytokeratin 
4 (Sheen et al., 2011). 
One of the reasons that GBS CC-17 is considered more virulent than other CCs is due to 
expression of hypervirulent adhesin HvgA, which is specific to CC-17 strains (Tazi et al., 
2010). Expression of HvgA allowed increased adhesion of GBS to intestinal epithelial 
cells, choroid plexus cells of the brain, and cells of the BBB. Moreover, expression of 
HvgA in normally non-adherent GBS strains facilitated adhesion to these cell types (Tazi 
et al., 2010). 
Alongside surface proteins, adherence of GBS to adult oral epithelial, foetal or 
embryonic cells was ablated in conditions where lipoteichoic acid (LTA) was not 
expressed on the GBS cell surface. In addition to this, pre-incubation of epithelium with 
purified LTA prevented adhesion of GBS to these tissues (Nealon and Mattingly, 1984), 
and a further study replicated this effect with neonatal buccal epithelial cells and VECs 
(Teti et al., 1987). Expression of LTA on the surface of GBS is also crucial for penetration 
of the BBB and subsequent establishment of meningitis (Doran et al., 2005). Mice 
challenged with a GBS LTA mutant survived in significantly higher numbers than those 
challenged with WT GBS (Doran et al., 2005). 
 
1.3.8.2 Crossing the blood brain barrier 
In addition to those mentioned above, proteins implicated in enabling GBS to cross the 
BBB include PilA and PilB (Maisey et al., 2007), Lmb (Tenenbaum et al., 2007), SfbA (Mu 
et al., 2014) and FbsA (Tenenbaum et al., 2005). GBS ΔpilA was 60% reduced in 
adherence but not invasion to human brain microvascular endothelial cells (HBMECs), 
while a ΔpilB strain was 40% reduced in internalisation but not adherence, suggesting a 
role for PilA in preliminary binding to the BBB, while PilB facilitates invasion (Maisey et 
al., 2007). WT function was restored by complementation. Supporting this, when pilA 




and pilB were heterologously expressed in L. lactis, PilA increased attachment to HBMEC 
by 20-fold, while PilB enhanced invasion by 55-fold (Maisey et al., 2007). 
Lmb, laminin-binding protein, plays a role in invasion of GBS across the BBB. Strains with 
Lmb deleted were impaired in HBMEC invasion by around 65%, but unaffected in 
adhesion (Tenenbaum et al., 2007). In competitive binding experiments, invasion of 
HBMEC by GBS was reduced by around 45% when in the presence of either excess 
purified recombinant Lmb or antibodies directed at the binding region of Lmb 
(Tenenbaum et al., 2007). 
SfbA is a fibronectin binding protein. In the absence of SfbA, GBS is 4-fold reduced in 
binding fibronectin (Mu et al., 2014). When SfbA was heterologously expressed in L. 
lactis, fibronectin binding was increased by 2-fold. GBS ΔsfbA is significantly reduced in 
invasion of HBMEC cells, with this effect reversed by complementation, as well as VECs 
and cervical cells. However, there was no significant difference between the HBMEC 
adherent colony forming units (CFU) of the ΔsfbA strain compared to WT (Mu et al., 
2014). SfbA has further been hypothesised to be involved in the pathogenesis of 
meningitis, as an in vivo mouse model found that mice infected with GBS ΔsfbA either 
did not have neutrophil infiltration and thickening of the meningeal layer (characteristics 
of GBS meningitis), or this was much reduced compared to WT-infected mice. This was 
attributed to the significantly lower number of ΔsfbA bacteria observed to penetrate the 
BBB compared to WT (Mu et al., 2014). 
FbsA is a fibrinogen binding protein. Attachment and invasion of HBMEC by GBS ΔfbsA 
was around 90% decreased when compared against WT, and this was reversed by 
complementation (Tenenbaum et al., 2005). When FbsA was heterologously expressed 
in L. lactis, there was a significant increase in attachment to but not invasion of HBMEC 
when compared against the empty vector control. This suggests that FbsA plays an 
important role in initial attachment to HBMEC but is not an invasin (Tenenbaum et al., 
2005). Adherence and invasion of HBMEC was competitively inhibited in a dose-
dependent manner by increasing concentrations of monoclonal antibodies directed 
against the binding region of FbsA (Tenenbaum et al., 2005). 
Another suggested mechanism by which GBS may cross the BBB is by binding plasmin 
and plasminogen to the GBS surface (Magalhaes et al., 2013). Although the GBS proteins 




involved in binding plasminogen have not been confirmed, they are hypothesised to be 
the GBS enolase and GAPDH (Magalhaes et al., 2013). 
 
1.3.8.3 Uterine infection 
As mentioned, EOD by GBS can be initiated following infection of the foetus in utero. 
Such infection can also lead to stillbirth, chorioamnionitis or preterm birth (Nan et al., 
2015;Muller et al., 2006), and requires that GBS ascends from the vaginal vault during 
pregnancy to cross the cervix and enter the uterus. Hyaluronic acid is a constituent of 
the host ECM and plays a critical role in epithelial barrier integrity. GBS expresses a 
hyaluronidase, HylB, which degrades hyaluronic acid and this has been implicated to aid 
in ascending GBS infection (Vornhagen et al., 2016). Clinical isolates of GBS from women 
who went into preterm birth exhibited higher levels of hyaluronidase activity than was 
observed in commensal GBS strains, and this was also the case for strains isolated from 
amniotic fluid or the blood of neonates (Vornhagen et al., 2016). Significantly fewer 
pregnant mice developed ascending infection when challenged with a ΔhylB mutant 
compared to WT, with fewer pups experiencing an adverse outcome and a lower rate of 
preterm birth (Vornhagen et al., 2016). Although there were similar levels of vaginal 
colonisation, bacterial load in the uterine horns was significantly lower in the ΔhylB-
infected pregnant mice (Vornhagen et al., 2016). Degradation of hyaluronic acid into its 
component disaccharides has been shown to block TLR2 and TLR4, thus 
circumnavigating the host immune response (Kolar et al., 2015), and this was supported 
by a greater proinflammatory immune response to ΔhylB than WT GBS (Vornhagen et 
al., 2016). 
Another virulence factor of GBS, β-haemolysin/cytolysin (β-H/C) is involved in promotion 
of GBS disease following ascending uterine infection. There was an ablation of stillbirth 
or preterm birth in pregnant mice challenged with a β-H/C deficient strain compared to 
WT, although both strains colonised and ascended (Randis et al., 2014). β-H/C induced 
inflammation in the placenta and GBS invasion of the foetus, particularly into the lungs 
and liver (Randis et al., 2014). Deletion of the two-component regulator of virulence 
CovR resulted in a hyper-haemolytic strain and increased the rate of preterm birth 
(Whidbey et al., 2015). β-H/C expression was also associated with increased foetal death 
in pregnant mice  (Whidbey et al., 2015). This was further supported in a model of non-




human primate pregnancy, in which β-H/C-expressing GBS strains were associated with 
preterm birth, amniotic infection and foetal sepsis (Boldenow et al., 2016). In this 
model, β-H/C induced neutrophil cell death and facilitated evasion of neutrophil 
extracellular traps (NETs), which allowed GBS to subsequently cause foetal infection 
(Boldenow et al., 2016).  
 
1.3.8.4 Evasion of host defences 
In order to successfully colonise and establish an infection, GBS must avoid clearance by 
host immune defences. One surface determinant that enables GBS to achieve this is the 
capsule. The GBS capsule is largely composed of monosaccharides of glucose, galactose 
and N-acetylglucosamine with side chains of sialic acid (Cieslewicz et al., 2005). The sialic 
acid component of CPS mimics host glycoproteins and glycolipids, masking GBS from the 
immune response (Cieslewicz et al., 2005). The capsule of GBS is resistant to 
complement-mediated killing by leukocytes, effectively evading the immune system 
(Marques et al., 1992). The amount of capsule expressed, specifically sialic acid within 
the capsule, was shown to be inversely proportional to the ability of complement C3 to 
bind the bacteria (Takahashi et al., 1999;Marques et al., 1992). Loss of capsule by GBS 
led to decreased virulence in a rat model of infection (Wessels et al., 1989). 
Other GBS virulence factors which prevent clearance of GBS from the host include C 
protein, C5a peptidase and CspA. C protein contains domains which bind secretory IgA 
(S-IgA) to sequester the antibody and prevent clearance (Jerlstrom et al., 1996). C5a 
peptidase degrades C5a, a potent neutrophil chemoattractant, allowing persistence of 
GBS (Bohnsack et al., 1997). CspA is a cell surface serine protease with some homology 
to C5a peptidase. CspA cleaves fibrinogen, the breakdown products of which were 
hypothesised to encourage GBS aggregation or possibly to coat GBS, thus masking the 
bacteria from the immune system (Harris et al., 2003). A CspA deficient strain was ten-
fold less virulent in a neonatal rat model of infection, and was more susceptible to 
neutrophil-mediated killing (Harris et al., 2003).  
Additionally, β-H/C has been shown to contribute to the survival of GBS within the 
phagolysosome of phagocytic cells. GBS strains deficient in β-H/C were more rapidly 
cleared from the blood stream of mice than WT, and were more susceptible to oxidative 




killing. This was related to the ability of GBS to induce cytolysis and apoptosis of 
phagocytic cells via β-H/C (Liu et al., 2004b). Protection against oxidative killing by 
macrophages is further mediated by expression of a superoxide dismutase, SodA (Poyart 
et al., 2001). A SodA mutant was shown to be significantly more vulnerable to oxidative 
stress when exposed to hydrogen peroxide or when grown with macrophages. 
Furthermore, there was a significant reduction in the ability of the SodA mutant to 
survive in the blood or brain of mice, although similar levels of bacteria were recovered 
from the liver and spleen as for WT (Poyart et al., 2001). 
 
1.3.9 GBS control measures  
1.3.9.1 Intrapartum antibiotic prophylaxis (IAP) 
Given the risk of maternal vertical transmission of GBS, a number of Western countries 
screen for GBS GU tract colonisation at 35-37 weeks of pregnancy, and offer intrapartum 
antibiotics as necessary (Schrag et al., 2002). Randomised controlled trials treating 
pregnant mothers who displayed likely risk factors for GBS colonisation with ampicillin 
and penicillin were carried out in the 1970s and 1980s; however, IAP was not 
implemented until the late 1990s due to issues with identifying which pregnant women 
should receive IAP (Schrag and Verani, 2013). Antibiotics prescribed around birth have 
reduced the rate of EOD in the US by 65%, yet they have not had an effect on the rate of 
LOD (Schrag et al., 2000). Unfortunately, GBS-related stillbirths are also unaffected by 
the intervention of IAP (Nan et al., 2015). A systematic review found that the rate of 
stillbirths was difficult to identify due to a lack of consistency in reporting (Nan et al., 
2015). 
A further issue with IAP is that, although the CDC has released clear guidelines for US 
health workers, these guidelines are not always followed. IAP usually consists of either 
intravenous penicillin or ampicillin, with cefazolin recommended as an appropriate 
alternative for women with penicillin allergies (Schrag and Verani, 2013). One study 
assessing the effectiveness of IAP found that less than a third of cases in which mothers 
had a risk factor which would qualify them for IAP resulted in provision of antibiotics (5 
of 16) (Darlow et al., 2016). A further study found that 40% of IAP cases reviewed 
received an inappropriate antibiotic (Bienenfeld et al., 2016), while another found that 
55% of women reporting a penicillin allergy were given an inappropriate antibiotic as 




substitute (Briody et al., 2016). In Italy, women delivering pre-term were found to be 
less likely to receive IAP, while 817 women were given IAP against recommendations 
(i.e. when culture-negative for GBS) (Berardi et al., 2017). Furthermore, despite similar 
levels in IAP compliance in the US, the rate of GBS EOD is twice as high in preterm 
neonates as among those born at term (Schrag and Verani, 2013). 
There are understandable concerns about widespread antibiotic use and resulting 
resistance. There have been reports that IAP increases colonisation by potentially 
harmful Enterobacteriaceae in the infant once born, as the microbes which are normally 
acquired by passage through the birth canal and make up the infant’s initial microbiota 
are less diverse (Mazzola et al., 2016;Aloisio et al., 2014). Diversity of intestinal microbes 
is important in early life, and plays a role in development of intestinal epithelium and 
associated lymphoid tissue (Gritz and Bhandari, 2015). IAP also increases the mother’s 
risk of diarrhoea, fungal infections and antibiotic resistance, while affecting the child by 
increasing the risk of E. coli infections, thrush and allergic sensitivity. As such, both 
mother and child are kept in for observation for 48 hours after birth, which is costly 
(Hanson et al., 2014). 
On average, countries which implement IAP have lower rates of neonatal GBS disease 
than countries which do not use IAP. However, this may be skewed by including poorer 
countries in which pregnant mothers have less access to regular medical treatment 
(Edmond et al., 2012). IAP has also only been described to be cost-effective in countries 
where there are higher rates of GBS recto-vaginal colonisation (Albright et al., 2017). 
Intravenous antibiotic treatment is not possible in resource poor settings, and neither is 
intrapartum GBS screening, as this involves resources and access to care facilities that 
are less than realistic in poorer countries and rural locations (Schrag and Verani, 
2013;Nishihara et al., 2017). 
 
1.3.9.2 Vaccines 
Given the issues associated with IAP, vaccination against GBS is an attractive alternative. 
CPS Ia, Ib, II, III and V are the five most common serotypes associated with GBS disease 
(Le Doare and Heath, 2013) and as such, these are the serotypes that have 
predominantly been used as targets in vaccine studies against GBS (Nuccitelli et al., 




2015). Native CPS alone was found to be of insufficient immunogenicity, but second 
generation vaccines in which the polysaccharides are conjugated to a strong immunogen 
such as tetanus toxoid have been shown to trigger a robust anti-CPS antibody response 
(Paoletti et al., 1994;Leroux-Roels et al., 2016;Madhi et al., 2017). Nonetheless, immune 
responses are serotype-specific, meaning that multivalent vaccines are required to 
obtain sufficient coverage. Furthermore, capsular switching of GBS serotype III CC-17 to 
serotype IV has been described (Bellais et al., 2012;Teatero et al., 2014;Meehan et al., 
2014), which could further reduce the efficacy of any CPS-based vaccine. No licensed 
vaccine is available as yet; however, serum containing high levels of antibodies against 
CPS among pregnant mothers has been described as protective against GBS invasive 
neonatal disease (Baker and Kasper, 1976). Modelling has estimated that a vaccine 
would be much more cost-effective and preventative than alternative strategies, 
preventing between 30-54% of neonatal infections, depending on efficacy against the 
most common CPS. This compares to 10% prevention, as observed with risk factor-based 
IAP (Kim et al., 2014). Despite cost-efficacy, vaccine compliance has been estimated to 
be required at high levels (~90%) before a reduction in disease rates would be observed 
at similar levels to those seen for screening/IAP (Kim et al., 2014). 
In response to the potential issues of a GBS vaccine based on CPS immunogens only, 
attempts are underway to identify highly protective protein antigens. One study 
screened GBS proteins for immunogenicity in mice and found that four antigens were 
sufficient for a significant rise in survival in progeny mice. These were Sag0032 (Sip 
protein), part of the core GBS genome, and Sag1408, Sag0645, and Sag0649, all of which 
encode cell surface-expressed pilus subunits (Maione et al., 2005;Lauer et al., 2005). 
Between 59-100% of neonatal mice were protected from lethal infection when 
challenged with 12 different GBS strains following maternal immunisation with all four 
proteins. Furthermore, opsonophagocytosis and neutrophil-mediated killing of GBS was 
enhanced following vaccination with these antigens (Maione et al., 2005). Protective 
antibodies have been generated to a conserved region of PI-2a in mice, and this 
evidence is being used to further the development of vaccines against pili (Nuccitelli et 
al., 2011). 
Other proteins of GBS have also been considered as vaccine targets. Pullulanase is a 
glycoside hydrolase involved in α-glucan degradation and attachment to cervical 
epithelial cells. Pullulanase is immunogenic, and serum from animals immunised with 




pullulanase prevented the activity of the enzyme and altered the ability of GBS to attach 
to cervical tissue (Gourlay et al., 2009). SRR protein SAN_1485 has also been found to be 
a protective cell surface antigen (Doro et al., 2009). MinervaX have announced positive 
results from a phase I clinical trial with a vaccine directed against GBS proteins Alpha C 
and Rib, which resulted in a 30-fold increase in maternal antibodies to these proteins 
(Minervax, 2017).  
 
1.4 Candida albicans 
1.4.1 Overview 
Only 600 of an estimated 611,000 fungal species are human pathogens, including those 
that cause relatively non-threatening superficial and cutaneous infections (Mayer et al., 
2013;Brown et al., 2012). Yeasts of the genus Candida can cause systemic infections 
with fatality rates up to 50%, and are the fourth most common cause of systemic 
nosocomial infections in the US, although these deaths are largely among 
immunocompromised individuals (Pfaller and Diekema, 2010;Pfaller and Diekema, 
2007;Zaas et al., 2010). Age and HIV infection are key risk factors because they impair 
the adaptive immune response, thus predisposing individuals to Candida infections 
(Pfaller and Diekema, 2010). 
Candida albicans is the principal cause of fungal infections affecting humans; however, 
C. albicans is also a common human commensal (Harriott and Noverr, 2011). C. albicans 
is responsible for approximately 90-99% of all mucosal Candida infections, and is able to 
infect a broad range of host tissues, causing disease even in otherwise healthy people 
(Harriott and Noverr, 2011;Zaas et al., 2010;Pfaller and Diekema, 2010). 
 
1.4.2 C. albicans polymorphism 
C. albicans is a pleomorphic yeast. The two most important morphological forms in 
terms of colonisation and pathogenesis are the budding yeast form (also known as 
blastospores) and the elongated (filamentous) hyphal form (Fanning and Mitchell, 2012) 
(Figure 1-5).  





Figure 1-5 Polymorphism of C. albicans.  
Brightfield microscopy with blastospores and hypha labelled. Scale, 50 µm. 
 
To be pathogenic, C. albicans must be in its hyphal form, which allows invasion of host 
tissues (Monif and Carson, 1998). A pH below 6 triggers yeast growth, whilst a pH above 
7 triggers hyphal growth (Mayer et al., 2013). Additionally, temperatures similar to that 
of the human body (~37 °C), supplementation of media with N-acetyl-D-glucosamine 
(GlcNAc) or serum, and 5% CO2 stimulate hyphae formation (Sudbery, 2011;Shapiro et 
al., 2009;Mardon et al., 1969;Simonetti et al., 1974;Taschdjian et al., 1960). Quorum 
sensing molecules of C. albicans also affect yeast to hypha transition. Farnesol inhibits 
hyphae formation (Hornby et al., 2001), while tyrosol promotes filamentation (Chen et 
al., 2004). These molecules are believed to be continuously secreted in response to 
environmental conditions to stimulate or limit growth and biofilm formation by C. 
albicans (Alem et al., 2006;Ramage et al., 2002). The pleomorphic nature of C. albicans is 
essential for colonisation and adherence to host tissues (Shirtliff et al., 2009). This was 
demonstrated through the use of a C. albicans strain which formed hyphae or 
blastospores under controllable conditions. Mice infected with this strain under 
conditions allowing hyphae formation were susceptible to infection, while mice under 
conditions predisposing to blastopores were not, despite equal loads of C. albicans 
(Saville et al., 2003). 
 




1.4.3 C. albicans carriage and disease 
1.4.3.1 Carriage  
C. albicans is estimated to be present in the oral cavity of 75% of people (Mayer et al., 
2013). C. albicans is also a commensal of the female GU tract, from which it is frequently 
isolated (Monif and Carson, 1998). It is the most commonly recovered yeast from the 
vaginal tract (Ng et al., 1998), with one study reporting C. albicans accounting for 83.5% 
of Candida species from vaginal swabs taken from pregnant women (Masri et al., 2015). 
Furthermore, C. albicans has been isolated from the vaginal tracts of around 30% of 




C. albicans causes 40-70% of candidemia (Candida within the blood stream) cases 
(Harriott and Noverr, 2011;Zaas et al., 2010;Pfaller and Diekema, 2010). The incidence of 
candidemia has been shown to be rising in both the US and France, where it stands at 
approximately 5.6 and 3.6 candidemia-related hospitalisations per 100,000 people, 
respectively, although this rate is higher among ICU patients (Zilberberg et al., 
2008;Bitar et al., 2014). Candidemia can have fatality rates of 30-60%, although this is 
predominantly amongst immunocompromised individuals (Flevari et al., 2013). Risk 
factors for candidemia include advanced age, catheter use, parenteral nutrition and 
broad-spectrum antibiotic use (Hirano et al., 2015;Luzzati et al., 2013). Other causative 
agents of candidemia include C. parapsilosis, C. tropicalis, C. glabrata and C. krusei and, 
together with C. albicans, these strains account for over 90% of all candidemia cases 
(Guinea, 2014;Falagas et al., 2010). 
 
1.4.3.3 Thrush 
C. albicans typically behaves as a commensal microorganism within the oral cavity, but 
can cause oral disease in immunocompromised individuals, for example the elderly or 
people who suffer from HIV. A further risk factor is wearing dentures (Pappas et al., 
2009), and among denture wearers smoking and diabetes has been correlated with a 
higher incidence and burden of C. albicans colonisation (Abu-Elteen and Abu-Alteen, 




1998). Symptoms of oral thrush include the formation of white plaques on the oral 
mucosa, a sensation of burning, changes in taste, and bleeding at the site of the plaques 
(Millsop and Fazel, 2016). 
It is estimated that around 75% of women will suffer from vaginal thrush, also known as 
vulvovaginal candidiasis (VVC), at least once in their lifetime, and 40-50% will suffer one 
or more subsequent infections (Harriott and Noverr, 2011;Sobel, 2007;Harriott et al., 
2010). Symptoms typically present as itching, soreness, pain during intercourse and 
odourless, white discharge (Sobel, 2015). Risk factors for VVC include oral contraception, 
hormone therapy, antibiotics, diabetes, and pregnancy (Harriott and Noverr, 
2011;Sobel, 2007;Andes et al., 2004). C. albicans is the most common Candida species 
involved in colonisation and infection of the vaginal tract (Pfaller and Diekema, 2007). C. 
albicans colonisation of the vaginal tract is enhanced by an oestrogen environment, and 
C. albicans can travel to the vaginal tract via the lower GI tract, similar to GBS (Sobel, 
2007). Amongst women with no symptoms of VVC, 20-30% will still be colonised with C. 
albicans (Achkar and Fries, 2010). 
 
1.4.3.4 Neonatal C. albicans infection 
C. albicans can cause neonatal sepsis and meningitis, although the affected infants are 
most commonly premature with a low birthweight (Lee et al., 1998;Botero-Calderon et 
al., 2015;Arsenault and Bliss, 2015). Although there is variation between studies, over 
60% of neonatal Candida infections are caused by C. albicans (Lee et al., 1998;Saiman et 
al., 2000;Lovero et al., 2016;Botero-Calderon et al., 2015;Fernandez et al., 2000), with C. 
parapsilosis being the second most common causative species (Saiman et al., 
2000;Lovero et al., 2016;Botero-Calderon et al., 2015). Disease has a high mortality rate 
and, as with GBS, meningitis survivors often develop neurological defects, such as sight 
or hearing loss, cognitive deficits or cerebral palsy (Lee et al., 1998;Saiman et al., 
2000;Lovero et al., 2016;Botero-Calderon et al., 2015;Arsenault and Bliss, 
2015;Benjamin et al., 2006;Benjamin et al., 2003). Risk factors for neonatal Candida 
infections are low birthweight, prematurity, use of a central venous catheter and third 
generation antibiotic prescription (Lovero et al., 2016;Botero-Calderon et al., 2015). One 
study suggested that Candida may be vertically transmitted from the mother during 
vaginal birth (Botero-Calderon et al., 2015). Furthermore, (Saiman et al., 2000) found 




that 43% of infants with candidemia had Candida-colonised GI tracts, with Benjamin et 
al. (2003) finding that only half of cases were colonised nosocomially, suggesting 
another source of transmission (Benjamin et al., 2003). Thus, alike to GBS, C. albicans 
can be transmitted to a neonate from a colonised mother or via horizontal transmission. 
  
1.4.4 Molecular basis for C. albicans pathogenesis and colonisation 
1.4.4.1 Adhesion 
C. albicans expresses a number of cell wall adhesins that have been associated with 
attachment to mucosal tissues. These include Als1, Eap1 and Tdh1. Als1 is a C. albicans 
protein with a high sequence identity to alpha-agglutinin, an adhesin of S. cerevisiae 
(Hoyer et al., 1995). A C. albicans Als1 null mutant was 20% less able to adhere to 
human umbilical vein endothelial cells and to cause damage to reconstituted oral 
epithelium than the WT (Zhao et al., 2004b). Expression of Als1 on the cell surface of S. 
cerevisiae also conferred 100-fold higher levels of adhesion to umbilical vein endothelial 
and FaDu oral epithelial cells (Fu et al., 1998). C. albicans adhesin Eap1 has homology to 
cell wall proteins Hwp1 of C. albicans, as well as Flo11 and Aga1 of S. cerevisiae (Li and 
Palecek, 2003). Eap1 has been shown to enhance attachment of C. albicans to kidney 
epithelial cells, and confers this function upon S. cerevisiae when heterologously 
expressed. While only 1% of the S. cerevisiae cells carrying empty vector were able to 
adhere to kidney epithelial cells, over 35% of the Eap1-expressing cells were adherent, 
and this was similar to WT C. albicans. Expression of Eap1 also conferred a filamentous 
phenotype in S. cerevisiae (Li and Palecek, 2003). Alongside direct attachment to host 
cells, C. albicans is able to target ECM proteins, and one such protein that facilitates this 
is Tdh1. Tdh1 is expressed at the cell surface of C. albicans both in vitro and in samples 
of infected tissue collected from patients with systemic candidiasis (Gil-Navarro et al., 
1997;Gil et al., 1999), and is capable of binding laminin and fibronectin (Villamon et al., 
1999).  
Other C. albicans adhesins are exclusively expressed on the surface of hyphae, such as 
Hwp1, Als3 and Ssa1 (Hoyer et al., 1998a;Staab et al., 1999;Sun et al., 2010). Hwp1 is 
necessary for C. albicans adhesion to buccal epithelial cells. A mutant strain was reduced 
in adhesion and was less able to initiate systemic infection in a mouse model of infection 
(Staab et al., 1999). Hwp1 is hypothesised to act as a target for host transglutaminases, 




enabling formation of cross links between hyphae and host cells (Sundstrom et al., 
2002). Severe systemic disease and subsequent killing was observed in immunodeficient 
mice infected orally with WT C. albicans, while no infection was established with a Hwp1 
null mutant (Sundstrom et al., 2002). Deficiency of heat shock protein Ssa1 also led to 
reduced virulence in a mouse model of systemic and oral candidiasis, as well as inducing 
markedly less endothelial and oral epithelial cell damage in vitro (Sun et al., 2010). The 
C. albicans Δssa1 mutant was less able to induce endocytosis by host cells, and this was 
attributed to an inability to bind N-cadherin and E-cadherin on endothelial and epithelial 
cells, respectively (Sun et al., 2010). Ssa1 has also been found to serve as a receptor for 
antimicrobial host protein histatin-5, and is necessary for fungal cell killing by defensins 
(Vylkova et al., 2006). This suggests that, although Ssa1 is important for C. albicans 
virulence, the host targets Ssa1 for clearance of the fungus. 
Upon contact with oral epithelial cells in vitro, C. albicans has been shown to 
significantly upregulate expression of Als3 and Hwp1 (Wachtler et al., 2011), and Als3 
has similarly been found to be frequently expressed in vivo by C. albicans found in 
vaginal fluid samples from patients with VVC (Cheng et al., 2005a). Loss of Als3 caused a 
reduction in adhesion to vascular endothelial cells of between 42% and 63%, depending 
on C. albicans strain, and around 60% in adhesion to buccal epithelial cells, signifying 
that Als3 is an important adhesin (Zhao et al., 2004b). To further support this, there was 
a significant reduction in numbers of C. albicans Δals3 able to colonise reconstituted oral 
epithelia, at an average of 0.1-0.2 C. albicans Δals3 cells attached per 250 µm tissue 
section, compared to 5.5 cells for WT, and this was observed alongside an ablation of 
epithelial cell damage in the mutant strains (Zhao et al., 2004b). 
 
1.4.4.2 Toxicity 
In addition to binding to mucosal epithelia, C. albicans is able to damage such tissues in 
a process that is associated with hyphal tissue penetration. Experiments using a range of 
C. albicans mutant strains found that only hyphae-producing strains initiated epithelial 
cell damage via phosphorylation of MKP1, c-Fos, neutrophil infiltration and cytokine 
release. However, one hyphae-producing strain deficient in ECE1 was unable to induce 
damage, despite similar adherence and invasion levels to WT (Moyes et al., 2016). It was 
subsequently discovered that ECE1 encodes a cytolytic pore-forming toxin, named 




candidalysin. Candidalysin has been shown to be responsible for the proinflammatory 
response and pathology observed in vaginal thrush (Richardson et al., 2017). 
Reconstituted vaginal epithelial cells produced proinflammatory cytokines such as IL-1α, 
IL-1β and IL-8 in response to candidalysin, and there was dose-dependent release of LDH 
from A431 cells in response to candidalysin (Richardson et al., 2017). There was also a 
significant reduction in the number of neutrophils infiltrating the vaginal tissue of mice 
infected with C. albicans lacking Ece1, while a strain complemented with the locus 
encoding candidalysin restored neutrophil infiltration to WT levels (Richardson et al., 
2017). Infiltration of neutrophils has not been correlated with clearance of fungal 
burden, but has instead been associated with a worsening of symptoms (Yano et al., 
2014;Yano et al., 2012). Release of components of antifungal defence such as 
antimicrobial peptides and S100 alarmins was also dependent on candidalysin 
expression (Richardson et al., 2017). Similarly, production of IL-36 by oral epithelial cells 
was induced in response to candidalysin (Verma et al., 2018). 
 
1.5 Interkingdom interactions 
Biofilms are communities of microorganisms which attach to a surface and are 
surrounded by extracellular polymeric substance (EPS) (Harriott and Noverr, 2011). 
Polymicrobial biofilms are very common throughout the human body. Most 
microorganisms are likely to exist in biofilms, rather than as free, planktonic cells 
(Douglas, 2003;El-Azizi et al., 2004), and the National Institutes of Health in America 
estimates that 80% of infections are caused by microorganisms present in biofilms (NIH, 
2002). This reflects the fact that biofilms increase the likelihood of microbial resistance 
to antimicrobial agents or components of the host immune system (Douglas, 
2003;Lewis, 2001;Costerton et al., 1999) due, in part, to protection afforded by the EPS. 
Polymicrobial biofilms involving C. albicans form at many sites within the human body 
(El-Azizi et al., 2004), including on catheters, dentures, or living tissue (Harriott and 
Noverr, 2011;Andes et al., 2004), and approximately 27-56% of hospital-acquired 
bloodstream infections caused by C. albicans involve other microorganisms (Harriott and 
Noverr, 2011). This reflects the capacity for C. albicans to mediate interspecies 
interactions with other yeasts or bacteria on both a physical (coaggregation/coadhesion) 
and chemical level, some examples of which are detailed below. 




1.5.1 C. albicans interactions with Staphylococcus aureus 
There is a well-documented synergistic interaction between C. albicans and S. aureus. S. 
aureus exhibits a strong tropism for C. albicans filaments, and the binding of hyphae 
allows S. aureus to “piggyback” into host cells, facilitating systemic disease (Schlecht et 
al., 2015b). This is the primary mechanism by which S. aureus can invade host cells 
(Schlecht et al., 2015b). Binding of S. aureus to Als3 on the surface of candidal hyphae is 
essential for this interaction to occur, as there was a significant decrease in S. aureus-C. 
albicans interactions when incubated with the Δals3 strain (Peters et al., 2012). In a 
mouse model of oral infection, mice incubated with only C. albicans exhibited symptoms 
of oral candidiasis but not invasive infection, while mice infected with only S. aureus 
showed no symptoms of disease. Mice infected with both C. albicans and S. aureus 
developed severe invasive disease and both microorganisms were isolated from the 
kidneys (which did not happen for either microorganism after single species infection) 
(Schlecht et al., 2015b). Furthermore, a mouse model of peritonitis showed that when C. 
albicans and S. aureus were both used to infect mice, infection was lethal in 40% of 
mice, compared to 0% for monomicrobial infection, and there was an increase in 
numbers of microbes present in the spleen and kidney (Peters and Noverr, 2013). This 
difference in mortality appeared to be driven by an enhanced inflammatory response to 
the dual-speces infection. There was a marked increase in production of 
proinflammatory cytokines and infiltration of neutrophils into host tissues in the 
polymicrobial versus the monospecies infected mice (Peters and Noverr, 2013). When 
mice were treated with a non-steroidal anti-inflammatory, there was a reduced 
production of proinflammatory cytokines and a reduction in neutrophil infiltrate and all 
mice survived, despite no inhibition in microbial growth in vitro (Peters and Noverr, 
2013). 
The biofilm matrix of C. albicans prevents infiltration of antibiotics into biofilms and this 
has been shown to promote tolerance of S. aureus to antibiotics. This was found to 
specifically be due to secretion of β-1,3-glucan. In dual-species biofilms, S. aureus was 
shown to become coated in C. albicans β-1,3-glucan, and this afforded protection 
against vancomycin. S. aureus could be sensitised to vancomycin by addition of 
caspofungin, an antifungal which inhibits synthesis of β-1,3-glucan (Kong et al., 2016). 




1.5.2 C. albicans interactions with oral streptococci 
C. albicans has been described to interact with a number of streptococcal species, 
particularly those that inhabit the oral cavity. This includes interactions with 
Streptococcus gordonii, Streptococcus mutans, and Streptococcus oralis. S. gordonii has 
been shown to secrete nutrients which are beneficial for C. albicans hyphae formation, 
promoting filamentation and biofilm formation (Bamford et al., 2009;Jenkinson et al., 
1990). This effect was also significantly impaired when autoinducer-2 of S. gordonii, a 
quorum sensing molecule, was not expressed (Bamford et al., 2009). In addition, C. 
albicans hyphae formation is induced by environmental hydrogen peroxide (Nasution et 
al., 2008), which S. gordonii is capable of generating (Barnard and Stinson, 1996). Levels 
of hydrogen peroxide naturally produced by S. gordonii are typically lower than those 
found to be necessary for an effect on C. albicans (Bamford et al., 2009), but 
concentrations may be elevated if the two microbes are in close proximity. This appears 
to be a synergistic relationship, as C. albicans similarly benefits S. gordonii through 
production of an environment with lower levels of oxygen (Shirtliff et al., 2009). Both 
microbes also benefit from their ability to coadhere, which can facilitate their binding 
and retention within the oral cavity. This physical interaction is mediated, in large part, 
by S. gordonii cell surface protein SspB specifically recognising C. albicans hyphal 
adhesin Als3 (Silverman et al., 2010). Accumulation of salivary proteins such as proline-
rich proteins on the surface of S. gordonii has also been shown to facilitate interaction 
with C. albicans (O'Sullivan et al., 2000). 
Physical interactions that promote biofilm formation between S. mutans and C. albicans 
have been identified. In this instance, S. mutans glycosyltransferase GtfB attaches to C. 
albicans cell surface α-mannans, and this was shown to enable multispecies biofilm 
formation in a rat model of oral infection (Hwang et al., 2017). Interkingdom biofilms 
were less established when S. mutans was grown with C. albicans strains deficient in N- 
or O-mannan, or when WT C. albicans was grown with a S. mutans GtfB null mutant 
(Hwang et al., 2017). A study investigating the effects of C. albicans on the S. mutans 
transcriptome also found that there was significant upregulation of transcripts relating 
to carbohydrate metabolism (He et al., 2017). S. mutans is an important causative agent 
of dental caries, in which acid generation following bacterial metabolism of sugars leads 
to destruction of the mineralised tooth surface. Such an upregulation of S. mutans 




transcripts relating to sugar catabolism by C. albicans may underpin the association of C. 
albicans and S. mutans in cases of severe early childhood caries (ECC) (He et al., 2017).  
S. oralis is unable to form robust, monospecies biofilms within the oral cavity. However, 
when co-incubated with C. albicans, biofilm biomass of S. oralis was increased by 45-fold 
(Diaz et al., 2012). S. oralis in turn promoted oral mucosa invasion by C. albicans (Diaz et 
al., 2012), and facilitated C. albicans hyphae formation via upregulation of EFG1 gene 
expression in polymicrobial biofilms in vitro and in vivo (Xu et al., 2017). This synergistic 
interaction between C. albicans and S. oralis facilitated degradation of E-cadherin from 
oral epithelial tight junctions, allowing systemic spread of C. albicans in a mouse model 
of infection (Xu et al., 2016). 
Taken together, these studies serve to demonstrate that not only do C. albicans-
streptococcal interactions promote adherence to host surfaces, they can facilitate 
establishment of disease. 
 
1.5.3 C. albicans interactions with Pseudomonas aeruginosa 
Not all polymicrobial interactions are synergistic, and a notable antagonistic relationship 
is that of C. albicans and P. aeruginosa. P. aeruginosa displays a tropism for C. albicans 
hyphae, which it binds to and kills (Hogan and Kolter, 2002). Binding to C. albicans 
filaments facilitated biofilm formation by P. aeruginosa, possibly via the bacteria 
harnessing nutrients from the fungus. This was supported by the observation that fungal 
cell death occurred only after commencement of biofilm formation (Hogan and Kolter, 
2002). Pyocyanin, a virulence factor of P. aeruginosa, has been shown to inhibit 
transition of blastospores to hyphae in C. albicans via reduction of intracellular cAMP 
concentrations (Kerr et al., 1999). P. aeruginosa also out-competes C. albicans for 
nutrients. When in the presence of C. albicans, P. aeruginosa upregulates proteins which 
sequester iron, and this leads to a reduction in C. albicans metabolism (Purschke et al., 
2012). 
This relationship is not one sided, however. Farnesol production by C. albicans reduces 
production of pyocyanin by P. aeruginosa (Cugini et al., 2007) and can prevent P. 
aeruginosa swarming motility (McAlester et al., 2008). If C. albicans is present prior to P. 




aeruginosa, the burden of P. aeruginosa in mouse lung tissue is significantly reduced, as 
is the presence of pathological lesions (Ader et al., 2011). This protection is mediated by 
activation and infiltration of NK cells, innate lymphoid cells, dendritic cells and 
macrophages into infected sites, and this was dependent on IL-22 secretion (Mear et al., 
2014). A murine model of GI tract infection found that C. albicans inhibits biosynthesis 
of siderophores and cytotoxic virulence factors of P. aeruginosa via an unidentified 
secreted protein. This led to a significant reduction in P. aeruginosa virulence and an 
increase in survival to almost 100% (Lopez-Medina et al., 2015).  
 
1.6 Hypothesis and objectives  
Both C. albicans and GBS are common colonisers of the female GU tract. Given the 
precedent for C. albicans to exhibit synergistic interactions with Gram-positive bacteria, 
including streptococci, it was hypothesised that a similar relationship may occur 
between C. albicans and GBS. Such interactions could have potential to modulate the 
colonisation or pathogenic capabilities of both of these microbes. Nonetheless, there 
was only limited understanding of this relationship. The aims of this study were 
therefore to better characterise the molecular basis of interactions between C. albicans 
and GBS and the capacity for such interactions to influence microbial association with 
vaginal epithelial cells (VECs). This, in turn, could have implications for disease risk for 
both opportunistic pathogens. Specifically, the objectives of this study were: 
i) To investigate whether GBS association with VECs is affected by C. albicans 
ii) To investigate whether C. albicans association with VECs is affected by GBS 
iii) To investigate the molecular basis for any interkingdom interactions 
iv) To investigate the effects of any GBS-C. albicans interactions on the host 
 




Chapter 2 Materials and Methods 
2.1 Bacterial strains and culture conditions 
The bacterial strains used in these studies are listed in Table 2-1. GBS was cultured in 10 
mL THY broth (3.64% Todd-Hewitt powder [Oxoid], 0.5% Yeast Extract [Oxoid]) in sterile 
glass universals or maintained on THY agar plates at 37 °C, 5% CO2. Media was 
supplemented with the following antibiotics as needed: 2 μg/mL chloramphenicol 
(Sigma), 5 μg/mL erythromycin (Sigma). 
C. albicans was cultured in 10 mL YPD broth (1% Yeast Extract, 2% Mycological peptone 
[Oxoid], 2% D-glucose) in sterile conical flasks incubated at 37 °C, 220 rpm or maintained 
on Sabouraud dextrose agar (SAB) plates (Lab M) incubated aerobically at 37 °C.  
L. lactis was cultured in 10 mL GM17 broth (3.725% M17 broth powder [Oxoid], 0.5% D-
glucose) in sterile glass universals or maintained on GM17 agar plates at 30 °C in a 
sealed candle jar. Media were supplemented with 5 μg/mL erythromycin, and 
heterologous protein expression was induced by the addition of 0.1 μg/mL nisin. 
S. cerevisiae was cultured in 10 mL Complete Supplement Media (CSM) without Uracil 
(0.077% CSM [Formedia], 0.67% Yeast Nitrogen Base, 2% D-glucose) in sterile conical 
flasks incubated at 30 °C, 220 rpm or maintained on CSM agar plates incubated 
aerobically at 30 °C. 




Strain / Relevant 
genotype 
Reference/Source 
C. albicans UB2947 SC5314 Neil Gow (University of 
Aberdeen) 
UB1941 SC5314; Δals3 (Zhao et al., 2004a) 




UB1931 NEM316 Shaynoor Dramsi (Institut 
Pasteur) 
UB2416 18RS21 Shaynoor Dramsi (Institut 
Pasteur) 
UB2417 2603V/R Shaynoor Dramsi (Institut 
Pasteur) 
UB2410 515 Victor Nizet, Univ 
California San Diego 




UB2873 515; ΔbspC (Pidwill et al., 2018), see  
Appendix B: Published 
manuscript 
UB2874 515; ΔbspC+pDC.bspC (Pidwill et al., 2018), see  
Appendix B: Published 
manuscript 
UB2414 COH1 Shaynoor Dramsi (Institut 
Pasteur) 
UB2866 COH1 Kelly Doran (San Diego 
State University) 
UB2919 COH1; ΔbspC Kelly Doran (San Diego 
State University) 
UB2875 COH1; ΔbspC+pDC.bspC Sara Rego (University of 
Bristol) 
L. lactis UB2635 NZ9800; pMSP (Rego et al., 2016b) 
UB2658 NZ9800; pMSP.bspA (Rego et al., 2016b) 
UB2659 
NZ9800; pMSP.bspC (Pidwill et al., 2018), see  
Appendix B: Published 
manuscript 
S. cerevisiae UB2161 BY4742; pBC542-CWP1 (Nobbs et al., 2010)  
UB2156 BY4742; pBC542-ALS3sm (Nobbs et al., 2010) 
E. coli UB2464 BL21; pET46.bspA Angela Nobbs (University 
of Bristol) 
UB2532 BL21; pET46.bspC Angela Nobbs (University 
of Bristol) 
 
2.2 Generation of GBS BspC mutants and L. lactis surrogate expression 
strains 
Mutant strains were developed by Dr Sara Rego and Dr Angela Nobbs.  
Using a previously described method (Maisey et al., 2007), ΔbspC mutants were 
produced in GBS strains 515 and COH1 by in-frame allelic replacement with a 
chloramphenicol resistance gene cassette by homologous recombination. To do this, 
flanking regions directly upstream and downstream of the bspC gene were amplified 
from genomic DNA using primer pairs bspC.F1/bspC.R1 and bspC.F2/bspC.R2, 
respectively (Table 2-2). Primers cat.F and cat.R were used to amplify the cat cassette 
from the chloramphenicol resistance plasmid pR326. Using stitch PCR, primers bspC.F1 
and bspC.R2 were used to combine upstream and downstream bspC and cat amplicons. 
The resultant amplicon was cloned into vector pHY304 (53) via XbaI and BamHI sites and 




propagated in E. coli Stellar cells (Clontech) prior to isolation and electroporation into 
GBS 515 or COH1 lacking the bspC gene. 
L. lactis expressing BspA and BspC were generated as described previously (Rego et al., 
2016b). Briefly, the bspA or bspC gene was amplified from GBS genomic DNA using 
primer sets pMSP.bspC.F and pMSP.bspC.R or pMSP.bspA.F and pMSP.bspA.R (Table 
2-2). This was then cloned into pMSP7517, a nisin-inducible expression vector, via NcoI 
and XhoI sites to generate plasmids pMSP.bspA and pMSP.bspC. The vector was 
transformed directly into electrocompetent L. lactis NZ9800 as described previously 
(Rego et al., 2016b).  
Transformants were confirmed by plasmid isolation and PCR, while expression of BspC in 
L. lactis was verified by dot immunoblotting. 
Table 2-2 Primers used for mutagenesis 











*Restriction endonuclease sites are underlined. 
 
2.3 Tissue culture 
Experiments were conducted using VK2/E6E7 cells (ATCC CRL-2616), an immortalised 
human vaginal epithelial cell line that behaves similarly to the natural tissue (Steele and 
Fidel, 2002;Donnarumma et al., 2014;Sheen et al., 2011;Fichorova et al., 2011). Vaginal 
epithelial cells (VECs) were cultured in K-SFM (Keratinocyte Serum-Free Medium 
[Gibco®]) supplemented with 0.4 mM CaCl2, 0.125 mg Bovine Pituitary Extract and 0.1 ng 
Epidermal Growth Factor. Cells were cultured in 75 cm2 flasks (Corning®) at 37 °C, 5% 




CO2 and were passaged upon reaching 70-80% confluence, as per ATCC 
recommendations. Briefly, VECs were incubated with 3 mL TrypLE™ trypsin replacement 
enzyme (Fisher) for 15 min. TrypLE™ was neutralised with 7 mL Dulbecco’s Modified 
Eagle’s Medium (DMEM [Sigma]) supplemented with 10% Foetal Bovine Serum (FBS 
[Sigma]), and VECs were harvested. Cells were seeded into a fresh 75 cm2 flask or 24-
well plate, as appropriate.  
 
2.4 Epithelial association assay 
Microbial association assays were carried out similarly to those by (Sheen et al., 2011), 
with some modifications. VECs were seeded into a 24-well plate (Corning®) at 2x105 
cells/well, as determined by a cell counter, and incubated at 37 °C, 5% CO2 until cells 
formed a confluent monolayer (24-48 h). An overnight broth culture of C. albicans was 
harvested (5000 g, 5 min), washed once in PBS (Lonza) and the pellet was suspended 
and adjusted to an OD600 1.0 in K-SFM before 1:2 dilution into K-SFM to give 
approximately 5x105 cells/mL. GBS or L. lactis cultures were similarly prepared and the 
adjusted suspension diluted 1:200 into K-SFM to give a suspension of approximately 
5x105 cells/mL. Wells containing VEC monolayers were washed once with PBS and, for 
monospecies assays, approximately 5x105 bacteria or C. albicans were then added to 
each well (MOI 2.5). Bacterial suspensions were incubated at 37 °C, 5% CO2 for 1 h, 
whilst C. albicans suspensions were incubated for 2 h. In dual-species assays, C. albicans 
suspensions were incubated for 1 h (with fresh K-SFM in control wells), then removed 
prior to addition of either GBS or L. lactis and incubated for a further 1 h. For all assays, 
wells were then washed three times with PBS. The plate was incubated at 37 °C, 5% CO2 
for 15 min following addition of 200 μL of TrypLE™ to disperse the cells, followed by two 
20 min incubations with ice cold water (500 μL) to lyse the epithelial cells. Lysates were 
transferred to 1.5 mL microcentrifuge tubes, vortexed for 10 s to mix and serially diluted 
with appropriate broth. Numbers of associated GBS, L. lactis or C. albicans were then 
determined by viable count. Lysates from dual-species assays were pipetted onto either 
THY agar plates (GBS) or GM17 agar plates (L. lactis) supplemented with 50 μg/mL 
nystatin (Sigma) to inhibit C. albicans growth. For experiments which required the 
colony forming units per mL (CFU/mL) of C. albicans to be determined, lysates were 
plated onto SAB agar plates supplemented with 5 μg/mL erythromycin to inhibit 




bacterial growth. All plates were incubated overnight before colonies were counted and 
numbers of associated bacteria (CFU/mL) determined. 
 
2.5 Invasion assay  
Invasion assays were carried out to determine the number of GBS or L. lactis cells that 
internalised into VEC monolayers during an epithelial association assay. Cells were 
inoculated with a ten times higher inoculum for GBS assays (MOI 25), or 100 times 
higher for L. lactis (MOI 200), to allow reliable detection of numbers of internalised 
bacteria. The invasion assay was performed as described above (section 2.4) with the 
exception that, following incubation of VEC monolayers with microbes, monolayers 
were incubated with 0.5 mL K-SFM supplemented with 200 μg/mL gentamicin (Sigma) 
and 10 μg/mL penicillin G (Sigma)]. These antibiotic concentrations were similar to those 
described in the literature as sufficient to kill GBS (Stoner et al., 2015;Sheen et al., 2011), 
and this was verified prior to use in the assays. Plates were then incubated at 37 °C, 5% 
CO2 for 2 h, before monolayers were washed with PBS and lysed as described above. 
Any bacteria that remained viable were assumed to have invaded the VECs and thus 
been protected from the antibiotics. To investigate the effects of longer incubation 
times on invasion, after 1 h incubation with GBS, media were removed and 1 mL of fresh 
K-SFM was added to each well. VECs were then incubated for a further 4 h before 
addition of antibiotic-supplemented K-SFM, as described above. 
 
2.6 Gram stain of VEC association assay 
In a variation of the association assay, VECs were grown on sterile 19 mm round glass 
coverslips, seeded at 2x105 cells/well, and grown at 37°C, 5% CO2 until confluent (48-72 
h). The assay was carried out as described in section 2.4 up to the final PBS washes, after 
which coverslips were air-dried and heat-fixed. The coverslips were then Gram stained 
and mounted with DPEX (VWR). Gram stained samples were visualised by light 
microscopy on a table-top Leica DMLB microscope. 
 




2.7 Confocal microscopy 
In a variation of the association assay, VECs were grown on sterile 19 mm round glass 
coverslips, seeded at 2x105 cells/well, and grown at 37°C, 5% CO2 until confluent (48-72 
h). The assay was carried out as described in section 2.4 up to the final PBS washes, after 
which calcofluor white (0.00001% in dH2O) was added to coverslips to stain chitin in the 
C. albicans cell wall. Coverslips were fixed in 2% paraformaldehyde (PFA) for a minimum 
of 45 min. Epithelial cells were permeabilised with 0.3% Triton X-100 for 10 min before 
blocking in 2% BSA for 45 min. Coverslips were then incubated with mouse anti-GBS 
antibody (0.5 μg/mL, Santa Cruz Biotechnology), before incubation with goat anti-mouse 
Alexafluor-488 (10 μg/mL, Fisher). Epithelial cells were labelled with phalloidin 
conjugated to TRITC (Sigma), which stains F-actin. Vectashield (Vector labs) was used to 
mount coverslips onto glass slides and nail varnish was used to fix coverslips in place. 
Coverslips were imaged on a Leica SP5-AOBS confocal scanning laser microscope (CSLM) 
attached to a Leica DM I6000 inverted epifluorescence microscope. Images were 
processed using Volocity® software and Imaris® v7.5 software (Bitplane AG) was used to 
calculate biovolumes (µm3). 
 
2.8 Transwell studies 
In a variation of an association assay (section 2.4), C. albicans was prepared as described 
above, and incubated with VECs for 1 h at 37 °C, 5% CO2. GBS was prepared as described 
(section 2.4) and was added to the top compartment of transwell inserts with high 
density 0.4 μm pores (Sarstedt) suspended above wells containing C. albicans and VECs. 
This was incubated for 1 h at 37 °C, 5% CO2. Cells were washed, lysed and lysate serially 
diluted as described for an association assay onto SAB agar for determination of C. 
albicans CFU/mL.  
 
Figure 2-1 Schematic of a transwell. 




Schematic showing a tissue culture well with a transwell insert. VECs (yellow) are seeded into a 24 well plate 
and grown to confluence before incubation with C. albicans(blue). A transwell insert is added to the well, 
and GBS (green) is added to the top compartment. 
 
2.9 Conditioned media studies 
In a variation of an association assay (section 2.4), C. albicans or GBS were prepared as 
described above, and incubated separately on VECs for 1 h at 37 °C, 5% CO2, or at the 
same concentration planktonically at 37 °C, 220 rpm. Media was pooled and filter 
sterilised. 
C. albicans or GBS were harvested from an overnight broth culture, washed once in 5 mL 
PBS and adjusted to OD600 1.0 in K-SFM. This suspension was diluted 1:2 (C. albicans) or 
1:200 (GBS) into either blank K-SFM, or sterilised media from either planktonic or cell-
grown C. albicans or GBS, as appropriate, and incubated with VECs at 37 °C, 5% CO2 for 1 
h. Cells were washed, lysed and the lysate serially diluted onto appropriate agar to 
determine viable counts, as for an association assay. 
 
2.10 AgI/II inhibition assay 
In a variation of an association assay, VECs were grown to confluence in 24 well plates. 
GBS was harvested from an overnight broth culture, washed in PBS (5 mL) and incubated 
for 30 min with 10 µg/mL anti-BspA or anti-BspC antibody (Eurogentec), as appropriate, 
or 10 µg/mL rabbit preimmune sera (Eurogentec) as negative control. GBS was 
harvested and adjusted to OD600 1.0, before 1 mL of adjusted GBS suspension (MOI 2.5) 
was added to VECs and incubated for 1 h at 37 °C, 5% CO2. Cells were lysed, and lysate 
was serially diluted onto agar to determine viable counts. 
 
2.11 Visualisation of dual-species planktonic interactions 
An overnight C. albicans broth culture was harvested at 5000 g for 5 min and washed 
once in YNBPT (0.67% Yeast Nitrogen Base [Appleton Woods], 20 mM Na2HPO4 adjusted 
to pH 7 with KH2PO4, 0.1% tryptone). The pellet was suspended and adjusted to OD600 




1.0 in YNBPT. The adjusted suspension was diluted 1:10 into YNBPTG (YNBPT 
supplemented with 0.4% glucose), 2 ml was transferred to a sterile glass bijou, and 
incubated at 37 °C, 220 rpm for 2 h before addition of bacteria. 
An overnight GBS or L. lactis broth culture was harvested at 5000 g for 7 min, washed 
once in YNBPT, and the pellet was suspended in 1.5 mM fluorescein isothiocyanate 
(FITC) dissolved in carbonate buffer (0.53% Na2CO3, 0.59% NaCl), then incubated for 30 
min at 50 rev/min to fluorescently stain the bacterial cells. Labelled bacteria were 
harvested, washed three times in carbonate buffer and the pellet suspended and 
adjusted to OD600 0.5 in YNBPTG. GBS or L. lactis (1 mL) was added to the C. albicans and 
incubated for a further 1 h at 37 °C, 220 rpm. Calcofluor white  was added to stain C. 
albicans, before visualisation of a 10-15 μL aliquot of the suspension by fluorescence 
microscopy using a table-top Leica DMLB microscope. For quantification assays, 
approximately 40 hyphae were randomly selected from each experimental group and 
imaged. Interactions were scored into one of four groups: 0 interacting bacteria per 
hyphae, 1-5 bacteria, 6-20 bacteria and more than 20 bacteria per hyphae. This was 
similar to semi-quantitation described by (Silverman et al., 2010). 
 
2.12 S. cerevisiae-L. lactis interactions in suspension 
In a variation of the above assay (section 2.11), S. cerevisiae was harvested from an 
overnight broth culture at 5000 g for 5 min and washed once in YNBPT (5 mL). Cells 
were then labelled in 1.5 mM FITC at 50 rev/min for 30 min to fluorescently stain the 
yeast cells. Stained S. cerevisiae was then harvested and washed in carbonate buffer 
three times. The pellet was suspended and adjusted to OD600 1.0 in YNBPTG, diluted 1:5 
into YNBPTG (final volume 2 mL), and incubated at 30 °C, 220 rpm for 3 h. L. lactis was 
harvested from an overnight broth culture at 5000 g for 7 min, washed once in YNBPT (5 
mL) and stained with TRITC (0.1 mg/mL in carbonate buffer) for 30 min with gentle 
agitation. Labelled L. lactis was harvested, washed in carbonate buffer three times and 
adjusted to OD600 0.5 in YNBPTG. 1 mL of this suspension was added to S. cerevisiae and 
microbes were incubated for a further 1 h at 30 °C, 220 rpm. 10 µL samples were 
visualised by fluorescence microscopy using a table-top Leica DMLB microscope.  
 




2.13 VEC viability testing  
Supernatants from association assays (section 2.4) were collected and investigated for 
the presence of lactate dehydrogenase (LDH) using the CytoTox 96® Non-Radioactive 
Cytotoxicity Assay (Promega), according to manufacturer’s specifications. Briefly, 50 μL 
of assay supernatant was mixed with 50 μL of reagent in a 96 well plate and incubated at 
room temperature for 30 min in the dark. The reaction was halted by the addition of 50 
μL of Stop Solution, and the absorbance was measured at 490 nm by a fluorescence 
plate reader (iMarkTM microplate absorbance reader, BioRad). To establish the maximum 
LDH release, lysis solution (Promega) was added to control cells. The percentage cell 
cytotoxicity was calculated by dividing experimental LDH release (OD490) by the 
maximum LDH release (OD490) and multiplying by 100. 
To further demonstrate the viability of the VEC monolayer, brightfield images were 
taken with a table-top Olympus CKX41 inverted microscope at each stage of microbial 
association assays. 
 
2.14 Microbial growth in dual-species broth cultures 
To test the effect of co-incubation on microbial growth, microbes were incubated 
together in suspension at 37 °C, 220 rpm in K-SFM. C. albicans was harvested from an 
overnight broth culture and washed once in PBS before adjustment to an OD600 of 1.0 in 
K-SFM. The adjusted suspension was diluted 1:10 into K-SFM (2 mL final volume) and 
incubated in sterile glass bijious at 37 °C, 220 rpm for 2 h. GBS was harvested from an 
overnight broth culture, washed once in 5 mL PBS and adjusted to OD600 0.5 in K-SFM. 1 
mL of this suspension was added to the C. albicans bijious (or to 2 mL K-SFM for 
controls). Suspensions were incubated for a further 1 h at 37 °C, 220 rpm. Bijious were 
vortexed for 10-15 s before serial dilution into THY broth. CFU/mL were determined by 
plating onto appropriate agar.  
 




2.15 Immunofluorescence staining of GBS 
An overnight broth culture of GBS was harvested, washed once in PBS (5 mL), and 
adjusted to OD600 1.0 in PBS. This suspension was harvested and resuspended in 4% w/v 
PFA(4 mL), before incubation at RT under gentle agitation for 30 min. The suspension 
was harvested and washed twice in PBS (1 mL) before incubation in 10% rabbit serum (1 
mL) for 30 min at RT under gentle agitation. Cells were then washed once in PBS (1 mL) 
before incubation with primary antibody (either anti-BspA or anti-BspC, as appropriate; 
1:200 dilution in PBS) for 1 h at RT under gentle agitation. Cells were washed twice more 
in PBS (1 mL), followed by incubation with anti-rabbit Alexafluor-555 secondary antibody 
(1:200 dilution in PBS) for 1 h at RT under gentle agitation. Cells were washed a final two 
times in PBS (1 mL), resuspended in 200 μL PBS, and 10 μL visualised by fluorescence 
microscopy using a table-top Leica DMLB microscope.  
For experiments investigating the effects of temperature on AgI/II family protein 
expression, overnight broth cultures were set up at either 30 °C in a candle jar, 34°C or 
37°C, 5% CO2, while for experiments investigating the effects of growth phase, bacteria 
were harvested from overnight broth cultures grown at 37°C, 5% CO2, washed once in 
PBS (5 mL), and adjusted to OD600 1.0 in THY broth (5 mL) before dilution 1:10 into pre-
warmed THY broth (15 mL). The optical density was tested every 30-60 min as 
appropriate until reaching OD600 0.2-0.3 (early exponential) or OD600 0.8-0.9 (late 
exponential). Cells were harvested and adjusted to OD600 1.0 in PBS prior to fixation and 
labelling, as described above. 
 
2.16 Dot blot 
Aliquots (2 μL) of GBS overnight broth culture, alongside aliquots of five successive 1:2 
dilutions, were transferred onto a nitrocellulose membrane and air dried. The 
membrane was blocked in Tris-buffered saline (TBS; 10 mM Tris, 0.15 M NaCl, pH 8) with 
10% milk for 1 h. The membrane was washed once in TBST (TBS with 0.1% Tween-20) 
before probing with rabbit anti-BspC antibody diluted 1:100 in TBST with 1% milk for 1 h. 
After 3 washes in TBST, the membrane was probed with swine anti-rabbit HRP diluted 
1:1000 in TBST with 1% milk for 1 h. The membrane was washed a further two times in 
TBST before a final wash in TBS. Enhanced chemiluminescence solution (GE Healthcare) 




was transferred onto the blots and incubated for 1 min. Blots were exposed to X-ray 
film. 
 
2.17 Real-time RT-PCR 
VECs were grown to confluence in 75 cm2 tissue culture flasks (Corning®) before 
incubation with C. albicans (10 mL, MOI 2.5) at 37 °C, 5% CO2 for 4 h, or with GBS strain 
NEM316 or COH1 (10 mL, MOI 5) for 3 h.  Alternatively, VECs were incubated with C. 
albicans for 1 h followed by GBS for a further 3 h. Flasks were washed three times with 
PBS to remove non-adherent microbes before TrypLE™ trypsin replacement enzyme (4 
mL) was added and flasks were incubated at 37 °C, 5 % CO2 for 15 min to suspend 
monolayers. DMEM with 10% FBS (4 mL) was added to neutralise the trypsin, and 
remaining adherent cells were scraped into solution using a cell scraper (Fisher). Cells 
were harvested at 800 g for 10 min, and RNA was extracted using the Qiagen RNeasy 
mini kit (Qiagen), as per manufacturer’s instructions. Purified RNA was digested with 
RQ1 DNase (Promega), followed by RNA clean-up using the RNeasy mini kit, as per 
manufacturer’s instructions. The concentration of RNA was measured at an absorbance 
of 260 nm using a Nanodrop spectrophotometer. RNA was converted to cDNA according 
to manufacturer’s instructions using iScript Reverse Transcriptase (Biorad), which 
contains oligo (dT) and random primers, and incubated at 25 °C for 5 min, followed by 
42 °C for 30 min, then 85 °C for 5 min, before being held at 4 °C. All cDNA samples were 
tested alongside equivalent NRT (no reverse transcriptase) control samples with GAPDH 
primers (Table 2-3) by end-point PCR to confirm successful cDNA synthesis and verify 
lack of DNA contamination in RNA preparations. 
Once generated, cDNA was used for real-time qPCR using iSYBR green (Biorad), 
according to manufacturer’s instructions, and seven primer sets (Table 2-3): IL-1α, IL-1β, 
IL-8, IL-17, IL-23, IL-36γ and GAPDH, the latter serving as endogenous control. A Biorad 
CFX Connect real time PCR machine was used with the following programme: 95 °C for 3 
min, followed by 40 cycles of 95 °C for 15 seconds, 58 °C for 30 seconds and 72 °C for 30 
seconds, and finishing with a melt curve analysis increasing by 0.5 °C from 58 °C to 95 °C. 
Data were analysed using the ∆∆Ct method. Ct value was defined as the change in the 
cycle number the data exceeded the significance threshold between a test sample for 
the endogenous control and the Ct value for the cytokine of interest, and this Ct 




difference was taken away from the equivalent value for the control sample (in this case 
VEC only) with the resulting figure interposed to the power of 2 to generate the 
expression ratio.  
Table 2-3 Primers used for RT-PCR 
Name Sequence (5’→3’) Target 
GAPDH_F GGAAGGACTCATGACCACAG RT-PCR primer: GAPDH 
GAPDH_R TTGGCAGGTTTTTCTAGACG RT-PCR primer: GAPDH 
IL-1α_F CCCAAAACCATCACAGGTAG RT-PCR primer: IL-1α 
IL-1α_R GCACACCCAGTAGTCTTGCT RT-PCR primer: IL-1α 
IL-1β_F AATCTCCGACCACCACTACA RT-PCR primer: IL-1β 
IL-1β_R GAAAGAAGGTGCTCAGGTCA RT-PCR primer: IL-1β 
IL-8_F GTTTTGCCAAGGAGTGCTAA RT-PCR primer: IL-8 
IL-8_R CCAGACAGAGCTCTCTTCCA RT-PCR primer: IL-8 
IL-17_F CTACAACCGATCCACCTCAC RT-PCR primer: IL-17 
IL-17_R CCACGGACACCAGTATCTTC RT-PCR primer: IL-17 
IL-23_F CAGTTCTGCTTGCAAAGGAT RT-PCR primer: IL-23 
IL-23_R ATCTGCTGAGTCTCCCAGTG RT-PCR primer: IL-23 
IL-36γ_F TGAGAAGGTTGGAGAACAGC RT-PCR primer: IL-36γ 
IL-36γ_R GGTGGAGGTCCTACCAGTCT RT-PCR primer: IL-36γ 
 
2.18 Proteomics 
VECs were grown to confluence in 75 cm2 tissue culture flasks (Corning®) before 
incubation with C. albicans (10 mL, MOI 2.5) at 37 °C, 5% CO2 for 4 h, or with GBS strain 
NEM316 (10 mL, MOI 10) for 3 h. Alternatively, VECs were incubated with C. albicans for 
1 h followed by addition of GBS and incubation for a further 3 h. Monolayers were 
washed three times with PBS (5 mL) before 2 mL of 8 M urea was added. Cells were 
scraped into suspension, before centrifugation at 17000 g for 10 min, 4 °C. Supernatants 
were recovered and the protein concentration determined using a Bradford assay, 
before being snap frozen in liquid nitrogen and stored at -70 °C. Samples were then 
transported to the biochemistry proteomics facility, where proteins were precipitated 
using acetone before total protein was digested with trypsin. 
Peptides were separated and identified by tandem mass-tagging (using Fisher 10-plex 
reagents) followed by mass spectrometry. Spectra were generated for each peptide 
which were used to identify the theoretical amino acid number, isoelectric point and 
molecular weight. This data was inputted into the FASTA database in order to identify 
the peptides. Peptide data were excluded if detected in only one of the two replicates 




per sample, or if only one of the replicates exceeded the threshold value which was 
considered significant (i.e. either more than 2-fold increase or decrease in protein 
expression relative to VEC only control). Peptides which were significantly altered in 
expression in relation to the VEC control were then analysed.  
 
2.19 Neutrophil isolation 
Blood was collected from anonymous, healthy volunteers, who provided written 
informed consent. The University of Birmingham School of Biosciences Institutional 
Review Board approved the protocol for blood collection and isolation of neutrophils 
from healthy volunteers. 1.098 density Percoll (GE Healthcare) was layered under 1.079 
density Percoll to create a sucrose gradient. Blood was layered on top of this, and 
separated by centrifugation at 150 g for 8 min, followed by 1200 g for 10 min. The 
neutrophil layer was collected and transferred to a fresh tube. Lysis buffer (0.83% 
ammonium chloride) was added, and cells were incubated at RT for 2 min to allow lysis 
of any contaminating red blood cells. Cells were harvested at 350 g for 6 min, and the 
pellet was suspended in 1 mL K-SFM. Neutrophils were counted using a 
haemocytometer, and cells were diluted into K-SFM as necessary.  
 
2.20 Neutrophil chemotaxis 
Neutrophils were tested for chemotaxis stimuli in response to supernatant harvested 
from VEC monolayers grown in 24-well plates that had been exposed to GBS strains 
NEM316, 515 or COH1 (MOI 2.5) for 5 h, or C. albicans (MOI 2.5) for 6 h, or C. albicans 
for 1 h followed by GBS for 5 h. Supernatant from each well was clarified by 
centrifugation (17000 g, 7 min), and 800 µL transferred to a sterile microcentrifuge tube 
for storage at -20 °C prior to use. 
Neutrophils were stained with 250 nM Syto13 (Fisher) and incubated in the dark at RT 
for 20 min. Neutrophils were then harvested at 300 g for 4 min and suspended in 1 mL 
K-SFM with 0.01% BSA. Chamber slides (Ibidi) were loaded with neutrophils in the 
central viewing chamber, as per manufacturer’s instructions. Neutrophils were 




incubated at RT for 10 min to allow initial adherence before exposure to stimuli. For all 
chambers used, K-SFM was added to the left hand chamber, while 1:2 diluted test 
sample was added to the right hand chamber. 200 nM FMLP (Sigma) was used as a 
positive control alongside VEC supernatants. A microscope was set up with the viewing 
area of each of the chamber slides in a tile scan. Images were taken of each of the 
viewing areas every 2 min for 1 h (i.e. 31 time points per sample) using a Zeiss 
microscope. Stacks of images were analysed in Fiji imaging software (ImageJ), using the 
‘Trackmate’ plugin to generate positional data about neutrophils in a stack of images. 
Neutrophils which could not be tracked for all 31 time points were excluded. These data 
were then subject to further analysis with the Ibidi Chemotaxis and Migration Tool 
software (Ibidi).  
 
2.21 Purification of recombinant Bsp protein and antibody generation 
E. coli strains expressing BspA and BspC protein (UB2464 and UB2532, respectively, 
Table 2-1) were inoculated into LB broth (100 mL) with 50 μg/mL carbenicillin and grown 
overnight at 37 °C, 180 rpm. Bacterial suspensions were then diluted 1:10 into LB broth 
with 50 μg/mL carbenicillin and grown to OD600 0.6. IPTG was added to a final 
concentration of 1 mM to induce protein expression, and suspensions were grown at 18 
°C, 180 rpm overnight. Bacteria were harvested at 5000 g for 15 min at 4 °C. Pellets were 
suspended in gel filtration buffer (20 mM Tris, 150 mM NaCl, pH 7.5), cells harvested at 
4500 g, 15 min, 4°C, and pellets stored at -80 °C. Frozen pellets were suspended in 45 
mL loading buffer (50 mM Tris, 150 mM NaCl, 20 mM imidazole, pH 7.5) with protease 
inhibitor cocktail (PIC; Sigma) and homogenised, before samples were passed through a 
cell disrupter. The resulting mixture was then centrifuged at 18000 g for 25 min at 4 °C. 
The supernatant was collected and loaded onto a nickel column (Sigma). Samples were 
processed by nickel affinity chromatography using an AKTA machine. Undesired proteins 
were washed off the column with loading buffer, while BspA or BspC was eluted with 
elution buffer (50 mM Tris, 150 mM NaCl, 1 M imidazole, pH 7.5). 10 μl aliquots of 
fractions that produced protein peaks were denatured at 95 °C for 5 min before being 
run on a pre-cast Tris-glycine SDS PAGE gel (NuSep) at 200 V for 40 min. Gels were 
stained with Coomassie Blue, and fractions with protein at ~100 kDa were combined and 
concentrated using a 50,000 molecular weight concentrator at 4500 g until the total 




volume was <5 mL. Aggregated protein was harvested at 14000 g for 10 min, 4 °C, and 
the supernatant was loaded onto an AKTA machine for separation by size exclusion 
chromatography. 10 μl aliquots of fractions that produced protein peaks were analysed 
by SDS PAGE, as above. Fractions containing purified Bsp protein were pooled, dialysed 
into dH2O with 0.1% PIC and 0.2% PMSF, concentrated as above, and stored at -80 °C. 
Pre-immune sera was collected from potential rabbits and screened against BspA and 
BspC purified proteins to test for reactivity. Rabbits with no antigenicity to BspA/C were 
selected for antibody generation. To do this, Eurogentec immunised rabbits with 
purified protein four times, once on day one of the immunisation schedule, then days 7, 
10 and 18. The final bleed was collected 28 days after initial immunisation and 
antibodies were purified from this.  
 
2.22 Statistical analysis 
Data were analysed by either Student’s unpaired t-test (with Bonferroni correction for 
multiple groups) or by one-way ANOVA with Tukey post-test in SPSS Statistics (version 
24; IBM), as indicated. All assays were independently repeated in triplicate with three 
experimental replicates unless otherwise stated. 




Chapter 3 Interactions between GBS and C. albicans 
3.1 Introduction 
As detailed in Chapter 1, C. albicans is commonly found as a member of polymicrobial 
communities within the human host. Moreover, these polymicrobial interactions have 
often been shown to modulate the colonisation and pathogenic capabilities of the 
microorganisms involved. Such precedent meant that a similar dynamic may occur 
between C. albicans and GBS, which are both opportunistic pathogens of the female 
genital tract. An association between these two microorganisms was also supported by a 
number of clinical observations. Bayo et al. (2002) found that 54.5% of GBS isolated 
from the vaginal tract of pregnant women co-isolated with C. albicans, although 
relatively few (43) women were colonised with GBS (Bayo et al., 2002). In a larger study, 
1284  vaginal swabs (32% of those collected) were identified as positive for GBS and of 
these, 457 (38%) were found to be colonised with C. albicans (Meyn et al., 2009). 
Consequently, C. albicans was described as a risk factor for GBS vaginal colonisation. 
This was also supported by earlier studies. Monif and Carson (1998) found that GBS was 
isolated from vaginal swabs more frequently with C. albicans than without (27.3% rather 
than 16%) (Monif and Carson, 1998). Likewise, risk of GBS vaginal colonisation in 
pregnancy was shown to be greater when Candida was co-isolated, with 35.8% of C. 
albicans positive swabs also testing positive for GBS (Regan et al., 1991). All of these 
studies focused on women in the US/Europe, but a comparable trend was also reported 
by a study of vaginal GBS carriage in Kenya and South Africa, where it was found that C. 
albicans colonisation was an independent risk factor for GBS vaginal colonisation, with 
25% (17 of 67) of GBS-positive vaginal swabs also testing positive for C. albicans (Cools 
et al., 2016).  
A correlation between occurrence of C. albicans and GBS had also been reported for 
studies from a candidal perspective. A study investigating vaginal colonisation by yeast 
(98% of which was identified as C. albicans), found that vaginal GBS co-colonisation was 
significantly associated with yeast colonisation (Beigi et al., 2004). Likewise, a study of C. 
albicans vaginal colonisation amongst pregnant women found that 36.8% (i.e. 419 of 
1139 women) of C. albicans-positive vaginal swabs were also positive for GBS, compared 
to 19.5% in uncolonised women (Cotch et al., 1998).  




The reported co-occurrence of GBS and C. albicans within the GU tract provided 
evidence that these two microorganisms had the potential to interact and modulate 
colonisation of the vaginal mucosa and thus subsequent disease risk. These studies 
therefore aimed to explore the relationship between GBS and C. albicans, and to 
determine what effect (if any) this had on colonisation of VECs. 
 
3.2 Results 
3.2.1 Planktonic interactions between GBS and C. albicans 
A common mechanism by which two microorganisms may interact is via coaggregation 
under planktonic conditions. The first step of this project was therefore to establish 
whether GBS and C. albicans were capable of coaggregating. To enable this, 5 strains of 
GBS were investigated: NEM316, 18RS21, 2603V/R, 515 and COH1. These 5 strains were 
selected to cover the most common GBS capsular serotypes associated with disease 
(Table 3-1). This would then potentially enable any capsular polysaccharide (CPS) 
specific effects on coaggregation capabilities to be identified. As several bacterial 
species, including GBS, had been reported to exhibit a tropism for C. albicans hyphae 
rather than blastospores (Rego et al., 2016b;Peters et al., 2012;Silverman et al., 2010), C. 
albicans was induced to form hyphae by pre-incubation in growth medium 
supplemented with glucose. Each GBS strain was then incubated with C. albicans in 
suspension for 1 h. Microbes were fluorescently labelled with FITC (GBS, green) or 
Calcofluor White (C. albicans, blue), before visualisation by fluorescence microscopy 
(Figure 3-1A). Semi-quantitative analysis was also performed, for which images were 
taken of approximately 40 randomly-selected hyphae per replicate, and each hypha was 
allocated a score according to the number of GBS bound to it (Figure 3-1B). 
Table 3-1 Overview of selected GBS strains used in these studies 
GBS strain CPS CC Pili 
NEM316 III 23 PI-1 and PI-2a 
18RS21 II 19 PI-1 and PI-2a 
2603V/R V 19 PI-1 and PI-2a 
515 Ia 23 PI-2a 
COH1 III 17 PI-1 and PI-2b 
 




From these data it was apparent that GBS interactions with C. albicans were strain-
dependent. GBS strains NEM316 and 515 exhibited the highest levels of coaggregation 
with C. albicans, with 51% and 43% of hyphae, respectively, observed with >20 
interacting bacteria, while this was <3% for 18RS21, 2603V/R and COH1 (Figure 3-1). For 
GBS strains 18RS21, 2603V/R and COH1, the majority (86%, 80% and 84%, respectively) 
of C. albicans hyphae randomly selected for semi-quantitation had only 0 or 1-5 
interacting bacteria (Figure 3-1). Despite these variations in coaggregation capacity, all 
of the GBS strains were observed to show a tropism for C. albicans hyphae rather than 
blastospores. This supported data previously described by (Rego et al., 2016b) for GBS 
strain NEM316.  





Figure 3-1 Planktonic suspension interactions between GBS and C. albicans.  
A) Representative fluorescence micrographs of planktonic interactions between C. albicans and GBS. C. 
albicans was grown in YNBPTG for 2 h at 37 °C, 220 rpm before addition of GBS strain NEM316, 2603V/R, 
18RS21, 515 or COH1 (as indicated) and incubation for a further 1 h. GBS was labelled with FITC (green), 
while C. albicans was labelled with Calcofluor White (blue). Scale bars, 20 μm. B) Semi-quantitation of 
numbers of C. albicans hyphae with 0 interacting GBS, 1-5, 6-20 or >20 interacting GBS; data are presented 
as mean ± SD; n=2. 




3.2.2 Association of GBS with VK2/E6E7 cells 
As this project was ultimately focused on the interactions of GBS and C. albicans with 
vaginal epithelium, it was also important to determine the capacity for each GBS strain 
to associate with vaginal epithelial cells. For these studies, vaginal epithelial cell (VEC) 
line VK2/E6E7 was used. This cell line has been generated from vaginal mucosa obtained 
from a premenopausal woman during routine surgery, which was immortalised with the 
E6 and E7 proteins from human papillomavirus (Fichorova et al., 1997). VECs were 
incubated with GBS for 2 h before VECs were disassociated and lysed, and numbers of 
associated GBS determined by viable count following plating of the lysates onto agar. 
There were significant differences in association between the GBS strains, as indicated in 
Figure 3-2, with overall numbers of recovered GBS ranging from 1.3x106 to 3.2x106. 
Strains 18RS21 and 2603V/R exhibited the highest levels of association, followed by 
COH1 and NEM316. Strain 515 exhibited the lowest level of association of the GBS 
strains. 
 
Figure 3-2 Association of GBS strains with VECs.  
VEC monolayers were incubated with GBS suspensions (MOI 2.5) for 2 h. Monolayers were then lysed and 
numbers of associated GBS enumerated by viable count. Data are presented as mean ± SD, ** indicates 
P<0.005, as determined by one-way ANOVA with a Tukey post-hoc test; n = 4. 
 




GBS interactions with VECs were also visualised by Gram stain, in which VEC monolayers 
were stained pink with safranin, while GBS bacteria stained purple with crystal violet (  
Figure 3-3). Corresponding with the CFU/mL data displayed in Figure 3-2, GBS strains 
18RS21 and 2603V/R were observed in greater numbers than NEM316, 515 and COH1. It 
was also noted that strain 2603V/R formed longer chains of bacteria than the other 
strains. Strain 515 was observed mainly interacting with ‘giant’ cells, which possibly 
represented cells that had failed to go through successful cytokinesis, while strain COH1 
appeared to principally interact with the matrix material seen surrounding the VECs (  
Figure 3-3). Importantly, VEC monolayers remained confluent after incubation with the 
bacteria (discussed further in sub-section 1.9). 
  
It was not feasible to work with all five GBS strains throughout this project. As such, 
strains NEM316, 515 and COH1 were chosen for further studies. This selection displayed 
a range of capacities for coaggregation with C. albicans and association with VECs, while 
also representing key capsular serotypes. Strains NEM316 and COH1 are capsular 
serotype III, while 515 is serotype Ia, these being two of the three most common 
serotypes associated with severe, invasive disease (Zhang et al., 2006;Jiang et al., 
2008;Farley, 2001).  
To optimise the VEC assay for future work, the effect of incubation period on the 
number of associating bacteria was tested using GBS strain NEM316. Figure 3-4 shows 
the number of NEM316 bacteria associating with VECs at 30 minutes, 60 minutes and 
120 minutes post-incubation. There was more than a quadrupling in the number of 
bacteria associating with the VECs between 60 min (2.9x105 CFU/ml) and 120 min (2x106 
CFU/ml). To minimise potential issues with cytotoxicity, particularly when introducing a 
second microorganism (C. albicans) in subsequent work, a 1 h timepoint was selected 
for GBS incubation, unless otherwise stated. 
 





Figure 3-3 Representative brightfield micrographs of VECs incubated with GBS strains.  
VEC monolayers were grown on 19 mm sterile glass coverslips and incubated with GBS suspensions (MOI 
2.5) for 2 h. Coverslips were then Gram stained, heat fixed and mounted onto a glass slide. 





Figure 3-4 Effects of incubation time on association of GBS with VECs.  
VEC monolayers were incubated with GBS suspensions (MOI 2.5) for either 30 minutes, 60 min or 120 min, 
as indicated. Monolayers were then lysed and numbers of associated GBS enumerated by viable count. Data 
are presented as mean ± SD, n=1. 
 
3.2.3 Testing influence of C. albicans hyphae formation on GBS association with 
VECs 
Hyphae tropism had been described for a number of bacteria when interacting with C. 
albicans, including S. gordonii and S. aureus (Peters et al., 2010;Silverman et al., 2010). 
Moreover, GBS was found to preferentially bind to C. albicans hyphae rather than 
blastospores in the coaggregation studies (Figure 3-1A). With the aim of developing a 
dual-species microbial association assay, a pilot study was performed to compare the 
effects of adding GBS and C. albicans to VECs at the same time, compared to ‘priming’ C. 
albicans on the VECs first to allow hyphae formation. To investigate this, microbes were 
either added to the VECs together and incubated for 1 h, or C. albicans was pre-
incubated for 1 h with VECs before GBS was added and incubated for a further 1 h 
(Figure 3-5). The number of NEM316 bacteria recovered from VEC monolayers was 39% 
lower at 1.7x105 CFU/mL when incubated with C. albicans for 1 h compared to the 
monospecies control (2.8x105 CFU/mL) (Figure 3-5). By contrast, when C. albicans was 
pre-incubated with the VECs for 1 h before NEM316 was added and incubated for a 
further 1 h, numbers of associated NEM316 were increased by 62% to 4.5x105 CFU/mL  
relative to monospecies control (Figure 3-5). It was hypothesised that this increase was 




due to C. albicans formation of hyphae during the initial 1 h period providing additional 
targets for GBS to interact with. 
 
Figure 3-5 Effect of C. albicans pre-incubation on GBS association with VECs.  
VECs were incubated with either GBS (MOI 2.5) for 1 h, C. albicans (MOI 2.5) and GBS for 1 h, or C. albicans 
for 1 h followed by GBS for 1 h. Monolayers were lysed and numbers of associated GBS were enumerated by 
viable count. Data are presented as mean ± SD, n=1. 
 
C. albicans had been previously tested for the ability to form hyphae in K-SFM tissue 
culture medium (data not shown). To confirm the ability of C. albicans to form hyphae 
when incubated with VECs, the experiment was repeated using VECs grown on glass 
cover slips that were Gram stained after incubation with C. albicans and NEM316. 
Hyphae were visibly longer when C. albicans was incubated with VECs for 2 h compared 
to 1 h (Figure 3-6, rows 1-2). Furthermore, these differences in hyphal length were not 
affected by the presence of GBS (compare Figure 3-6, row 1 with 3, row 2 with 4), 
implying that GBS NEM316 did not inhibit the ability of C. albicans to form hyphae. Thus, 
it was concluded that C. albicans initiates hyphae formation after approximately 1 h 
incubation with VECs. Furthermore, the presence of C. albicans hyphae may enhance 
the association of GBS NEM316 with VECs. 
 





Figure 3-6 Representative brightfield micrographs of VECs incubated with C. albicans and NEM316. 
VEC monolayers were grown on 19 mm sterile glass coverslips, and incubated with C. albicans suspensions 
(MOI 2.5) for 1 or 2 h, or with C. albicans and NEM316 (MOI 2.5) for 1 h, or with C. albicans for 1 h before 
addition of NEM316 and incubation for a further 1 h. Coverslips were then Gram stained, heat fixed and 
mounted onto a glass slide. 
 




To confirm that the effects observed in Figure 3-5 were not restricted to GBS strain 
NEM316, the experiment was repeated using GBS strains 515 and COH1 alongside 
NEM316. No significant difference in GBS association was observed for any of the strains 
when C. albicans was added at the same time as GBS compared to monospecies controls 
(Figure 3-7, grey bars). However, each GBS strain was found to significantly increase in 
association with VECs when added 1 h after C. albicans (Figure 3-7, black bars). NEM316 
was promoted by 2.9-fold, 515 by 3.1-fold and COH1 by 4.5-fold. 
 
Figure 3-7 Effects of C. albicans on association of GBS with VECs.  
VEC monolayers were incubated with GBS suspensions (MOI 2.5) for 1 h (white bars) or with C. albicans 
(MOI 2.5) and GBS suspensions for 1 h (grey bars), or with C. albicans for 1 h followed by GBS for a further 1 
h (black bars). Monolayers were then lysed and numbers of associated GBS enumerated by viable count. ** 
P<0.01, NS P>0.01 when compared against the monospecies controls, as determined by unpaired Student’s 
t-test with Bonferroni correction. Data are presented as mean ± SD, n=4. 
 
These data indicated an intriguing potential relationship between C. albicans and GBS, 
which became the focus of subsequent studies. Thus, for all future experiments, C. 
albicans was pre-incubated with the VECs for 1 h before addition of bacteria. 
At this point, the COH1 GBS strain was exchanged. This was due to a personal 
communication from Dr Kelly Doran (San Diego State University) in which it was 
indicated that the COH1 strain should interact strongly with VECs. Dr Doran kindly gifted 
a stock of COH1 (designated unique reference number UB2866), and this was found to 
associate with VECs in higher numbers than seen for the previous stock. Importantly, 




however, this new stock interacted with C. albicans similarly to the previous version i.e. 
the stock coaggregated at only low levels yet was promoted in association with VECs by 
C. albicans (data not shown). 
3.2.4 Confocal micrographs of GBS and C. albicans interactions with VECs at 2 h 
In an effort to verify the apparent enhancement of GBS association with VECs by C. 
albicans as determined by viable count data, confocal micrographs of the VECs 
incubated with C. albicans and GBS were taken. VECs were grown to confluence on 19 
mm glass coverslips before incubation with C. albicans for 1 h, after which GBS strains 
NEM316, 515 or COH1 were added and monolayers were incubated for a further 1 h. C. 
albicans was labelled with Calcofluor White (blue), while the VEC actin was stained with 
phalloidin-TRITC (red) and GBS was immunolabelled with an Alexafluor-488 antibody 
(green). For NEM316, a visible increase in the number of bacteria was observed when 
incubated with C. albicans compared to monospecies controls (Figure 3-8). This was not 
as obvious for strains 515 or COH1. However, biovolume (µm3) data for GBS was also 
collected as a semi-quantification method using the Volocity® software and Imaris® v7.5 
software. NEM316 biovolume rose by 1.8-fold, increasing from 936 µm3 in the 
monospecies to 1748 µm3 when incubated with C. albicans, while 515 biovolume 
increased by 3.8-fold from 118 µm3 to 449 µm3. COH1 biovolume increased by 8.9-fold, 
rising from 85 µm3 to 761 µm3. This demonstrated that for all three GBS strains, there 
was a clear increase in the number of fluorescently-stained bacteria when co-incubated 
with C. albicans on VECs than when incubated alone (Figure 3-9). This supported the 
viable count data from Figure 3-7.  





Figure 3-8 Representative confocal micrographs of C. albicans-GBS association with VECs.  
VEC monolayers were incubated with GBS (MOI 25) alone for 1 h (rows 1 and 2) or with C. albicans (MOI 2.5) 
for 1 h followed by GBS for a further 1 h (rows 3 and 4). Cells were then fixed, stained and mounted onto 
glass slides. GBS was labelled using Alexafluor-488-conjugated antibody (green), while C. albicans was 
labelled with Calcofluor White (blue), and VEC cells were labelled with phalloidin-TRITC (red). GBS strains 
NEM316 (top panels), 515 (middle panels) and COH1 (bottom panels) were tested. Rows 2 and 4 are 
duplicates of rows 1 and 3, respectively, in which the red filter (i.e. the VECs) has been removed. Scale bars, 
100 μm.  





Figure 3-9 Semi-quantification of GBS from confocal micrographs illustrated in Figure 3-8.  
Images were processed using Volocity® software and Imaris® software was used to calculate GBS 
biovolumes (µm3). White bars represent biovolume of GBS from monospecies images, while black bars show 
biovolume of GBS from dual-species images. Data are presented as mean ± SD, n=1. 
 
3.2.5 Invasion studies 
All studies thus far determined the number of associated microbes, which represents 
both the number of adherent bacteria plus any internalised bacteria. A hallmark of 
pathogenesis for these microorganisms is their ability to invade host tissues.  
Furthermore, it has been shown that invasion of epithelia by S. aureus can be facilitated 
by binding C. albicans hyphae and subsequently ‘piggy-backing’ into host cells (Peters et 
al., 2012). As such, a variation of the association assay was conducted to monitor the 
number of internalised GBS in the presence or absence of C. albicans. For these studies 
C. albicans was incubated with VEC monolayers for 1 h, followed by GBS addition and 
incubation for a further 1 h, as before. Monolayers were then exposed to media 
containing antibiotics for 2 h to kill any extracellular GBS. VECs were lysed and recovered 
GBS represented those cells that had been internalised within VECs and thus protected 
from the antibiotics. 
There was a significant (2.8-fold) decrease in the number of internalised NEM316 when 
in the presence of C. albicans compared to monospecies infection (Figure 3-10). This was 
somewhat surprising, as one might have predicted that the increase in numbers of 
associated GBS in the presence of C. albicans seen in Figure 3-7 would include 




internalised bacteria. It was hypothesised that GBS were preferentially binding C. 
albicans hyphae over VECs, which offered the potential for ‘piggy-backing’ into the VECs, 
but that 2 h may have been too early for C. albicans hyphae to have initiated invasion. 
To test this theory, the association/invasion assay was extended to 6 h (1 h C. albicans + 
5 h GBS).  
 
Figure 3-10 Effects of C. albicans on GBS invasion of VECs.  
VECs were incubated with C. albicans (MOI 2.5) for 1 h before addition of GBS strain NEM316 (MOI 25) and 
incubation for a further 1 h. Epithelial cell monolayers were then exposed to 200 μg/mL gentamicin  and 10 
μg/mL penicillin for 2 h, lysed and numbers of internalised GBS enumerated by viable count. Data are 
presented as mean ± SD,* P<0.05 when compared against the monospecies control as determined by 
Student’s t test; n=3. 
 
Under these conditions, numbers of associated bacteria were significantly promoted in 
the presence of C. albicans for all three GBS strains when compared against 
monospecies controls (Figure 3-11A). This was similar to the effect seen after 1 h 
incubation (Figure 3-7), but rather than the 2.9-fold increase observed in Figure 3-7 
when C. albicans was present, NEM316 was 5.8-fold promoted, while for 515 this was 
39.4-fold and for COH1 this was 14.7-fold.  The corresponding numbers of internalised 
GBS are represented in Figure 3-11B. Unlike the reduced levels of invasion shown in 
Figure 3-10, numbers of internalised NEM316 and COH1 were both significantly higher 
in the presence of C. albicans than for the corresponding monospecies infection. 
Invasion levels were enhanced by 6.6-fold for NEM316 and by 3.2-fold for COH1 (Figure 




3-11B). By contrast, 515 invasion levels were significantly lower in the presence of C. 
albicans, amounting to a 6-fold decrease in invasion relative to the monospecies control 
(Figure 3-11B).  
 
Figure 3-11 Effects of C. albicans on GBS association (A) and invasion (B) of VECs.  
VECs were incubated with C. albicans (MOI 2.5) for 1 h before addition of GBS (MOI 25) and incubation for a 
further 5 h. For invasion studies, epithelial cell monolayers were then exposed to 200 μg/mL gentamicin and 
10 μg/mL penicillin for 2 h, lysed and numbers of internalised GBS enumerated by viable count. ** P<0.01 
when compared to the monospecies control, as determined by unpaired Student’s t-test. Data are 
presented as mean ± SD, n=4. 
 




3.2.6 Confocal micrographs of GBS and C. albicans interactions with VECs at 6 h 
To further validate the viable count data, the confocal microscopy studies detailed in 
section 3.2.4 were repeated, with the modification that the incubation period with GBS 
was extended by 4 h, i.e. VECs were incubated with C. albicans for 1 h before GBS strains 
NEM316, 515 or COH1 were added and monolayers were incubated for a further 5 h. In 
contrast to the equivalent 2 h studies (Figure 3-8), there was a visible increase in the 
number of GBS present with C. albicans for all three GBS strains compared to the 
monospecies controls (Figure 3-12). This was particularly striking with NEM316 (Figure 
3-12, top panels) and was supported by corresponding biovolume data (Figure 3-13). 
NEM316 biovolume rose by 5.6-fold, increasing from 474 µm3 in the monospecies 
control to 2677 µm3 when incubated with C. albicans, while 515 biovolume increased by 
3.8-fold from 114 µm3 to 435 µm3. COH1 biovolume increased by 103-fold, rising from 
19 µm3 to 1996 µm3. Unfortunately, GBS strain COH1 (Figure 3-12, bottom panel) did 
not stain well with the anti-GBS primary antibody, possibly due to the fact that this 
strain is known to have a particularly thick capsule (Rubens et al., 1993;Tissi et al., 1998). 
This lack of staining likely accounts for the apparent lower numbers/biovolume of COH1 
compared to NEM316, contrary to the quantitative data represented in Figure 3-13. 
Of note, GBS was seen to be interacting with C. albicans hyphae (as indicated by white 
arrows), but there was also an increase in the numbers of bacteria interacting with areas 
of the epithelium that were not seemingly colonised by C. albicans (as indicated by red 
arrows). This suggested that direct physical interactions between GBS and C. albicans 
may not wholly explain the capacity for C. albicans to promote GBS association with 
VECs.  
Although there were examples from the confocal micrographs where C. albicans hyphae 
appeared to have invaded VECs, it could not be clearly established whether GBS were 
intracellular or extracellular. Efforts were made to establish a confocal assay which used 
differential antibody staining, so that intracellular GBS would be stained a different 
colour to extracellular bacteria. Unfortunately, however, these attempts were 
unsuccessful.  





Figure 3-12 Representative confocal micrographs of C. albicans-GBS association with VECs.  
VEC monolayers were incubated with GBS (MOI 25) alone for 5 h (rows 1 and 2) or with C. albicans (MOI 2.5) 
for 1 h followed by GBS for a further 5 h (rows 3 and 4). Cells were then fixed, stained and mounted onto 
glass slides. GBS was labelled using Alexafluor-488-conjugated antibody (green), while C. albicans was 
labelled with Calcofluor White (blue), and VECs were labelled with phalloidin-TRITC (red). GBS strains 
NEM316 (top panels), 515 (middle panels) and COH1 (bottom panels) were tested. Rows 2 and 4 are 
duplicates of rows 1 and 3, respectively, in which the red filter (i.e. the VECs) has been removed. White 
arrows indicate areas where GBS is bound to C. albicans hyphae, while red arrows indicate areas where GBS 
is found in the absence of C. albicans. Scale bars; 100 μm. 





Figure 3-13 Quantification of GBS from confocal micrographs illustrated in Figure 3-12.  
Images were processed using Volocity® software and Imaris® software was used to calculate GBS 
biovolumes (µm3). White bars represent biovolume of GBS from monospecies images, while black bars show 
biovolume of GBS from dual-species images. Data are presented as mean ± SD, n=1. 
 
3.2.7 Association of C. albicans with VECs and GBS 
Having demonstrated that C. albicans could enhance association of GBS with VECs, it 
was of interest to investigate if this effect was reciprocal. This was assessed using the 
experiment described earlier to determine numbers of GBS, with C. albicans quantified 
instead. As such, levels of C. albicans associated with VECs were determined in the 
presence or absence of GBS. Elevated numbers of C. albicans were recovered from the 
VECs for all three GBS strains (Figure 3-14). Furthermore, levels of enhancement were 
comparable (4.6-fold by NEM316, 4-fold by 515, 4.5-fold by COH1), despite the varying 
capabilities that these GBS strains exhibited in their interactions with VECs in 
monospecies infections (Figure 3-7).  





Figure 3-14 Effects of GBS on C. albicans association with VECs.  
VEC monolayers were incubated with C. albicans (MOI 2.5) for 1 h before addition of GBS (MOI 2.5) and 
incubation for a further 1 h. Monolayers were then lysed and numbers of associated C. albicans enumerated 
by viable count. Data are presented as mean ± SD,** P<0.01 when compared against the monospecies 
control as determined by unpaired Student’s t-test with Bonferroni correction; n=3. 
 
Taken together, these data suggested a synergistic relationship between C. albicans and 
GBS, in which coassociation between these two microorganisms facilitated interactions 
of both species with vaginal epithelium. 
 
3.2.8 VEC viability during microbial association assays 
Integrity of the VEC monolayers was critical to correct interpretation of the data for the 
assays performed in this chapter, as otherwise the data could simply reflect the capacity 
for the microbes to adhere to the polystyrene microtitre plate. To ensure the 
monolayers were maintained during the microbial association assays presented here, 
every time a new assay was devised, brightfield images were taken of the cell monolayer 
at each step (Figure 3-15). This confirmed that VEC monolayers were retained following 
mono- or dual-species infections after both 2 h and 6 h incubation periods. Only 
following trypsin incubation and subsequent water washes was VEC lysis apparent, as 




would be expected. The appearance of the VECs also gave some indication as to their 
apparent ‘health’. After 1 h GBS incubation and after 2 h or 6 h C. albicans incubation 
(Figure 3-15), VECs were similar in appearance to monolayers at the start of the assay. 
However, VECs incubated with NEM316 for 5 h +/-C. albicans for 1 h appeared less 
healthy. This likely reflected the fact that a higher MOI for GBS was used for the invasion 
assays, due to the fact that a much lower number of bacteria were internalised 
compared to numbers of adherent bacteria. This higher MOI could be expected to have 
greater cytotoxic effects.  
To further assess the cytotoxic effects of the mono- and dual-species infections on VECs, 
an LDH assay was used. The percentage cytotoxicity was calculated as experimental LDH 
detected over maximum LDH release (as determined following complete VEC lysis) and 
multiplied by 100. After 2 h (association assay), there was no major change in LDH levels 
for any of the strain combinations compared to the VEC-only control level of 5.7% 
(Figure 3-16A). Conversely, at 6 h post-infection (Figure 3-16B), there was a slight 
increase in cytotoxicity to 25.8% for VECs incubated with just C. albicans, although this 
was not significant. When VECs were incubated with only GBS (MOI 2.5), there was a 
slight increase in cytotoxicity with all three strains (to 23.3% for NEM316, 10.4% for 515, 
12.1% for COH1), but this was not significant. There was a steep and significant increase 
in cytotoxicity for cells incubated with both microorganisms, rising to 84.8% for C. 
albicans with NEM316, 84.1% with 515 and 62% with COH1. The high cytotoxicity of 
VECs exposed to both C. albicans and GBS over 6 h corroborates their ‘unhealthy’ 
appearance at this time point (Figure 3-12), and there is a distinct difference in cell 
morphology which can be observed when the side view of images taken at 2 h versus 6 h 
are compared (Figure 3-17). 
 





Figure 3-15 Representative brightfield images of VEC monolayers at each stage of microbial association 
assays.  
From top left to right: before an assay, after 1 h GBS incubation (MOI 2.5); after 1 h GBS incubation (MOI 
2.5) followed by PBS washes and 15 min trypsin incubation; after two 500 µL cold water washes at the end 
of an assay; after 2 h incubation with C. albicans (MOI 2.5); after 6 h incubation with C. albicans (MOI 2.5); 
after 5 h incubation with NEM316 (MOI 25); after 1 h C. albicans incubation (MOI 2.5) followed by 5 h 
incubation with NEM316 (MOI 25). Scale bars; 100 µm. 





Figure 3-16 Percentage cytotoxicity of VEC monolayers after microbial association assays.  
Supernatants were collected at the end of association assays and tested for LDH. Percentage cytotoxicity 
was calculated as experimental LDH release (OD490) divided by maximum LDH release (OD490) and multiplied 
by 100. A) Percentage cytotoxicity of VEC monolayers in response to incubation with C. albicans (MOI 2.5) 
for 2 h, GBS strains NEM316, 515 or COH1 (MOI 2.5) for 1 h, or C. albicans for 1 h followed by GBS for a 
further 1 h; n=1. B) Percentage cytotoxicity of VEC monolayers in response to incubation with C. albicans 
(MOI 2.5) for 6 h, GBS strains NEM316, 515 or COH1 (MOI 2.5) for 5 h, or with C. albicans for 1 h followed by 
5 h with GBS. ** indicates P<0.01 when compared to VEC control, § indicates P<0.01 when compared to 
monospecies GBS or C. albicans, as calculated by one-way ANOVA with Tukey post-test. Data are presented 
as mean ± SD, n=4. 





Figure 3-17 Comparison of confocal micrographs.  
A) Side view of VEC+C. albicans+NEM316 from Figure 3-8, i.e. 2 h post-infection. B) Side view of VEC+C. 
albicans+NEM316 from Figure 3-12, i.e. 6 h post-infection. Scale; 100 µm. 
 
3.3 Discussion 
The studies presented in this chapter sought to investigate the interactions of GBS with 
C. albicans, and the capacity for any such interactions to modulate association with 
VECs. Under planktonic conditions, all five strains of GBS tested were able to 
coaggregate with C. albicans, albeit to variable levels. Moreover, all five GBS strains 
were observed to exhibit a tropism for C. albicans hyphae rather than blastospores, as 
has been described for other bacteria, including streptococci such as S. gordonii, S. oralis 
and S. sanguinis (Jenkinson et al., 1990;Silverman et al., 2010;Bamford et al., 2009). This 
implies that GBS and C. albicans are coaggregation partners, although the precise nature 
of this partnership, at least for GBS, is clearly strain-dependent. The extent to which 
different GBS strains coaggregated with C. albicans did not correlate with capsular 
serotype, suggesting that capsular polysaccharide does not directly mediate the 
coaggregation interactions. Nonetheless, levels of CPS expression may impact 
coaggregation capacity via potential masking of the GBS receptor(s) targeted by C. 
albicans. Indeed, GBS strain COH1, which exhibited the lowest levels of coaggregation of 
the five GBS strains tested, is known to produce a particularly thick capsule (Rubens et 
al., 1993;Tissi et al., 1998). Alternatively, differences in the coaggregation profiles of the 
GBS strains may reflect variations in the expression levels of another surface-expressed 
determinant(s). Despite variable levels of coaggregation, the fact that all five GBS strains 
preferentially bound candidal hyphae suggested that GBS strains may target a common 
hyphal receptor. This was investigated and is presented in Chapter 4.   
The tropism of GBS for C. albicans hyphae was also seen in the context of these 
microorganisms associating with VECs. When C. albicans blastospores and GBS strains 
NEM316, 515 or COH1 were added to VEC monolayers simultaneously, comparable 




numbers of GBS cells were recovered relative to monospecies control. This implies that 
blastospores and GBS cells were not competing for VEC binding sites, and thus suggests 
that either these microorganisms target different VEC receptors, or that receptor 
availability was of sufficient abundance to support association by both microbes. By 
contrast, the presence of candidal hyphal filaments that had already associated with VEC 
monolayers resulted in enhanced association levels by all three GBS strains. 
Coaggregation studies had indicated the capacity for GBS to bind directly to C. albicans 
hyphae. One likely explanation for these effects was therefore that C. albicans hyphae 
provided additional binding sites to GBS alongside the VECs. In support of this, confocal 
micrographs showed GBS cells bound to C. albicans hyphae, and with increasing 
incubation period and thus extent of hyphal filamentation, so the interactions between 
GBS and candidal hyphae became more apparent, and the scale of enhanced GBS 
association with VECs in the presence of C. albicans more pronounced. Genes controlling 
hyphae formation were found to be upregulated when C. albicans was grown in the 
presence of S. gordonii (Dutton et al., 2016). If a similar effect was mediated by GBS, this 
could further enhance GBS interactions with VECs. However, while not quantified 
directly, there was no indication that GBS affected fungal morphology. 
Alongside the direct physical C. albicans-GBS interactions in the presence of VECs, there 
was also a significant increase in the number of bacteria binding VECs in areas where C. 
albicans was not present. This raised the possibility that C. albicans hyphae might 
engage with the vaginal epithelium in a way that made the VECs more permissive to GBS 
association. Such an indirect effect could explain why VEC association by GBS strain 
COH1 was significantly elevated in the presence of C. albicans, despite the fact that 
COH1 exhibited only a low level of coaggregation with C. albicans under planktonic 
conditions. The potential for indirect effects between C. albicans and VECs to modulate 
GBS association levels was investigated further and is presented in Chapter 4. 
Similar to the effects of C. albicans on VEC association by GBS, GBS was also shown to 
significantly promote association of C. albicans with VECs. Again, given the 
coaggregation capabilities of these two microbes, it is possible that such effects reflect 
the capacity for bound GBS to directly serve as additional binding sites for candidal 
hyphal filaments. However, while the three GBS strains tested exhibited variable levels 
of VEC association when incubated alone, C. albicans was promoted to similar levels of 




association regardless of GBS strain. This might suggest that GBS mediates its effects on 
C. albicans via an indirect mechanism, as discussed above. 
It is worth noting that the conditions used for the planktonic coaggregation assays and 
VEC association assays were different. Thus, it cannot be ruled out that the surface 
receptor profile of C. albicans and/or GBS changed following binding to VECs or in 
response to the different media, which in turn impacted C. albicans interactions with 
GBS. For example, glucose concentration was found to affect the expression of a 
number of GBS genes, including those controlling expression of virulence factor BibA (Di 
Palo et al., 2013), while GBS virulence genes encoding pili and BibA were differentially 
expressed in relation to pH (Santi et al., 2009). Likewise, the secreted aspartyl 
proteinases (SAPs) of C. albicans have been found to be differentially expressed in 
response to pH and presence of amino acids (Hube et al., 1994), while phospholipase B 
was expressed when C. albicans was grown in rich media at 30 °C but not 37 °C 
(Mukherjee et al., 2003). Expression of different surface molecules was hypothesised to 
be the reason that there was an increase in coaggregation between C. albicans and S. 
gordonii or S. sanguinis under starvation conditions (Jenkinson et al., 1990). Further 
investigations were performed to explore the coordinated responses of C. albicans, GBS 
and VECs. These data are presented in Chapter 5. 
C. albicans has been shown to facilitate invasion of oral epithelium by S. aureus 
(Schlecht et al., 2015a). S. aureus bacteria bind to the C. albicans hyphae, and as the 
hyphae invade oral epithelium, S. aureus cells are carried with them. Since GBS was also 
observed to exhibit a tropism for C. albicans hyphae, it was possible that a similar ‘piggy-
back’ mechanism was occurring for GBS invasion of VECs. As such, it was originally 
assumed that elevated numbers of GBS associated with VECs in the presence of C. 
albicans may correspond to both externally bound and internalised bacteria. However, 
this was not seen at 2 h and, in fact, levels of internalised GBS NEM316 were reduced in 
the presence of C. albicans. One potential explanation for this observation was that GBS 
was preferentially binding to C. albicans over VECs. However, this was not supported by 
confocal micrographs taken at this time point.  Alternatively, it was possible that, 
although C. albicans could promote GBS attachment to VECs, C. albicans may also 
occlude the receptors that GBS utilises for invasion of VECs. C. albicans has been 
described to interact with epidermal growth factor receptor (Zhu et al., 2012), cadherins 
such as E-cadherin (Phan et al., 2007), and components of the extracellular matrix 




(ECM), including laminin, fibronectin, collagen and vitronectin (Klotz, 1990;Limper and 
Standing, 1994). Although only one GBS receptor-adhesin pair has been identified 
(cytokeratin-4 and SRR-1), GBS has also been described to interact with ECM 
components, including collagen, fibronectin and laminin (Samen et al., 2007;Spellerberg 
et al., 1999;Beckmann et al., 2002;Banerjee et al., 2011). As such, GBS and C. albicans 
could target similar components of the ECM. However, these interactions have not been 
explicitly associated with subsequent epithelial internalisation. 
For a ‘piggy-back’ mechanism to occur, candidal hyphae must invade the VECs and so 
consideration was also given as to whether or not this would occur after a 2 h 
incubation. Studies have been carried out with oral epithelia which found that C. 
albicans did invade at 2 h, or even as early as 45 min post-inoculation (Phan et al., 
2007;Dalle et al., 2010). Nonetheless, invasion dynamics may be tissue-specific, and 
(Shroff et al., 2017) found that hyphae of C. albicans strain 3153A did not invade VECs 
until 6 h post-infection. Levels of internalised GBS NEM316 and COH1 were significantly 
higher when C. albicans was present compared to monospecies control after 6 h 
incubation. In line with (Shroff et al., 2017), this supports the hypothesis that C. albicans 
can carry GBS into VECs. Such an effect was not seen, however, with GBS strain 515, 
which may indicate that 515 preferentially bound VECs over C. albicans hyphae. Further 
experiments would be needed to confirm the dynamics of C. albicans and GBS 
internalisation into VECs. For example, differential antibody-labelling techniques could 
be used to distinguish between external and internalised cells, although this would be 
challenging when using 2 microorganisms simultaneously. 
Correlating with levels of internalised GBS and C. albicans, 6 h assays were also 
associated with the highest levels of cytotoxicity, as determined by LDH assay. LDH 
normally exists within the cytoplasm of cells, thus if quantities of LDH above background 
levels are detected, these are assumed to be from lysed or severely damaged cells. 
Brightfield and confocal micrographs showed no evidence of significant lysis of the VEC 
monolayers after 6 h, and these cells were able to support considerable numbers of 
internalised GBS that would otherwise have been killed by the antibiotics in the 
surrounding growth medium. Nonetheless, cell rounding was evident, indicating that the 
VECs were under considerable stress after 6 h, and levels of cytotoxicity were highest in 
the presence of both microbes rather than with GBS or C. albicans alone. This is perhaps 
unsurprising, as both microbes are known to mediate cytotoxic effects. For example, C. 




albicans produces candidalysin, which damages the membranes of epithelial cells, while 
β-H/C expressed by GBS can form pores in the membranes of a variety of host cells (Liu 
et al., 2004a;Moyes et al., 2016). However, the level of cytotoxicity measured following 
dual-species infection was greater than the two monospecies cytotoxicity levels 
combined. This implies that C. albicans and GBS may also have synergistic effects on 
their pathogenic potential. Investigation of the effects on specific virulence 
determinants and ultimately use of relevant disease models would be needed to explore 
this in more detail. 
There are some potential limitations with the microbial association assays used in this 
chapter. GBS grow as chains of bacteria, but these may appear as a single colony by 
viable count, which could lead to an underestimation of the number of bacteria present. 
In particular, this may have affected GBS strain 2603V/R, which exhibited especially long 
chains of bacteria when bound to VECs, while strains NEM316, 515 and COH1 appeared 
to form smaller chains of similar lengths. Nonetheless, overall levels of VEC association 
for all five GBS strains were in the range of 1-3x106 CFU/monolayer. Additionally, 
microscopy revealed that multiple GBS were often bound to one C. albicans hypha, 
however these bacteria would generate only one colony on agar. Similarly, C. albicans 
can form extensive mats of hyphae across the surface of the VECs. These aggregates can 
be difficult to dissociate into individual cells, which could again lead to an 
underestimation of cell number by viable count. Furthermore, C. albicans cells in hyphal 
form will contribute more biomass, yet appear as the same number of colonies by viable 
count. Nonetheless, there was no evidence that GBS strains modulated candidal hyphae 
formation and thus the numbers of hyphal filaments should have been similar across the 
experimental groups in any given assay. 
The experiments described in this chapter aimed to determine whether there was an 
interaction between GBS and C. albicans, and whether this might affect the colonisation 
of VECs by either species. Taken together, the results presented in this chapter describe 
a synergistic interaction between C. albicans and GBS. C. albicans is shown to promote 
GBS association with VECs, and vice versa. 




Chapter 4 Mechanistic basis of GBS-C. albicans interactions 
4.1 Introduction 
The data presented in Chapter 3 implied that GBS and C. albicans were interacting 
synergistically to promote colonisation of VECs. It was considered likely that these 
interactions would be mediated, at least in part, by surface protein interactions. Due to 
the precedent for antigen I/II family proteins and Als3 in facilitating Streptococcus-C. 
albicans interactions, these adhesins were the primary candidates. Nonetheless, data 
presented in Chapter 3 also raised the possibility that the GBS-C. albicans synergism may 
be mediated by non-physical means, such as diffusible chemical signals or modulation of 
microbial growth. Studies to investigate all of these potential mechanisms are the focus 
of this chapter. 
 
4.1.1 AgI/II family proteins 
Antigen I/II (AgI/II) family proteins were first discovered in Streptococcus mutans in 1980 
(Russell et al., 1980) and are adhesins that protrude from the bacterial cell surface. Their 
name derives from the fact that these proteins were originally thought to be two 
separate proteins: antigen I and antigen II; however, antigen II was later found to be the 
breakdown product of antigen I (Kelly et al., 1989). Since this discovery, AgI/II proteins 
have been found in practically all oral streptococcal species, including S. gordonii, S. 
oralis and S. intermedius (Ma et al., 1991;Demuth et al., 1996). More recently, AgI/II 
proteins have been characterised in Group A Streptococcus (GAS) and GBS (Zhang et al., 
2006;Chuzeville et al., 2015;Sitkiewicz et al., 2011). 
 
4.1.1.1 AgI/II structure 
The primary sequence of AgI/II family proteins can be divided into 7 distinct domains: an 
N-terminal leader peptide, an N-terminal domain, an alanine-rich domain (A domain), a 
variable region, a proline-rich domain (P domain), a C-terminal domain and a cell wall 
anchor containing an LPxTG motif (Figure 4-1). The N-terminal leader domain directs the 
protein to the Sec secretion system, by which it is transported across the membrane 
until the sorting signal (the LPxTG motif) is reached. Upon translocation across the cell 




membrane, the protein folds in half with the variable domain presented at the ‘tip’, 
while α-helices of the A domains and the polyproline II-helices of the P domains  
interact, enabling these domains to coil around one another and form the ‘stalk’ of the 
protein (Rego et al., 2016b). The N-terminal domain stabilises the protein structure by 
interacting with the C-terminal domain which is anchored to the cell wall (Figure 4-1).  
The variable region is thought to enable specificity of binding (Brady et al., 2010). 
The gene encoding GAS AgI/II protein, AspA, is present on an integrative and conjugative 
element named region of difference 2 (RD2), and it has been proposed that this was 
acquired by GAS via horizontal gene transfer from GBS (Sitkiewicz et al., 2011;Brochet et 
al., 2008;Zhang et al., 2006). Four homologues of GBS AgI/II proteins have been 
described, designated BspA-D. Bsp proteins can be split into two groups based on 
homology, BspA/B and BspC/D. BspA and BspB share over 90% similarity, while BspD is 
essentially identical to BspC except for the absence of the leader peptide for targeting to 
the Sec translocation machinery (Rego et al., 2016b). When compared against BspC/D 
proteins, BspA/B proteins have two extra sequences; an additional 51 amino acids in the 
A domain and an additional 25 amino acids in the P domain (Rego et al., 2016b). Bsp 
proteins share high sequence homology (39-42% amino acid identity) with the AgI/II 
proteins of GAS (Chuzeville et al., 2015;Rego et al., 2016b).  





Figure 4-1 Structure of the AgI/II family proteins of GBS, which have been named Bsp proteins.  
The V region is presented at the tip of the protein, while the A domain (red) and the P domain (blue) coil 
around one another to form a supporting ‘stalk’ structure. The N-terminal domain (black) stabilises the 
protein through interactions with the C-terminal domains, which anchor the protein to the cell surface via 
the LPxTG motif. Adapted from (Rego et al., 2016b). 
 
4.1.1.2 AgI/II functions 
AgI/II proteins have been most widely researched in oral streptococci. Streptococcal 
AgI/II family proteins are multifunctional and have been found to aid streptococcal 
colonisation, biofilm development and interactions with other microorganisms (Franklin 
et al., 2013;Hall et al., 2014;Xu et al., 2014a). For example, S. gordonii AgI/II proteins 
SspA/B have been shown to aid in association with and invasion of HEp-2 cells (Nobbs et 
al., 2007). AgI/II family proteins are also able to bind to a wide variety of host molecules, 
including laminin, collagen and salivary proteins such as glycoprotein-340 (gp-340) 
(Brady et al., 2010). Gp-340 is produced at mucosal surfaces and functions to aggregate 
microbes for expulsion from the body when secreted in liquid-phase, but can also act as 
a receptor for microbial attachment when in surface-bound phase (Loimaranta et al., 
2005). For example, S. mutans AgI/II protein SpaP binding to gp-340 plays a major role in 
facilitating attachment to the salivary pellicle and enabling colonisation of the oral cavity 
(Brady et al., 2010). The AgI/II proteins of both GAS and GBS have also been found to 




bind gp-340 (Zhang et al., 2006;Rego et al., 2016b). Alongside binding host molecules, 
AgI/II proteins have been shown to be involved in promoting colonisation of host tissues 
by binding to other microorganisms, such as Actinomyces oris, Porphyromonas 
gingivalis, and C. albicans (Jakubovics et al., 2005;Lamont et al., 2002;Silverman et al., 
2010). Interactions between C. albicans and oral streptococci have been described as 
synergistic, with microorganisms cooperating in order to persist for longer within the 
oral cavity (Shirtliff et al., 2009). AgI/II family proteins have been shown to contribute to 
this synergism. 
 
4.1.2 Als3 proteins 
Als3 is a cell surface protein expressed by C. albicans that is a member of the agglutinin-
like sequence (Als) gene family (Hoyer et al., 2008). One study found that >70% of C. 
albicans isolated from vaginal swabs taken from women with vaginal thrush express Als3 
(Roudbarmohammadi et al., 2016). Thus, it is likely that Als3 is expressed in the vaginal 
tract. Coleman et al. (2009) published fluorescence micrographs of C. albicans cells that 
had been probed with an anti-Als3 antibody, with the result that only the C. albicans 
hyphae were labelled (Coleman et al., 2009). This is particularly relevant given the 
hyphal tropism GBS was observed to exhibit.  
 
4.1.2.1 ALS3 gene structure 
ALS genes all share a similar three-domain structure (see Figure 4-2), with a conserved 5’ 
domain, a central domain comprising of a variable number of tandemly repeated copies 
of an 108 base pair motif, and a 3’ domain that differs in length and sequence across the 
genes (Hoyer et al., 1998b). There is variation in the number of tandem repeats in each 
ALS gene between C. albicans strains and alleles, however the most common number of 
repeats for ALS3 in C. albicans SC5314 are 9 or 12 (Hoyer et al., 2008). The difference in 
the number of tandem repeats was found to correlate with function, with the larger 
protein demonstrating greater adhesive abilities than the smaller protein when cultured 
with vascular endothelial or pharyngeal epithelial cells (Oh et al., 2005). However, it was 
found that C. albicans possesses one large ALS3 allele and one short allele (Oh et al., 
2005). 





Figure 4-2 ALS gene structure.  
The 5’ domain is conserved in length and sequence across the ALS gene family. However, the tandemly 
repeated domain and 3’ domain are variable in length. In ALS3, the 3’ domain is relatively short (879 bp). 
Adapted from (Hoyer et al., 1998b). 
 
4.1.2.2 Als3 function 
Monoclonal antibodies against Als3 were able to reduce adhesion by C. albicans to FaDu 
oral epithelial cells, and Als3 was found to be required for induced endocytosis by two 
oral epithelial cell lines and human umbilical vein endothelial cells (Phan et al., 2007). 
Furthermore, a C. albicans als3/als3 double mutant was significantly reduced in oral 
epithelial adhesion and damage (Zhao et al., 2004a). This highlights the role of Als3 as an 
important C. albicans adhesin. Additionally, Als3 was found to specifically bind to N-
cadherin and E-cadherin on endothelial and oral epithelial cells, respectively (Phan et al., 
2007).  
Alongside interactions with host substrata, Als3 has been implicated in the interactions 
between C. albicans and a number of bacterial species. These include S. aureus, which 
has been shown to specifically bind Als3 (Peters et al., 2012). Via this interaction, S. 
aureus is carried into host epithelial cells as C. albicans hyphae invade, and this has been 
described as the main mechanism for S. aureus host tissue invasion (Schlecht et al., 
2015a). Rothia dentocariosa and C. albicans are the most common microorganisms 
identified in mixed species biofilms on failed voice implants, and it was found that R. 
dentocariosa also targets Als3 on C. albicans hyphae (Uppuluri et al., 2017). C. albicans 
had been described to interact with the AgI/II proteins of S. gordonii (Bamford et al., 
2009). When investigating this interaction further, (Silverman et al., 2010) found that a 
als3/als3 double mutant was ablated in coassociation with S. gordonii, whether in 
biofilms or suspension. Heterologous protein expression of Als3 on Saccharomyces 
cerevisiae and SspB on L. lactis showed that the C. albicans-S. gordonii interaction was 
facilitated by specific protein binding between Als3 and SspB (Silverman et al., 2010).  




4.1.3 Non-physical interactions 
Most sites of the body are colonised by communities consisting of multiple species of 
microorganisms, which are sustained by inter-species interactions. While many of these 
interactions involve direct receptor-ligand binding between microbial surface molecules, 
this is not the only mechanism by which microbes can influence one another. A number 
of microbial species have been shown to interact with one another indirectly. Rather 
than specific binding of microbial cell surface adhesins, these microbes may interact 
through excretion of small diffusible signals, modulating host responses or by altering 
the dynamics of the host environment in a way which is beneficial to other organisms. 
Microorganisms can produce metabolites which may benefit other microorganisms. This 
has been described for the synergistic interaction between Treponema denticola and 
Porphyromonas gingivalis. Biofilm growth of T. denticola is promoted by P. gingivalis 
production of isobutyric acid, while growth of P. gingivalis is likewise promoted by T. 
denticola production of succinic acid and chemotrypsin-like proteinase (Grenier, 
1992;Cogoni et al., 2012). Additionally, modulating the environment may promote 
growth of other microorganisms. For example, Fusobacterium nucleatum has been 
shown to enhance P. gingivalis biofilm formation by reducing the amount of oxygen, 
enabling anaerobic growth (Bradshaw et al., 1998). Small, diffusible molecules may also 
be produced which facilitate growth of other microorganisms. For example, interspecies 
biofilm interactions between S. gordonii and Veillonella atypica are facilitated by V. 
atypica inducing expression of the amyB amylase gene by S. gordonii (Egland et al., 
2004). Upregulation of amylase when in the presence of digestible starch leads to larger 
quantities of glucose, which can be fermented to produce lactic acid, promoting V. 
atypica (Egland et al., 2004). Furthermore, autoinducer-2 produced by S. gordonii has 
been found to induce formation of hyphae in C. albicans by suppressing the quorum 
sensing molecule farnesol (Bamford et al., 2009). In mixed species biofilms between S. 
mutans and C. albicans, sigX-induced competence was triggered in S. mutans. This was 
also triggered by the supernatant from mixed, but not single-species, biofilms (Sztajer et 
al., 2014). Although C. albicans typically exists in its yeast form at low pH, when co-
incubated with oral streptococci, C. albicans can form hyphae at pH <4.5. Furthermore, 
streptococci producing H2O2 trigger oxidative stress and thus induce formation of 
hyphae by C. albicans (Jenkinson et al., 1990;Nasution et al., 2008). 
 





4.2.1 Expression of AgI/II family proteins 
(Rego et al., 2016b) showed that GBS carries genes encoding AgI/II family proteins. 
However, the conditions under which these proteins are expressed, or the levels of 
expression were not determined. The first step of these studies was therefore to test for 
expression of AgI/II family proteins on the surface of GBS. This included obtaining 
antibodies against BspA and BspC, which were generated in rabbits using full-length 
recombinant proteins purified from E. coli as the antigens (see Chapter 2 for details).  
To validate these antibodies, aliquots from overnight broth cultures of GBS strain 
NEM316 (Figure 4-3, upper rows) or 515 (Figure 4-3, lower rows) and successive 1:2 
dilutions were dotted onto nitrocellulose membranes. Membranes were exposed to 
either anti-Bsp purified antibody or pre-immune sera from the rabbits used to generate 
either BspA or BspC antibody, as indicated (Figure 4-3). As anticipated, NEM316 and 515 
reacted with BspA or BspC sera respectively in a dose-dependent manner (Figure 4-3). 
Importantly, no reactivity was seen with the preimmune sera, confirming the specificity 
of antibody binding. Cross-reactivity was also observed, as NEM316 reacted with anti-
BspC antibody, and 515 with anti-BspA antibody, despite these strains not expressing 
the target antigen. This is likely due to the high degree of sequence similarity between 
the two proteins (Rego et al., 2016b). 
 
Figure 4-3 Dot immunoblots to indicate Bsp expression by GBS.  
Aliquots (2 µL) from overnight THY broth cultures of strains NEM316 (upper rows) or 515 (lower rows) were 
transferred to nitrocellulose membranes, alongside five successive 1:2 dilutions (from right to left). 
Membranes were then probed with either purified anti-BspA or anti-BspC antibody (top panels) or 
corresponding rabbit pre-immune sera (bottom panels), followed by a secondary antibody conjugated to 
horseradish peroxidase, and developed by chemiluminescence. 
 




In an attempt to better visualise surface expression of BspA and BspC, and to explore 
the effects of environmental parameters or growth phase on expression levels, GBS 
strains NEM316 and 515 were grown at different temperatures in an overnight broth 
culture, or to either early or late exponential growth phase. Cells were fixed in PFA and 
stained with anti-BspA or -BspC antibodies, as appropriate. Cells were then probed with 
a secondary antibody conjugated to Alexafluor-555 and visualised by fluorescence 
microscopy (Figure 4-4). NEM316 was found to have a greater level of reactivity 
compared to strain 515 under each of the conditions tested (Figure 4-4, left panels), 
which may be due to cross-reactivity of the antibody with BspB alongside BspA. 
However, a similar binding profile was seen for both strains, in that only a small 
proportion (approximately 10%) of the cell population was brightly labelled by the 
antibodies. For some cells the antibody labelling appeared to cover the entire surface 
(Figure 4-4, white arrows), while other cells exhibited a punctate binding pattern (Figure 
4-4, blue arrows). Labelling of bacteria grown to early exponential phase (OD600 0.25) 
was brighter than for those grown to late exponential phase (OD600 0.9), but of the two 
growth phases, early exponential phase exhibited a higher proportion of punctate-
labelled cells. Incubation temperature also affected expression of the Bsp proteins 
(Figure 4-4), with a larger proportion of cells fully labelled by the antibodies at 30 and 34 
°C compared to cells grown at 37 °C. Taken together, these data confirmed surface 
expression of Bsp proteins by GBS strains NEM316 and 515, but implied that overall 
expression levels may be strain-dependent and affected by growth phase and 
temperature. 
 





Figure 4-4 Expression of BspA and BspC under differing growth conditions.  
GBS strains NEM316 (left panels) and 515 (right panels) were grown overnight in THY broth at 30 °C, 34 °C or 
37 °C, 5% CO2 as indicated. For investigations on the effect of growth phase on AgI/II family protein 
expression, bacteria were grown at 37 °C, 5% CO2 in an overnight broth culture before cells were adjusted to 
an OD600 of 0.1. Bacteria were then grown to either early (OD600 ~0.25) or late (OD600 ~0.8) exponential 
growth phase. Bacteria were probed with either α-BspA (NEM316) or α-BspC (515) antibodies, followed by 
an Alexafluor-555-conjugated secondary antibody. White arrows indicate GBS which is entirely labelled by 
anti-Bsp antibody, while blue arrows indicate GBS which is partially labelled. Scale bars, 20 μm.  




4.2.2 Direct Bsp interactions with VECs 
AgI/II family homologues from other streptococci have been implicated in colonisation 
and invasion of host tissues (Nobbs et al., 2007). As such, initial studies explored the 
capacity for Bsp proteins to influence VEC colonisation, using bsp gene knockout and 
complemented mutant strains. These strains were made by (Rego et al., 2016b). 
NEM316 has one copy of the bspA gene and three copies of the bspB gene, while 515 
and COH1 have only one copy of the bspC gene (Rego et al., 2016b). These latter two 
strains were therefore selected for mutagenesis. 
WT, ΔbspC and ΔbspC+bspC strains of 515 and COH1 were tested for association and 
invasion of VECs (Figure 4-5). There was a significant and almost identical reduction in 
association and invasion levels of 39% and 41%, respectively, for 515ΔbspC relative to 
WT (Figure 4-5A, B). Likewise, COH1ΔbspC was significantly impaired in association and 
invasion of VECs (Figure 4-5C, D) compared to WT, but the reduction was more 
extensive than seen for strain 515 at 95% and 94% for association and invasion, 
respectively. For both GBS strains, complementation with bspC restored association and 
invasion to WT levels (Figure 4-5). 
 





Figure 4-5 Effects of BspC expression on GBS interactions with VECs.  
VEC monolayers were incubated with (A,B) 515 WT or (C,D) COH1 WT and corresponding BspC knockout 
(ΔBspC) or complemented (ΔBspC+BspC) strains (MOI 25) for 1 h. Monolayers were either (A,C) lysed (for 
association) or (B,D) incubated with media containing 200 µg/mL gentamicin and 10 µg/mL penicillin for 2 h 
(for invasion) prior to lysis. Numbers of associated/internalised GBS were then enumerated by serial dilution 
onto THY agar. Data are presented as mean ± SD, ** indicates P<0.01 when compared to WT, NS indicates 
P>0.01 when compared to WT, as determined by unpaired Student’s t-test with Bonferroni correction; n=3.  
 
To further verify the contribution of BspC to mediating GBS interactions with VECs, and 
to investigate the potential role of BspA also, antibody inhibition studies were 
performed. For these assays, GBS strains 515 or NEM316 were incubated with either 
pre-immune sera or anti-Bsp antibody for 30 min prior to incubation with VECs (Figure 
4-6). For both GBS strains, compared to pre-incubation with preimmune sera, there was 
a significant decrease of 50-60% in the number of GBS able to associate with VECs when 
pre-incubated with anti-Bsp antibody (Figure 4-6). Taken together, these data indicate a 
role for BspA and BspC in mediating GBS interactions with VECs.   





Figure 4-6 Effects of anti-Bsp antibodies on GBS interactions with VECs.  
GBS (MOI 2.5) was pre-incubated for 30 min with 10 µg/mL anti-BspA (NEM316) or -BspC (515) antibody, or 
10 µg/mL pre-immune sera as control. Bacteria were then added to wells containing VECs and incubated for 
1 h. Monolayers were lysed and numbers of GBS were enumerated by serial dilution onto THY agar. Data 
are presented as mean ± SD, ** indicates P<0.01 as determined by unpaired Student’s t-test with Bonferroni 
correction; n=3. 
 
4.2.3 Role of Bsp proteins in coassociation with C. albicans 
The AgI/II family protein SspB of S. gordonii has been found to specifically associate with 
C. albicans (Silverman et al., 2010). To explore if a similar function could be ascribed to 
the Bsp proteins of GBS and if this influenced the coassociation seen with VECs, VEC 
association assays were performed with strains 515 WT, 515ΔbspC and 515ΔbspC+bspC, 
in the presence or absence of C. albicans (Figure 4-7). As was observed in Figure 4-5, 
there was a significant reduction in the number of 515ΔbspC able to associate with VECs 
when compared to 515 WT (Figure 4-7A). However, the 86% reduction was greater than 
seen previously and more similar that shown for strain COH1 in Figure 4-5. Association 
levels for all three 515 strains were significantly promoted by 3.6-fold for WT, 6.4-fold 
for ΔbspC and 3.4-fold for ΔbspC+bspC in the presence of C. albicans (Figure 4-7A). 
However, absolute numbers of 515ΔbspC recovered remained significantly lower than 
those of WT or 515ΔbspC+bspC either without (6-7-fold lower) or with (3-4-fold lower) 
C. albicans. Numbers of recovered C. albicans cells were significantly higher in the 
presence of each of the three 515 strains (Figure 4-7B). Of potential note, however, was 
that while C. albicans numbers were promoted by 3.3-fold and 3.2-fold by 515 WT and 
515ΔbspC+bspC respectively, levels were only 1.9-fold elevated in the presence of 
515ΔbspC. Thus, these data imply that BspC plays a role in the coassociation seen 














Figure 4-7 Effects of BspC expression on interactions of GBS and C. albicans with VECs.  
VEC monolayers were incubated with C. albicans (MOI 2.5) for 2 h, or with GBS 515 WT, 515ΔbspC and 
515ΔbspC+bspC (MOI 2.5) for 1 h. Alternatively, monolayers were incubated with C. albicans for 1 h 
followed by incubation with GBS for a further 1 h. Monolayers were lysed and (A) GBS or (B) C. albicans 
were enumerated by serial dilution onto THY agar supplemented with 50 μg/mL nystatin or SAB agar 
supplemented with 5 μg/mL erythromycin, respectively. Data are presented as mean ± SD, ** indicates 
P<0.01 relative to monospecies control, § indicates P<0.01 relative to 515 WT (A) or C. albicans+515 WT (B) 
as determined by one-way ANOVA with Tukey post-test; n=4.  
 




To further investigate the role of AgI/II family proteins in mediating GBS interactions 
with VECs and with C. albicans, while avoiding potential issues with functional 
redundancy across other GBS proteins, Gram positive surrogate host Lactococcus lactis 
was used to express BspA or BspC. The bspA or bspC gene was carried on plasmid 
pMSP7517 under the control of nisin-inducible promoter PnisA, enabling levels of 
heterologous protein expression to be regulated by addition of nisin to the growth 
medium (Rego et al., 2016b). These surrogate expression strains were then tested in VEC 
association assays in the presence or absence of C. albicans. There was a modest yet 
significant increase in numbers of L. lactis expressing BspA or BspC recovered from VECs 
relative to the empty vector control strain (Figure 4-8). For all three strains of L. lactis, 
numbers of recovered cells were significantly elevated in the presence of C. albicans. 
However, for the empty vector control strain this increase was only 1.4-fold, while the 
BspA-expressing strain was promoted by 2.8-fold, and the BspC-expressing strain by 4-
fold (Figure 4-8). This provided further evidence that the AgI/II family proteins facilitate 
the interactions of GBS with VECs and C. albicans. 
 
Figure 4-8 Effects of C. albicans on the association of L. lactis Bsp surrogate expression strains with VECs.  
VEC monolayers were incubated with suspensions of L. lactis pMSP vector control, pMSP.BspA or 
pMSP.BspC (MOI 2.5) for 1 h (white bars), or with C. albicans (MOI 2.5) for 1 h followed by addition of L. 
lactis suspensions for a further 1 h (black bars). Monolayers were then lysed and numbers of associated L. 
lactis were enumerated by serial dilution onto GM17 agar supplemented with 50 μg/mL nystatin. Data are 
presented as mean ± SD, ** indicates significance relative to monospecies controls; Ω indicates significance 
relative to pMSP empty vector control; § indicates significance relative to pMSP empty vector control in the 
presence of C. albicans. Significance indicates P<0.01, as determined by one-way ANOVA with Tukey post-
test; n = 4.  




The L. lactis surrogate expression strains were also utilised to explore the role of Bsp 
proteins in VEC invasion, and any potential influence of C. albicans on this.  These 
studies were carried out in a similar way to the invasion experiments detailed for Figure 
4-5 with the exception that, due to the non-invasive nature of L. lactis, the multiplicity of 
infection (MOI) had to be increased to 200 before the number of colonies recovered was 
quantifiable. As observed with GBS in Chapter 3, there was no significant difference 
between the numbers of internalised L. lactis in the monospecies controls when 
compared against L. lactis incubated with C. albicans (Figure 4-9). However, for L. lactis 
alone, there was a significant increase in the numbers of internalised bacteria when 
expressing BspA or BspC relative to the empty vector control. This amounted to a 4.4-
fold increase for BspA, and a 2.5-fold increase for BspC. There was no statistically 
significant difference between L. lactis invasion levels upon expression of BspA 
compared to BspC. However, Figure 4-9 suggests that BspA may facilitate invasion with 
greater efficiency than BspC, as on average invasion levels were 2-fold higher for L. lactis 
expressing BspA than BspC.  
 
Figure 4-9 Effects of Bsp expression or C. albicans on invasion of VECs by L. lactis.  
VEC monolayers were incubated for 1 h with C. albicans (MOI 2.5), before L. lactis pMSP vector only control, 
pMSP.BspA or pMSP. BspC were added (MOI 200) and incubated for a further 1 h. Monolayers were then 
incubated with media containing 200 µg/mL gentamicin and 10 µg/mL penicillin to kill any extracellular 
bacteria, before lysis and enumeration of internalised L. lactis by serial dilution onto GM17 agar plates 
supplemented with 50 μg/mL nystatin. Data are presented as mean ± SD, ** indicates P<0.01 when 
compared to pMSP vector control, NS indicates P>0.01 when compared to monospecies controls, as 
determined by one-way ANOVA with Tukey post-test; n=4. 




4.2.4 Role of Als3 in coaggregation with GBS   
As discussed, there is evidence to suggest that C. albicans mediates interactions with 
other microbial species via adhesin Als3 (Peters et al., 2012). To investigate whether or 
not Als3 was involved in the interactions with GBS, a homozygous mutant strain of C. 
albicans was used in which ALS3 was deleted (designated C. albicansΔals3), alongside 
the corresponding complemented strain (designated C. albicansΔals3+als3) (Zhao et al., 
2004a). Initially, the role of Als3 in mediating planktonic (coaggregation) interactions of 
C. albicans with GBS was investigated. C. albicans was grown in YNBPTG for 2 h, before 
addition of GBS and incubation for a further 1 h. Cells were differentially labelled with 
fluorescent dyes and then visualised by fluorescence microscopy (Figure 4-10A). Levels 
of coaggregation were semi-quantitatively determined by scoring hyphae based on the 
number of interacting GBS (Figure 4-10B). GBS strains NEM316 and 515 exhibited strong 
interactions with C. albicans WT, with 40-50% of the hyphae achieving a score of >20 
bound GBS. By contrast, these strains were not able to coaggregate strongly with C. 
albicansΔals3, for which either 0 or 1-5 bound GBS was scored for the majority of 
hyphae. The number of bacteria interacting with C. albicans Δals3+als3 was similar to 
WT levels, suggesting that complementation of Als3 restored the WT coaggregation 
phenotype. Strain COH1 rarely interacted with any of the three C. albicans strains. 
However, numbers of hyphae devoid of bound COH1 were higher for C. albicansΔals3 
compared to WT (Figure 4-10). Taken together, these data suggested that C. albicans 
adhesin Als3 plays a major role in mediating coaggregation with permissible GBS partner 
strains.  
  





Figure 4-10 Role of Als3 in coaggregation of C. albicans with GBS.  
(A) Representative fluorescence micrographs of planktonic interactions between C. albicans WT (left panel), 
Δals3 (middle panel) or Δals3+als3 (right panel) and GBS strains NEM316 (top panels), 515 (middle panels) 
or COH1 (bottom panels). C. albicans was grown in YNBPTG for 2 h at 37 °C, 220 rpm before addition of GBS 
and incubation for a further 1 h. GBS was labelled with FITC (green), while C. albicans was labelled with 
Calcofluor White (blue). Scale bars, 20 μm. (B) Semi-quantitation of numbers of C. albicans hyphae with 0 
interacting GBS, 1-5, 6-20 or >20 interacting GBS. Data are presented as mean ± SD, * P<0.05; NS P>0.05, as 
determined by linear regression analysis of datasets; n = 4. 
 
While the data presented in Figure 4-10 highlighted Als3 in facilitating C. albicans-GBS 
coaggregation, it was not possible to ascertain from these data which adhesin(s) on the 
surface of GBS were involved. Previous studies had shown that AgI/II family protein SspB 
can specifically interact with Als3 (Silverman et al., 2010). To determine if such functions 
extended to the Bsp adhesins of GBS, coaggregation assays were repeated with the L. 
lactis heterologous expression strains and the C. albicans Als3 strains (Figure 4-11). The 
L. lactis pMSP vector only control strain coaggregated weakly with C. albicans, 




regardless of strain, and there was no significant difference in the semi-quantitatively 
scored interactions with any of the three C. albicans strains (Figure 4-11B). L. lactis 
expressing BspA or BspC tended to bind along the length of the C. albicans WT or C. 
albicansΔals3+als3 hyphae (Figure 4-11A). However, neither strain bound C. 
albicansΔals3, and semi-quantitative analysis revealed that L. lactis expressing BspA or 
BspC coggregated at significantly lower levels with C. albicansΔals3 than with WT (Figure 
4-11B). There were no significant differences in coaggregation levels between C. 
albicans WT and C. albicansΔals3+als3, with the majority of hyphae exhibiting >20 
bound L. lactis expressing BspA or BspC. Thus, Als3 was shown to be critical for 
coaggregation between C. albicans and the AgI/II-expressing L. lactis strains. These data 
raised the possibility that there may be a specific Als3-Bsp interaction.  
 
 





Figure 4-11 Role of Als3 in coaggregation of C. albicans with L. lactis Bsp-expressing strains.  
(A) Representative fluorescence micrographs of planktonic interactions between C. albicans WT (left panel), 
Δals3 (middle panel) or Δals3+als3 (right panel) and L. lactis strains pMSP vector control (top panels), 
pMSP.BspA (middle panels) or pMSP.BspC (bottom panels). C. albicans was grown in YNBPTG for 2 h at 37 
°C, 220 rpm before addition of L. lactis and incubation for a further 1 h. GBS was labelled with FITC (green), 
while C. albicans was labelled with Calcofluor White (blue). Scale bars, 20 μm. (B) Semi-quantitation of 
numbers of C. albicans hyphae with 0 interacting L. lactis, 1-5, 6-20 or >20 interacting L. lactis. Data are 
presented as mean ± SD, * P<0.05; NS P>0.05, as determined by linear regression analysis of datasets; n = 4. 
 
4.2.5 Role of Als3 in coassociation with GBS 
Having demonstrated a role for C. albicans Als3 in mediating coaggregation with GBS, 
the next step was to determine if this interaction also influenced the coassociation seen 
between these microbes on VECs. C. albicans WT, C. albicansΔals3 and C. 
albicansΔals3+als3 were incubated with VECs in the presence or absence of GBS (Figure 
4-12). As before, there was a significant increase in the numbers of GBS recovered from 
VECs in the presence of C. albicans WT, and comparable effects were seen with C. 
albicansΔals3+als3. NEM316 was promoted by 2.3-fold, 515 by 6.1-fold, and COH1 by 5-




fold (Figure 4-12A). Reciprocal effects were also seen for C. albicans, with numbers of 
associated C. albicans WT or C. albicansΔals3+als3 being enhanced by approximately 3-
fold in the presence of each GBS strain (Figure 4-12B). By contrast, there were no 
significant differences in GBS association levels when incubated with C. albicansΔals3 
compared to the monospecies control (Figure 4-12A), and the numbers of recovered C. 
albicansΔals3 in the presence of GBS were comparable to those of the monospecies 
control (Figure 4-12B). These data strongly implied that the synergistic promotion of 
GBS-C. albicans association with VECs was dependent on Als3. 





Figure 4-12 Role of Als3 in coassociation of C. albicans and GBS with VECs.  
(A) VEC monolayers were incubated with GBS suspensions for 1 h (white bars) or with C. albicans WT (black 
bars), Δals3 (grey bars) or Δals3+als3 (striped bars) for 1 h followed by GBS for a further 1 h. Monolayers 
were lysed and then numbers of associated GBS were enumerated by serial dilution onto THY agar 
supplemented with 50 μg/mL nystatin. (B) VEC monolayers were incubated with C. albicans WT, Δals3 or 
Δals3+als3 for 1 h followed by GBS strains NEM316 (black bars), 515 (grey bars) or COH1 (striped bars) for a 
further 1 h. Monolayers were lysed and numbers of associated C. albicans were enumerated by serial 
dilution onto SAB agar supplemented with 5 μg/mL erythromycin. Data are presented as mean ± SD; ** 
P<0.01, NS P>0.01, as determined by one-way ANOVA with Tukey post-test; n = 4.  
 




4.2.6 Direct Bsp-Als3 interaction 
These studies had demonstrated a role for Bsp adhesins of GBS and Als3 of C. albicans in 
mediating coaggregation between these two microbes and in their coassociation on 
VECs. However, while strongly implicated, direct binding between these adhesins had 
not been shown. To try and resolve this, coaggregation assays were performed using L. 
lactis Bsp-expressing strains together with a Saccharomyces cerevisiae Als3 heterologous 
expression strain (Figure 4-13). The L. lactis pMSP vector control strain did not interact 
with S. cerevisiae expressing Als3 (Figure 4-13, left panel). However, L. lactis expressing 
BspA (Figure 4-13, middle panel) or BspC (Figure 4-13, right panel) coaggregated with 
Als3-expressing S. cerevisiae. These micrographs provided supporting evidence for a 
direct Als3-Bsp interaction.  
 
Figure 4-13 Fluorescence micrographs of planktonic interactions between S. cerevisiae Als3 and L. lactis 
Bsp surrogate expression strains.  
S. cerevisiae (Als3+) was grown in YNBPTG for 3 h at 30 °C, 220 rpm before addition of L. lactis pMSP control 
(left), L. lactis pMSP.BspA (middle) or L. lactis pMSP.BspC (right) and incubation for a further 1 h. L. lactis 
was labelled with TRITC (red), while S. cerevisiae was labelled with FITC (green). Scale bars, 20 μm. 
 
4.2.7 Non-physical interactions 
4.2.7.1 Effects on microbial growth 
In Chapter 3 it was found that the promotion of GBS association with VECs may not be 
entirely dependent on direct binding with C. albicans. Confocal micrographs revealed 
that, although there were many bacteria bound to C. albicans hyphae (indicating a 
direct, physical interaction between the two organisms), there was also a visible 
increase in the number of adherent bacteria to the epithelium in areas where C. albicans 




was not present. To investigate whether this could have been due to an increase in the 
overall number of microorganisms present resulting from enhanced growth/replication, 
GBS and C. albicans were grown together planktonically in conditions to mirror an 
association assay and the CFU/mL determined by viable count and compared to 
monocultures (Figure 4-14). Numbers of neither GBS (Figure 4-14A) nor of C. albicans 
(Figure 4-14B) displayed any significant difference between the dual-species and 
monospecies cultures, suggesting that neither species significantly affected growth of 
the other.  
 
Figure 4-14 Effects of mono- or dual-species incubation on numbers of C. albicans or GBS in suspension 
culture.  
K-SFM broth cultures were inoculated with C. albicans (MOI 2.5) at 37 °C, 220 rpm for 1 h before addition of 
GBS and incubation for a further 1 h (black bars). Alternatively, broth cultures were inoculated with C. 
albicans or GBS alone and incubated for 2 h or 1 h respectively (white bars). GBS CFU/mL were then 
determined by viable count onto THY agar supplemented with 50 μg/mL nystatin (A), while C. albicans 
CFU/mL were determined by viable count onto SAB agar supplemented with 5 μg/mL erythromycin (B). Data 
are presented as mean ± SD, NS indicates P>0.05 compared to the monospecies control, as determined by 
unpaired Student’s t-test; n = 3. 




4.2.7.2 Role of diffusible signals 
It is known that alongside physical interactions, chemical communication exists in 
polymicrobial communities. Thus, it was hypothesised that small diffusible molecules 
may be produced by GBS or C. albicans that could affect their interactions with VECs. To 
explore this possibility, VEC association assays were performed as before with the 
modification that GBS was physically separated from C. albicans using transwell plates. 
C. albicans were pre-incubated with VECs before GBS were added in the top 
compartment of transwell baskets (Figure 4-15). In theory, if chemical signals were 
produced by GBS that promoted C. albicans interactions with VECs, these would be able 
to pass through the small pores in the transwell membrane and mediate their effects. 
However, there were no significant differences in the numbers of C. albicans cells 
recovered from VECs in the presence of GBS under these conditions compared to C. 
albicans alone (Figure 4-15). 
 
Figure 4-15  Association of C. albicans with VECs when exposed to GBS in a contact-independent manner.  
C. albicans was grown on VEC monolayers for 1 h, before GBS suspensions or K-SFM alone were placed into 
transwell baskets suspended above. After a further 1 h incubation, C. albicans was enumerated by serial 
dilution onto SAB agar. Data are presented as mean ± SD, NS indicates P>0.01, as determined by unpaired 
Student’s t-test with Bonferroni correction; n=3.  
 
Another possibility was that stimulatory signals may only be produced when microbes 
are in contact with the VECs. To investigate this hypothesis, C. albicans was grown with 




VECs in conditioned media from GBS grown either planktonically or with VECs, and vice 
versa (Figure 4-16). Conditioned media were sterilised through a 0.4 µm pore filter 
before inoculation with GBS or C. albicans and incubation with VEC monolayers. There 
were no significant differences in the numbers of GBS associated with VECs in 
conditioned media from C. albicans grown planktonically (Figure 4-16A, striped bars) or 
incubated with VECs (Figure 4-16A, black bars) when compared against the blank 
medium control (Figure 4-16A, white bars). Likewise, there were no significant 
differences in the numbers of C. albicans associated with VECs when incubated in GBS 
planktonic or VEC conditioned media relative to blank medium control (Figure 4-16B). 
 
Figure 4-16 Effects of conditioned media on microbial association with VECs.  
A) VEC monolayers were incubated with C. albicans (MOI 2.5) for 1 h. Alternatively, C. albicans was 
incubated planktonically at 220 rpm for 1 h. Suspensions were collected and filter sterilised. GBS was diluted 
into either fresh K-SFM or C. albicans conditioned media and incubated with fresh VECs (MOI 2.5) for 1 h. 
Monolayers were lysed and GBS was enumerated by serial dilution onto THY agar; n=5. B) VEC monolayers 
were incubated with GBS strains NEM316, 515 or COH1 (MOI 2.5) for 1 h. Alternatively, GBS were grown 
statically in suspension for 1 h. Suspensions were collected and filter sterilised. C. albicans was diluted into 
either fresh K-SFM or GBS conditioned media, and incubated with fresh VECs (MOI 2.5) for 1 h. Monolayers 
were lysed and C. albicans was enumerated by serial dilution onto SAB agar. Data are presented as mean ± 
SD; n=3; NS indicates that P>0.05, as determined by one-way ANOVA with Tukey post-test. 




4.2.7.3 Effects of VEC fixation on GBS-C. albicans coassociation 
While chemical signals did not seem to play a significant role in GBS-C. albicans 
coassociation with VECs, one final mechanism to explore was if C. albicans may interact 
with VECs to make them more permissive to GBS. Such a process would require an 
active response from VECs and so the effects of VEC fixation on this coassociation were 
investigated. VEC monolayers were fixed with paraformaldehyde prior to incubation 
with GBS and/or C. albicans. Fixation of VECs did reduce the overall levels of association 
for GBS strains NEM316 and 515 (Figure 4-17A, white bars). However, association levels 
were significantly promoted by ~20-fold in the presence of C. albicans for both GBS 
strains (Figure 4-17A, black bars) relative to GBS alone. These effects of C. albicans were 
greater than seen in previous assays, but this likely reflects the fact that much lower 
levels of GBS association were seen for the monospecies controls. Fixation did not 
significantly impact the capacity for C. albicans to bind VECs (Figure 4-17B). In the 
presence of GBS NEM316 or 515, numbers of recovered C. albicans cells were promoted 
by 2.4-fold or 2.9-fold respectively compared to C. albicans alone (Figure 4-17B).  





Figure 4-17 Effects of VEC fixation on GBS-C. albicans interactions.  
VEC monolayers were fixed with 2% paraformaldehyde overnight, before A) incubation with GBS 
suspensions (MOI 2.5) for 1 h (white bars) or with C. albicans (MOI 2.5) for 2 h, or with C. albicans for 1 h 
followed by GBS for a further 1 h (black bars). Monolayers were then lysed and GBS CFU/mL determined by 
viable count onto THY agar supplemented with 50 μg/mL nystatin, or (B) C. albicans CFU/mL were 
determined by viable count onto SAB agar supplemented with 5 μg/mL erythromycin. Data are presented as 
mean ± SD, ** indicates P<0.05 relative to the monospecies control, as calculated by unpaired Students t-
test; n=3. 
 
Taken together, these data imply that neither GBS nor C. albicans produce diffusible 
signals that significantly influence the association of these microbes with VECs. 
Furthermore, no active response from VECs is required to facilitate these synergistic 




effects. Rather, it seems likely that the direct physical interaction of these 
microorganisms is the critical mechanism that underpins their coassociation with VECs. 
 
4.3 Discussion 
The data presented in this chapter explored the molecular basis for GBS-C. albicans 
interactions. Investigations into non-physical interactions found neither chemical signals 
nor active response by VECs to play a significant part in the coassociation between GBS 
and C. albicans. Thus, the implication was that these interactions were predominantly 
driven via physical interactions between the two microbes, for which AgI/II family (Bsp) 
proteins and Als3 were found to be the principal mediators. 
Antibodies raised against BspA and BspC were used to confirm surface expression by 
GBS strains NEM316 and 515 and these exhibited cross-reactivity between the two 
strains. NEM316 possesses one copy of bspA and three copies of bspB, while 515 
possesses only one copy of bspC. Aside from the additional sequences in the A and P 
domains of the BspA/B homologues when compared to BspC/D homologues, there is a 
high level of sequence identity between these proteins (Table 4-1). This likely explains 
why the antibodies appeared to label both strains comparably.  
Table 4-1 Domain similarity across Bsp proteins.  
% amino acid identity given for each of the AgI/II domains when compared against BspA. Adapted from 


















BspB 87% 97% 97% 100% 88% 90% 64% 
BspC 90% 97% 96% 97% 96% 83% 82% 
BspD N/A 97% 97% 100% 88% 90% 64% 
 
Expression of the AgI/II proteins was monitored under a variety of conditions, including 
different temperatures and growth phases. Two populations of labelled GBS were 
observed: completely labelled cells and partially labelled cells. When bacteria were 
grown to early exponential growth phase (at 37 °C), both populations of cells were 




observed, while at late exponential phase, cells were mostly completely labelled. This 
implies that Bsp expression may be constitutive but that levels of surface expression are 
optimal as the cells enter stationary phase. There are examples of such expression 
variation within this adhesin family, as for S. gordonii the sspA promoter was found to 
increase activity throughout growth, while the sspB promoter induced most activity at 
late exponential phase (El-Sabaeny et al., 2000). This aspect of Bsp expression could be 
further investigated in the future if reporter strains were generated using the bsp 
promoter sequences, thereby allowing transcription of the bsp genes to be monitored 
throughout the growth cycle. It was also noted that fluorescence levels with the anti-Bsp 
antibodies were brighter in early rather than late exponential phase. This may indicate 
impaired antibody access as the GBS cell matures and produces increasing levels of 
capsular polysaccharide, which could be explored further by including capsular staining 
in these experiments. Only around ~10% of the bacteria viewed under brightfield 
microscopy were clearly fluorescent. However, more information would be needed 
about the sensitivity of the anti-Bsp antibodies to confirm whether the remaining GBS 
cells were expressing Bsp at lower levels. 
Completely labelled GBS cells were more prevalent at 30 and 34 °C, whereas partially 
labelled cells were most common at 37 °C. This implies that Bsp expression may be 
temperature-responsive. Smoot et al. (2001) described a number of GAS proteins which 
were regulated in response to temperature (29 oC vs. 37 oC), with 28 proteins containing 
secretion signals differentially expressed according to temperature (Smoot et al., 2001). 
Furthermore, expression of the S. gordonii AgI/II proteins SspA and SspB has been found 
to vary in response to temperature, as well as pH and osmolarity (El-Sabaeny et al., 
2000). At 34 °C, the SspB promoter induced similar expression as at 37 °C, while the 
SspA promoter was decreased in activity (El-Sabaeny et al., 2000). Temperature-related 
regulation of proteins can be advantageous to bacteria by conferring the ability to 
colonise different host environments. Although GBS is predominantly found in the 
gastrointestinal and genitourinary tracts, GBS is also capable of causing a range of 
diseases in non-pregnant adults. These normally present as non-specific bacteraemia or 
infections of the skin and soft tissue, although in rare cases GBS may cause endocarditis 
or meningitis (Fujita et al., 2015;Scully et al., 1987b;Sambola et al., 2002). To survive, 
GBS must therefore be able to adapt and grow under the different conditions, including 
temperature, found in these multiple niches. It is interesting to note that pH also 
affected expression of S. gordonii SspA/B proteins, with a neutral pH favoured by both 




promoters (El-Sabaeny et al., 2000). As the vaginal environment is more acidic than the 
oral cavity, it could be hypothesised that expression of Bsp proteins may occur over a 
larger pH range; however, this needs further investigation. 
It is widely documented that AgI/II family proteins are important adhesins of 
streptococci, particularly those that colonise the oral cavity (Brady et al., 2010). Rego et 
al. (2016) showed that BspA expression by L. lactis conferred an increased capacity to 
bind VECs (Rego et al., 2016b). Here, knockout and complemented strains of GBS 515 
and COH1 have been used to demonstrate a role for BspC expression in VEC binding and 
internalisation. There was a significant reduction in numbers of ΔbspC strains associated 
with or internalised within VECs compared to WT, and complementation restored WT 
phenotype. Furthermore, anti-Bsp antibodies impaired the ability of GBS NEM316 and 
515 to interact with VECs by 50%, while L. lactis strains expressing BspA or BspC were 
enhanced in both VEC association and invasion compared to the L. lactis vector control 
strain. These data provide strong evidence that BspA and BspC, and thus possibly all Bsp 
family proteins, may facilitate vaginal colonisation by GBS through direct interactions 
with the vaginal mucosa. Nonetheless, bsp knockout strains were not ablated in 
association with VECs, highlighting the common strategy utilised by several bacterial 
species of adhesin redundancy, whereby bacteria have multiple proteins that carry out 
the same function to maximise survival (Kline et al., 2009). Bsp proteins may therefore 
play a role in GBS-GU tract interactions but are not the only GBS proteins involved. 
There is precedent for AgI/II family proteins binding directly to epithelial cell receptors 
or to ECM proteins. For example, S. gordonii SspA/B can adhere to integrin receptor α5β1 
and collagen type I (Heddle et al., 2003;Nobbs et al., 2007), while SpaP of S. mutans and 
Pas of S. intermedius have both been found to bind fibronectin (Petersen et al., 2002). 
Identifying the VEC receptor(s) targeted by GBS Bsp proteins will be the focus of future 
studies.  
Copy numbers of bsp genes differ across the GBS strains tested here and it was 
hypothesised that these differences could affect the capacity of GBS strains to associate 
with VECs. Bsp antibody labelling, as detected by immunofluorescence, appeared to 
confirm that NEM316 expresses greater levels of AgI/II proteins on its surface than 515. 
In turn, GBS NEM316 interacted with VECs in higher numbers than GBS 515. However, in 
the previous chapter, COH1 was shown to associate with and invade into VECs at similar 
levels to NEM316 and yet COH1 only carries a single bspC gene. This could reflect the 




role of other proteins in mediating GBS association with VECs. Alternatively, the 
different Bsp proteins may exhibit varying binding affinities. Indeed, the L. lactis strain 
expressing BspA interacted with VECs in higher numbers than the L. lactis strain 
expressing BspC. These possibilities may not be mutually exclusive. 
The C. albicans cell surface adhesin Als3 was identified as a protein that is critical for the 
interaction between C. albicans and GBS. Als3 is hypha-specific (Coleman et al., 2009), 
which correlates with the tropism GBS was observed to exhibit for hyphae. There was a 
significant reduction in interactions with C. albicans hyphae when all three strains of 
GBS were incubated with the C. albicans Δals3 strain relative to WT, while interactions 
with C. albicans Δals3+als3 were comparable to WT. Likewise GBS could promote 
association of C. albicans WT and C. albicans Δals3+als3 with VECs but not of C. albicans 
Δals3. C. albicans Δals3 was not impaired in formation of hyphae and associated with 
VECs similar to WT C. albicans. Thus, it was explicitly loss of Als3 expression on candidal 
hyphae that impaired interactions with GBS. There was even a significant reduction of 
GBS COH1 binding to C. albicans Δals3 hyphae compared to WT, which is perhaps 
surprising given the rarity of COH1-C. albicans interactions in suspension. This suggests a 
difference in the protein profile of COH1 cells in VEC association assays when compared 
to planktonic suspension. However, this would have to be confirmed, for example, with 
proteomic analyses. 
Heterologous expression of BspA or BspC on L. lactis conferred the capacity to 
coaggregate with C. albicans expressing Als3 but not C. albicans Δals3. Furthermore, 
these L. lactis strains could coaggregate with Saccharomyces cerevisiae expressing Als3. 
These data strongly suggest that Bsp proteins directly target Als3 on C. albicans hyphae, 
as has been found for the S. gordonii AgI/II protein SspB (Bamford et al., 2009;O'Sullivan 
et al., 2000;Jenkinson et al., 1990). Bsp proteins share only 6-22% overall protein 
identity with SspA/B (Chuzeville et al., 2015) and so it is unclear if common binding 
domains exist in BspA/C and SspB for engaging Als3. Hoyer et al. (2014) found that S. 
gordonii was significantly less able to bind C. albicans Als3 with mutations in the peptide 
binding cavity of the N-terminus of Als3 (Hoyer et al., 2014), which had been shown to 
interact with the C-terminus of ECM protein ligands (Lin et al., 2014). However, as SspB 
is covalently linked to the peptidoglycan of the streptococcal cell wall (Nobbs et al., 
2009), the logistics of such a binding mechanism for S. gordonii were less clear. To 
address this, (Hoyer et al., 2014) proposed that portions of the SspB C-terminus were 




stably linked to the bacterial cell wall, yet others are free to interact with Als3 following 
selective proteolytic cleavage by either C. albicans, bacterial or even host proteases. A 
major difference between SspB and Bsp proteins is that while SspB has the typical three 
C-terminal domains (C1, C2 and C3) (Brady et al., 2010), Bsp proteins of GBS only 
possess two C-terminal domains, which are analogous to C2 and C3 (Rego et al., 2016b). 
Further domain mutagenesis studies, combined with more detailed structural analyses 
of the Bsp and Als3 adhesins, are needed to determine if Bsp-Als3 interactions and SspB-
Als3 interactions occur via a common mechanism. 
In conclusion, the data represented in this chapter suggest that the synergistic 
promotion between GBS and C. albicans was due to direct physical interactions between 
GBS and the C. albicans cell surface protein, Als3. AgI/II proteins on the surface of GBS 
contribute to this interaction but other, as of yet unidentified, GBS proteins are also 
involved.




Chapter 5 Host response to GBS-C. albicans interactions 
5.1 Introduction 
The previous work indicated that C. albicans and GBS interact in a way that 
synergistically enhances the capacity of both microorganisms to associate with vaginal 
epithelium. A primary mechanism by which microbes may achieve this is by modulation 
of host responses in a way that makes the VECs more permissive to microbe 
engagement (Xu et al., 2014a). Host responses to the microbes may also have important 
implications for the outcomes of these initial interactions in the context of colonisation 
and disease. Examples of modulation of host responses by C. albicans-Streptococcus spp. 
have been documented. Coinfection of a mouse model of oral infection with C. albicans 
and S. oralis was found to induce a strong host inflammatory response. In this case, the 
most commonly upregulated genes related to neutrophil response and cytokine activity 
(Xu et al., 2014b). Cytokines involved in neutrophil activity, such as IL-17, IL-1α and IL-1β 
were induced to elevated levels, facilitating infiltration of neutrophils. This led to an 
enhanced frequency and severity of oral candidiasis plaques and facilitated systemic 
spread of C. albicans in a mouse model of infection (Xu et al., 2014b). 
 
5.1.1 Host responses to C. albicans within the GU tract 
Neutrophils are the predominant immune cell in the vaginal tract (Nandi and Allison, 
1993), and have been found to be most responsible for killing of C. albicans (Edwards et 
al., 1987;Gazendam et al., 2014;Urban et al., 2009). This correlates with reports of 
neutropenic patients more commonly experiencing systemic Candida disease (Martino 
et al., 1989). Nonetheless, neutrophils have also been described as more susceptible to 
killing by C. albicans than other immune cells, such as macrophages (Rudkin et al., 2013). 
Furthermore, despite the role of neutrophils in killing C. albicans, rather than clearing 
the infection, neutrophil infiltration into oral thrush lesions has been found to 
exacerbate symptoms in the host, and this observation has been extended to vaginal 
thrush (Yano et al., 2010;Dongari-Bagtzoglou et al., 2009;Xie et al., 2012).  
It has been suggested that vaginal (and oral) epithelial cells are directly capable of 
fungistatic, but not fungicidal, activity in response to C. albicans (Nomanbhoy et al., 
2002). Oral epithelial cells have been shown to constrain blastospore and hypha growth, 




although this was dependent upon cell-fungal contact and was not achieved by saliva or 
cell supernatant (Steele et al., 2000). Growth inhibition was also dependent on the 
immune status of the host, as oral epithelium sampled from HIV-infected individuals was 
incapable of inhibiting Candida growth (Steele et al., 2000). A study using mouse VECs 
found that vaginal cells were able to inhibit growth of C. albicans at a MOI of as low as 
1:1, but only exhibited a limited amount of fungal killing (Steele et al., 1999). Again, 
inhibition was not mediated by cell supernatant alone, indicating a direct cell-cell 
contact mechanism (Steele et al., 1999). Oestrogen reduces the ability of VECs to control 
C. albicans growth, which may explain why woman who suffer from VVC are more 
susceptible to bouts of symptomatic disease during the luteal phase of menstruation 
and during pregnancy (Fidel et al., 2000). VECs are also able to produce S100 alarmins in 
response to C. albicans, which have been identified as neutrophil chemoattractants 
within the vaginal tract (Yano et al., 2014;Yano et al., 2012). 
A hallmark of vaginal thrush is an upregulation of inflammatory pathways. Roselletti et 
al. (2017) highlighted the presence of IL-1β and IL-8, which correlated with an influx of 
neutrophils (Roselletti et al., 2017). Another study found that reconstituted vaginal 
epithelium produced IL-1α, IL-1β, IL-6, IL-8, IL-10, G-CSF and IFN-γ following infection 
with C. albicans (Schaller et al., 2005). IL-1α, IL-1β, IL-17 and IL-23 were significantly 
increased in expression in a model of murine C. albicans vaginal infection when 
compared against control mice (Shroff et al., 2018), and mice were found to be 
protected from a C. albicans infection by a competent IL-17 pathway, which required IL-
23 secretion (Gladiator et al., 2013). Of note, C. albicans mutants which lacked 
expression of secreted aspartyl proteinases (SAP) 1 or 2 were less able to induce 
cytokine production and cause tissue damage (Schaller et al., 2005), implicating these 
SAPs as modulators of the host immune response. Additionally, injection of SAP2 into 
the vagina of mice induced an influx of neutrophils and secretion of IL-1β (Pericolini et 
al., 2015), while C. albicans SAP-2 and -6 induced production of IL-8 and MIP-2 by VECs, 
both of which are neutrophil chemoattractants (Gabrielli et al., 2016). Proinflammatory 
cytokines such as IL-1α, IL-1β and IL-8 were induced from VECs in a dose-dependent 
manner by the C. albicans virulence factor candidalysin (Richardson et al., 2017). 
Candidalysin was found to activate c-Fos and MAPKs, and there was a marked reduction 
in VEC damage and neutrophil infiltration in mice challenged with a candidalysin-
deficient strain (Richardson et al., 2017).  




Oral and vaginal epithelial cells are known to be able to distinguish which fungi are 
commensal and which are pathogenic through MAPK, c-Fos and MKP1 signalling (Moyes 
et al., 2010;Moyes et al., 2011;Moyes et al., 2012). This seems, in part, to be related to 
whether fungi are present as blastopores or hyphae, with one study outlining how a 
hypha-deficient strain was a competent coloniser, yet did not induce cell damage 
(measured by LDH release) or immunopathology (measured by neutrophil infiltration 
and proinflammatory cytokine production) (Moyes et al., 2010). Stimulation of VECs 
with C. albicans hyphae leads to activation of p38-MAPK and ERK1/2 signalling 
pathways, causing upregulation of proinflammatory cytokines (Moyes et al., 2011). C. 
albicans also stimulated intracellular signalling events via activation of NF-kappa-B; 
however this occurred earlier in infection and was independent of C. albicans 
morphology (Moyes et al., 2011). NF-kappa-B is thought to be activated upon 
recognition of C. albicans cell wall constituents such as chitin, β-glucan and mannan. 
Candidalysin has been shown to be able to lyse oral epithelial cells, as well as stimulate 
intracellular signalling pathways, including MAPKs (Moyes et al., 2016). 
 
5.1.2 Host responses to GBS within the GU tract 
Similar to C. albicans, GBS infection can promote the release of proinflammatory 
cytokines. Mice models have shown that when injected with GBS intravenously or 
interperitoneally, proinflammatory cytokines including IL-1β, IL-6, IL-8, IL-10, TNF-α and 
IFN-γ are generated (Ernst et al., 2013;Puliti et al., 2002;Rosati et al., 1998). In vitro, GBS 
has been shown to induce IL-1α, IL-1β, IL-8, IL-23 and IL-36γ expression following 
incubation with VECs, endocervical and ectocervical cells (Patras et al., 2013;Patras et 
al., 2015a). Furthermore, GBS has been found to stimulate expression of IL-8 in A549 
lung epithelial cells in a dose- and time-dependent manner (Doran et al., 2002). 
Proinflammatory cytokines are also important in the context of protecting against 
neonatal GBS infection. IL-12 and IL-18, which are capable of inducing IFN-γ, as well as 
IFN-γ itself, have been shown in models of neonatal infection to protect the host from 
GBS infection (Mancuso et al., 1997). Mice pups had a significantly higher number of 
bacteria in the blood, as well as a higher likelihood of death due to infection, if they 
were pre-incubated with anti-IL-12 antibodies prior to GBS challenge, while treatment 
with recombinant IL-12 reversed these effects (Mancuso et al., 1997;Cusumano et al., 




2004;Cusumano et al., 1996). Similarly, neonatal mice with GBS sepsis had significantly 
increased morbidity and mortality when pre-incubated with anti-IL-18 antibody 
(Cusumano et al., 2004). Treatment of the mice with recombinant IL-18 increased 
survival rates and lowered the CFU of GBS in the blood. The protective effects conferred 
by recombinant IL-12 or IL-18 when administered prophylactically were outweighed by 
pre-incubation with anti-IFNγ antibodies, suggesting that the role of IL-12 and IL-18 in 
host defence against GBS was due to upregulation of IFN-γ (Mancuso et al., 
1997;Cusumano et al., 2004). To support this, inoculation of neonatal mice with 
recombinant IFN-γ after GBS challenge enhanced chances of survival and decreased 
levels of GBS in the blood (Cusumano et al., 1996). 
Neutrophils are important components of the immune response for clearance of GBS. 
Neutrophils are recruited to sites of infection upon secretion of IL-1β, as this induces 
expression of chemokines CXCL1, CXCL2, KC and MIP-1α (Biondo et al., 2014a;Biondo et 
al., 2014b). This is magnified by neutrophils expressing IL-1β themselves, causing a 
positive feedback loop (Mohammadi et al., 2016). IL-1β-deficient mice were much more 
susceptible to GBS infection, and were killed by levels of GBS that WT mice survived, 
with GBS exhibiting an enhanced ability to systemically spread (Biondo et al., 2014a). 
Furthermore, mice deficient in the IL-1 receptor had not only reduced neutrophil 
infiltrate, but also showed a reduction in GBS clearance (Biondo et al., 2014b). 
Nonetheless, GBS can counteract neutrophil-mediated clearance through the expression 
of serine protease CspA. This cleaves CXC chemokines, including GRO-α (CXCL1), GRO-β 
(CXCL2), and GRO-γ (CXCL3), preventing these chemokines from attracting and activating 
neutrophils (Bryan and Shelver, 2009). In addition to neutrophils, macrophages can play 
an important role in controlling pathogenesis of GBS within the GU tract. Protein kinase 
D1 is activated in macrophages by both live and killed GBS. This is necessary for 
triggering activation of MAPKs and NF-kappa-B, leading to production of 
proinflammatory cytokines and chemokines in the vaginal tract (Upadhyay et al., 2017). 
GBS is recognised by Toll-like receptors (TLRs) on the surface of host cells. Activation of 
TLRs leads to activation of p38 MAPK and NF-kappa-B, which are involved in triggering 
secretion of proinflammatory cytokines and reactive oxygen species (ROS) from immune 
cells (Henneke et al., 2002). The single-stranded RNA produced by GBS is recognised by 
MyD88, a TLR adaptor protein, on macrophages and causes release of proinflammatory 
cytokines as a result (Deshmukh et al., 2011). Moreover, the activation of p38 and NF-




kappa-B by TLRs in response to GBS is dependent on expression of MyD88 (Henneke et 
al., 2002). Again, however, GBS can evade such immune responses. The pore-forming 
toxin β-H/C has been shown to activate p38 in macrophages to induce expression of IL-
10, which is anti-inflammatory and immunosuppressive, and macrophages deficient in 
p38 are more effective in mounting a robust anti-GBS response (Bebien et al., 2012). 
GBS two-component regulator CovR also influences pathogenicity of GBS in terms of 
vaginal adherence, invasion and host response (Patras et al., 2013). A CovR null mutant 
exhibited increased binding to VECs, but decreased invasion, as well as inducing higher 
levels of chemokines including IL-8 from host cells in vitro (Patras et al., 2013). 
Interestingly, the WT strain persisted longer within the vaginal tract of mice than the 
CovR mutant, possibly due to the dampened proinflammatory (IL-8) response.  
Alongside modulation of host cytokine responses, GBS can induce epithelial exfoliation 
via integrin and β-catenin signalling (Vornhagen et al., 2018). Transepithelial resistance 
was shown to be significantly reduced when VECs were incubated with GBS, and 
epithelial cells demonstrated increased permeability to fluorescein and nanoparticles 
after infection with GBS, meaning that GBS affects the barrier function of VECs. GBS 
were consequently more able to migrate across the epithelium into the lower 
compartment of a transwell. In a mouse model of vaginal infection, VECs were observed 
to exfoliate 48 h after GBS challenge. Increased permeability and a decrease in barrier 
function are hallmarks of epithelial-mesenchymal transition (EMT), and this was the 
mechanism found to be the cause of GBS-induced exfoliation, with VECs expressing a 
reduced level of E-cadherin in favour of N-cadherin. Exfoliated cells also had changes in 
transcription of EMT genes such as SNAIL1 (Vornhagen et al., 2018). β-catenin signalling 
is involved in EMT, and blocking β-catenin prevented epithelial exfoliation. GBS-infected 
cells had higher levels of active integrin than control cells, with competitive inhibition of 
integrin signalling reducing VEC exfoliation. As such, integrin signalling was hypothesised 
to be the mechanism for activation of β-catenin (Vornhagen et al., 2018). Although 
studies of other GU pathogens have shown that vaginal epithelial exfoliation is a host 
defence mechanism which decreases the bacterial load (Muenzner et al., 
2005;Muenzner et al., 2010), epithelial exfoliation induced by GBS actually enhanced 
numbers of colonising bacteria in the uterus, suggesting that exfoliation facilitated GBS 
ascension of the vaginal tract (Vornhagen et al., 2018). This was supported using a 
mouse model of ascending GBS infection, whereby pregnant mice were infected with 
GBS and treated with either recombinant α1β1 integrin (to competitively inhibit integrin 




signalling) or PBS. Treatment with α1β1 integrin reduced GBS ascension, as shown by 
reduced bacterial load in the placenta, uterus and foetal tissues, and there was a 
reduction in preterm birth or stillbirth (Vornhagen et al., 2018). This could suggest a role 
in blocking these signalling pathways in order to reduce the morbidity and mortality 
associated with ascending GBS infection. 
Given the well-characterised capacity for GBS and C. albicans to modulate their host 
during monospecies infections, it was hypothesised that the synergistic interactions of 
these microbes with VECs may, in turn, affect the host response to these 
microorganisms. To investigate this in greater detail, studies were performed to explore 
the relationship between GBS-C. albicans interactions and neutrophil chemotaxis, 
proinflammatory cytokine production and host protein modulation.  
 
5.2 Results 
5.2.1 Neutrophil chemotaxis studies 
Although it had been identified that there was a synergistic partnership between C. 
albicans and GBS, it remained to be established what effect this had on the host. To 
begin to examine the host response, a neutrophil chemotaxis model was used. These 
studies were performed in the laboratories of Dr Rebecca Hall (Univ Birmingham). 
Neutrophils were isolated from human blood, stained with syto-13 and adhered to the 
viewing chamber of an Ibidi chemotaxis slide. To the left-hand chamber of the slide was 
added K-SFM, while 1:2 diluted spent medium from VEC association assays was added to 
the right-hand chamber. K-SFM was used as a negative control, and 200 nM N-
formylmethionine-leucine-phenylalanine (FMLP) as a positive control. FMLP is a 
chemoattractant, first characterised from E. coli (Marasco et al., 1984). 
Chemotaxis slides were transferred to a microscope and images were taken of the 
viewing chambers every 2 min for 1 h, i.e. 31 images were taken per field. These images 
were analysed for neutrophil movement using the Fiji Trackmate plugin (ImageJ), data 
from which were further analysed with the Ibidi Chemotaxis and Migration program 
(Ibidi®). Due to the orientation of the microscope camera, the neutrophil gradient was 




along the y axis. To maximise the variability assessed by the assays, a different 
neutrophil donor was used with each VEC assay spent medium replicate. 
Representative chemotaxis plots were generated to display the difference in neutrophil 
activity and consequent movement (Figure 5-1). The start point of each neutrophil was 
normalised to the origin of the graph, to better present the direction of movement of 
each neutrophil. The green dot at the centre of each neutrophil population represents 
the centre of mass, i.e. the average movement of all of the neutrophils which have been 
tracked. If there was a positive chemotactic effect (i.e. neutrophils were moving towards 
the test sample), the centre of mass would move down the y axis. This was observed for 
the positive control, FMLP, alongside spent medium from VECs incubated with each of 
the three GBS strains or with C. albicans+COH1 (Figure 5-1). The chemoattractant effect 
was most noticeable with COH1, which may account for a chemotactic effect only being 
seen using spent medium from dual-species assays with COH1 rather than with NEM316 
or 515 (Figure 5-1). The chemotaxis plots for spent medium from C. albicans alone 
showed some neutrophil activation, and this was visibly more than was observed with 
the negative VEC-only spent medium control. However, there was no direction, 
indicating that the neutrophils were stimulated but were not attracted to the source of 
stimulation. Similar plots were observed for neutrophils exposed to spent medium from 
C. albicans+NEM316 and C. albicans+515 (Figure 5-1); however the neutrophils 
appeared to show more overall activity than the C. albicans plot. No neutrophil activity 
or chemotaxis was observed for the VEC plot, which showed neutrophils clustered 
around the origin of the graph, indicating that the majority of neutrophils were 
stationary throughout the assay (Figure 5-1). A similar plot was generated with 
neutrophils exposed to K-SFM (data not shown).  





Figure 5-1 Plots of neutrophil chemotaxis in response to conditioned media from VEC association assays.  
VECs were incubated with C. albicans (MOI 2.5) for 6 h, or GBS (MOI 2.5) for 5 h. Alternatively, VECs were 
incubated with C. albicans for 1 h followed by addition of GBS and incubation for a further 5 h. Conditioned 
media were collected from well plates and microbes were pelleted for removal. Neutrophils were adhered 
to Ibidi chemotaxis slides. K-SFM, 200 nM FMLP or conditioned media, as indicated, were added and slides 
were imaged with a microscope every 2 min over 1 h (31 time points in total). Neutrophils were tracked 
using Fiji TrackMate, from which data were inputted into Ibidi Chemotaxis and Migration tool to generate 
chemotaxis plots. Red dots indicate neutrophil end points, while green dots indicate the centre of mass of 
the neutrophil population. Studies were performed on 4 occasions. Data are presented from one 
representative experiment.  
 
Neutrophil tracks were analysed for centre of mass and forward migration (Figure 5-2), 
and for directionality, distance and velocity (Figure 5-3). For all parameters tested, 
neutrophils did not respond any differently to blank K-SFM medium than they did to 
conditioned media from VECs (Figure 5-2 and Figure 5-3). Centre of mass is the average 
movement of the population of neutrophils across the duration of the assay, while 




forward migration index (FMI) is a measure of whether the neutrophils are moving 
randomly. Strong chemotaxis effects are described as having large FMI parallel to the 
gradient (FMI║, Figure 5-2D) and a perpendicular FMI that is close to zero (FMI┴, Figure 
5-2C). A strong chemotactic effect was seen in the presence of GBS; when VECs were 
incubated with GBS, both centre of mass║ and FMI║ were found to be large. However, 
considerably less chemotaxis was observed in response to dual-species-infected VECs 
(Figure 5-2B, D). The chemotactic effects of conditioned media from VECs incubated 
with GBS were found to be significantly different to those of the VEC-only control 
conditioned media for both centre of mass and FMI parallel to the gradient (Figure 5-2B, 
D), while the effects of conditioned media from VECs incubated with only C. albicans or 
both species were not significantly different. For centre of mass║, conditioned media 
recovered from VECs incubated with C. albicans or both microorganisms, with the 
exception of C. albicans+COH1, were significantly different from the FMLP positive 
control (Figure 5-2B). For FMI║, this was only true for conditioned media from VECs 
incubated with C. albicans or C. albicans+NEM316 (Figure 5-2D). This implied an 
inherent difference in the way VECs responded to GBS alone compared to GBS with C. 
albicans. Little neutrophil movement was observed perpendicular to the gradient 
(Figure 5-2A, C) for either centre of mass or FMI, indicating that neutrophils 
predominantly moved in the direction of the gradient, if at all. This reinforces the 
representative chemotaxis plots (Figure 5-1), indicating that the neutrophils generally 
responded to positive signals. 
 





Figure 5-2 Chemotaxis of neutrophils in response to conditioned media from VEC association assays.  
VECs were incubated with C. albicans (MOI 2.5) for 6 h, or GBS (MOI 2.5) for 5 h. Alternatively, VECs were 
incubated with C. albicans for 1 h followed by addition of GBS and incubation for a further 5 h. Conditioned 
media were collected from well plates and microbes were pelleted for removal. Neutrophils were adhered 
to Ibidi chemotaxis slides. K-SFM, 200 nM FMLP or conditioned media from VEC assays was added and slides 
were imaged every 2 min over 1 h (31 time points in total). A, B) centre of mass of the population of 
neutrophils; C, D) forward migration index of neutrophil population. A, C) examine these parameters on the 
x axis (perpendicular to the gradient); B, D) examine these parameters on the y axis (parallel to the 
gradient). Data are presented as mean ± SEM. * indicates P<0.05 relative to VK2/E6E7 control, NS indicates 
P>0.05 relative to VK2/E6E7 control, § indicates P<0.05 relative to FMLP positive control as determined by 
independent samples Kruskal Wallis; n=4. 
 
Further parameters that the neutrophils were tested for were velocity and 
directionality, a measure of how direct the neutrophils’ movement was (Figure 5-3A, B). 
Additionally, the accumulated and Euclidean distance were tested (Figure 5-3C, D). 
Accumulated distance was defined as the total distance covered by the neutrophils, 
while Euclidean distance was defined as the distance between the neutrophil start and 
end point. Similar to the pattern seen for FMI║ and centre of mass║in Figure 5-2, there 
were no significant differences between neutrophil response to the VEC-only 
conditioned media when compared to conditioned media from VEC infected with either 




C. albicans or C. albicans+GBS for velocity (Figure 5-3B), accumulated or Euclidean 
distance (Figure 5-3C,D). However, there was also no significant difference for the 
conditioned media from VEC infected with NEM316 for accumulated and Euclidean 
distance (Figure 5-3C, D), suggesting an attenuated neutrophil response to NEM316 
which may enable persistence. Additionally, for directionality only conditioned media 
from cells infected with just C. albicans or C. albicans+NEM316 were not significant 
when compared against the neutrophil response to VECs. The other experimental 
groups exhibited similar levels of directionality (Figure 5-3A).  
For each of these parameters, there were no significant differences between the 
neutrophil response to FMLP compared to the GBS-only groups, while there were 
significant differences between FMLP and C. albicans-only or the negative controls. 
However, for directionality, there were also no significant differences between FMLP 
and C. albicans with any of the GBS strains. For velocity, there was no significant 
difference between FMLP and C. albicans+515. Meanwhile, for both accumulated and 
Euclidean distance, all of the dual-species groups were significantly different to FMLP. 
This further suggests that, in general, when GBS was incubated with VECs alone, release 
of chemoattractants was stimulated, while when GBS was co-incubated with C. albicans, 
this response was attenuated. 
 





Figure 5-3 Chemotaxis of neutrophils in response to conditioned media from VEC association assays.  
VECs were incubated with C. albicans (MOI 2.5) for 6 h, or GBS (MOI 2.5) for 5 h. Alternatively, VECs were 
incubated with C. albicans for 1 h followed by addition of GBS and incubation for a further 5 h. Supernatant 
was collected from well plates and microbes were pelleted for removal. Neutrophils were adhered to Ibidi 
chemotaxis slides. K-SFM, 200 nM FMLP or conditioned media from VEC assays were added and slides were 
imaged with a microscope every 2 min over 1 h (31 time points in total). A) Directionality or B) velocity of 
the population of neutrophils; C) accumulated or D) Euclidean distance of the neutrophil population. Data 
are presented as mean ± SEM. * indicates P<0.05 relative to VK2/E6E7 control, NS indicates P>0.05 relative 
to VEC control, § indicates P<0.05 relative to FMLP positive control as determined by independent samples 
Kruskal Wallis; n=4. 
  




5.2.2 Proteome analysis 
To investigate, on a protein level, the VEC response to GBS-C. albicans interactions, 
mixed-species association assays were carried out using GBS strain NEM316. Cells were 
then lysed by recovery into 8 M urea, followed by tryptic digestion of the total protein. 
Peptides were analysed by tandem mass tagging and subsequent mass spectrometry, 
and identified using the FASTA database. Peptides generated spectra which could be 
used to identify which species they belonged to, alongside the calculated theoretical 
number of amino acids, molecular weight and isoelectric point. Following identification, 
further analysis excluded proteins which were detected in only one of the experimental 
infection replicates or that were not changed in expression relative to the VEC-only 
control. Proteins were considered upregulated if expression was at least 2-fold higher 
than the VEC-only control or considered downregulated if expression was 2-fold or more 
reduced (i.e. expression at 0.5-fold or lower). These shortlisted proteins were then 
further analysed using the Protein ANalysis THrough Evolutionary Relationships 
(PAnThER) database, which collects Gene Ontology (GO) annotations for each protein. 
Some of the proteins had multiple annotations, while others were uncharacterised or 
had limited information available, which restricted the analysis (Table 5-1). The three GO 
terms ‘biological process’, ‘cellular component’, and ‘molecular function’ were 
investigated as well as the additional PAnThER terms ‘protein class’ and ‘pathway’. 
These were selected as they are believed to be effective for classifying proteins based on 
their functions (Thomas et al., 2003;Mi et al., 2013). 
 




Table 5-1 Overview of VEC proteins that were upregulated or downregulated in response to infection 
















Dual-species Upregulated 136 1  175 hits 81 hits 95 hits 72 hits 43 hits 
Downregulated 299 7  354 hits 186 hits 200 hits 196 hits 170 hits 
C. albicans-only and 
C. albicans+GBS 
Upregulated 146 87 98 hits 39 hits 52 hits 36 hits 43 hits 
Downregulated 150 77 103 hits 46 hits 58 hits 35 hits 19 hits 
GBS-only and  
C. albicans+ GBS 
Upregulated 8 4 0 hits 0 hits 0 hits 0 hits 0 hits 
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5.2.2.1 VEC response to GBS 
There were 30 VEC proteins significantly altered in response to GBS between the VEC-
only control and VECs exposed to GBS monospecies infection. Few proteins were 
directly associated with what is known regarding the pathogenesis of GBS. The most 
common theme amongst upregulated proteins was the cytoskeleton, including 
cytokeratin 4, which has been described as a binding partner for the GBS adhesin Srr1 
(Sheen et al., 2011). Of the downregulated proteins, the most common themes were 
transcriptional regulation and cytoskeletal organisation (Appendix 1 and Appendix 2).  
Somewhat surprisingly, there were only 14 VEC proteins which were significantly altered 
in expression between the VEC-only control and VECs exposed to GBS monospecies or 
dual-species infection: 8 upregulated and 6 downregulated. Due to the small number of 
proteins altered in expression within this group, it is not possible to draw many major 
conclusions from these data. Although few proteins correlated with pathogenesis, the 
particularly steep increase in expression of actin gamma 1 (from 9.5 in monospecies to 
100 in dual-species infection, Table 5-2) may suggest that the presence of C. albicans can 
exacerbate cytoskeletal rearrangements induced by GBS. Likewise, the 10-fold increase 
in abundance of heat shock protein 90Af (from 2.7 to 28.3, Table 5-2) may indicate an 
elevated stress response in VECs following dual-species infection relative to 
monospecies infection. This may reflect evidence from previous chapters that VECs are 
exposed to increased numbers of GBS when in the presence of C. albicans. Three other 
cytoskeleton proteins were upregulated, all of which were keratins (Table 5-2). This 
suggests major upregulation of cytoskeletal proteins, which GBS may be able to target as 
sites for adhesion to the epithelial cells. Among the downregulated proteins, there was 
no clear theme in protein function and, aside from one protein involved in 
reorganisation of the cytoskeleton, there was not a clear link between function and 
what is known about the pathogenesis of these microorganisms (Table 5-3).  
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Table 5-2 Overview of proteins that were upregulated only in the GBS-infected and C. albicans+GBS-
infected VECs relative to the VEC-only control. 
Protein 
code 








(VECs + C. 
albicans + 
GBS) / (VECs) 
V9HVZ7 Actin gamma 1  Actin 9.483 100 
Q58FF9 Heat shock 
protein 90Af  
Protein folding 2.747 28.277 
Q9BSM1 Polycomb group 
RING finger 






Biosynthesis of GAGs 2.492 3.558 
H0Y459 Nuclear receptor 




P35527 Keratin, type I 
cytoskeletal 9 
Keratin 2.265 2.435 
Q86Y46 Keratin, type II 
cytoskeletal 73  
Keratin 2.099 2.266 
H6VRG1 Keratin 1  Keratin 2.011 2.328 
 
Table 5-3 Overview of proteins that were downregulated only in the GBS-infected and C. albicans+GBS-
infected VECs relative to the VEC-only control. 
Protein 
code 








(VECs + C. 
albicans + 
GBS) / (VECs) 
B2R6X5 Heat shock 
70kDa protein 6  
Folding of proteins 0.285 0.257 
Q66K64 DDB1- and 
CUL4-associated 
factor 15  










protein 19  
Regulates 
organisation of the 
cytoskeleton 
0.488 0.476 
P55060 Exportin-2  Export receptor 0.498 0.425 
B4DY32 Asparagine 
synthetase  
Asparagine synthesis 0.498 0.463 
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5.2.2.2 VEC response to C. albicans  
A total of 68 VEC proteins were modulated by C. albicans, but not in the presence of 
GBS: 28 upregulated and 34 downregulated (see Appendix 3 and Appendix 4 for 
complete lists). B-cell lymphoma 3 protein was upregulated in response to C. albicans-
only infection, and has a role in activation of NF-kappa-B, while another upregulated 
protein was found to be a subunit of NF-kappa-B, which could suggest an increase in 
host defence-related signalling. Another key theme among the upregulated proteins was 
cytoskeletal organisation, while for the downregulated proteins this was transcriptional 
regulation. Overall, however, there was no strong correlation with the precise pathways 
known to be targeted by C. albicans.  
A total of 146 VEC proteins were upregulated and 150 were downregulated in response 
to C. albicans, independent of the presence of GBS (i.e. were identified for both the C. 
albicans-only sample and the C. albicans+GBS sample) (Table 5-1; see Appendix 5 and 
Appendix 6 for complete lists). A high proportion were not annotated in the PAnThER 
database, but available proteins were assessed against the three GO terms as well as 
two additional PAnThER categories. ‘Biological process’ comprised 12 categories (Figure 
5-4A), ‘cellular component’ comprised 7 (Figure 5-4B), ‘molecular function’ comprised 7 
(Figure 5-4C), ‘protein class’ comprised 19 (Figure 5-5) and ‘pathway’ comprised 38 
(Figure 5-6). Among the ‘biological process’ category, the most significantly 
overrepresented terms were ‘cellular process’ and ‘metabolic process’. This was seen for 
both up- and downregulated proteins, although the latter were most abundant. A 
similar pattern was seen for category ‘cellular component’, for which the most 
significantly enriched terms were ‘cell part’ and ‘organelle’. Within the ‘molecular 
function’ category, downregulated proteins belonging to the terms ‘catalytic activity’ or 
‘binding’ were the most abundant. The most enriched, downregulated proteins within 
the category ‘protein class’ were assigned across a number of different terms, the top 
three of which were ‘enzyme modulator’, ‘nucleic acid binding’ and ‘transcription 
factor’. The most abundant proteins that were upregulated in this category belonged to 
the terms ‘hydrolase’ and ‘transporter’. For the category ‘pathway’, significantly 
expressed proteins were distributed across numerous terms. However, more proteins 
were up- than downregulated and of these, proteins associated with terms ‘CCKR 
signaling map’, ‘gonadotropin-releasing hormone receptor pathway’, ‘inflammation 
mediated by CXC/CK signaling’ and ‘integrin signaling pathway’ were the most abundant. 




Figure 5-4 Distribution of VEC proteins grouped into GO categories that were significantly altered in C. 
albicans and C. albicans+GBS infected cells. 
Significantly upregulated proteins, white bars; significantly downregulated proteins, black bars. A) Biological 
process, B) cellular component, C) molecular function. Proteins included across all terms exhibited ≥2-fold 
expression difference relative to uninfected VECs; n=2. 




Figure 5-5 Distribution of VEC proteins grouped into the category ‘protein class’ that were significantly 
altered in C. albicans and C. albicans+GBS infected cells.  
Significantly upregulated proteins, white bars; significantly downregulated proteins, black bars. Proteins 
included across all terms exhibited ≥2-fold expression difference relative to uninfected VECs; n=2.  
 




Figure 5-6 Distribution of VEC proteins grouped into the category ‘pathway’ that were significantly altered 
in C. albicans and C. albicans+GBS infected cells.  
Significantly upregulated proteins, white bars; significantly downregulated proteins, black bars. Proteins 
included across all terms exhibited ≥2-fold expression difference relative to uninfected VECs; n=2. 
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To build on the overview provided by the PAnThER analysis and to try and understand 
the VEC response to C. albicans infection in greater detail, the individual proteins were 
also investigated. To aid this process, particular focus was given to those proteins that, 
based on functionality, had potential relevance to the context of microbial infection (e.g. 
surface-bound proteins, those with antimicrobial properties, major regulators, those 
that engage with the immune response). Of the proteins which were upregulated in the 
VECs infected with C. albicans alone and C. albicans+GBS (Table 5-4), the most abundant 
protein was an inhibitor of the complement cascade, which inactivates complement 
components C3b and C4b. Two other abundant proteins, chromogranin and lactoferrin, 
have antimicrobial activity. Chromogranin is a precursor of five peptides, one of which 
(catestatin) has antimicrobial activity and acts as a chemoattractant of macrophages 
(Egger et al., 2008;Briolat et al., 2005;Radek et al., 2008), while another (chromofungin) 
has antifungal activity (Lugardon et al., 2002). Lactoferrin is found in mucosal secretions 
and binds strongly to iron, causing a static effect on microbial growth, as well as directly 
causing cell lysis in a broad range of microbes (Garcia-Montoya et al., 2012). Other 
common themes seen among the upregulated proteins were proteins associated with 
organisation of the actin cytoskeleton, such as β-actin and FAK-1, and with cell-cell or 
cell-ECM adhesion. These included a variety of surface-exposed receptors such as CD44, 
ICAM-1 and integrin receptors. 
Table 5-4 VEC proteins which were upregulated both when VECs were incubated with C. albicans and C. 
albicans+GBS which were most relevant to infection 
Protein 
code 
Protein name Protein function 
Relative 
abundance 





(VECs + C. 
albicans + 
GBS) / (VECs) 





P02787 Serotransferrin  Iron transport, 
membrane protein 
5.582 5.758 
P10645 Chromogranin-A  Antimicrobial peptide 4.833 5.083 








E5RJP0 Focal adhesion 






ATPase, cell adhesion, 
membrane protein 
2.935 3.061 





Protein name Protein function 
Relative 
abundance 





(VECs + C. 
albicans + 
GBS) / (VECs) 
ATPase subunit 
beta-1  
A1E282 Beta-actin  Actin 2.803 2.384 














binding protein Li 
97n  
Regulates NF-kappa-B 2.681 3.219 
SET SET translocation 
(Myeloid leukemia-
associated)  
Apoptosis, transcription 2.642 3.015 
E7EWM2 Centrosomal 
protein of 170 kDa  
Cytoskeletal organisation 2.634 3.096 
P18084 Integrin beta-5  Cell adhesion, membrane 
protein 
2.585 2.484 
P08123 Collagen alpha-2(I) 
chain  
Collagen 2.553 2.296 
U3KQV3 Unnamed protein  GTPase, membrane 
protein 
2.536 3.125 
P51884 Lumican  Collagen binding and 
organisation 
2.522 2.704 











G8JLH6 Tetraspanin  Cell surface protein, 
membrane protein 
2.39 2.063 
U3KQE2 Calpain small 





TNC Tenascin C 
(Hexabrachion)  
ECM protein 2.339 2.827 
F5GZS6 4F2 cell-surface 
antigen heavy 
chain  
Ion transport, membrane 
protein 
2.323 2.375 





Protein name Protein function 
Relative 
abundance 





(VECs + C. 
albicans + 










family, member L1 
variant  


















expressed in kidney and 
intestine 
2.221 2.302 








Q8NI35 InaD-like protein  May regulate protein 
targeting, cell polarity 







M member 1  
Regulation of endosomal 
trafficking 
2.131 3.123 










Q9Y639 Neuroplastin  Cell adhesion, activation 
of p38 MAPK, membrane 
protein 
2.094 2.38 
B4DL55 Laminin beta-3 
chain  
Laminin 2.084 2.395 





Protein name Protein function 
Relative 
abundance 





(VECs + C. 
albicans + 









Of the proteins which were downregulated in only the VECs infected with C. albicans 
alone or C. albicans+GBS (Table 5-5), eight are involved in apoptosis regulation. Several 
other proteins are associated with organisation of the cell cytoskeleton. 
Table 5-5 VEC proteins relevant to infection which were downregulated both when VECs were incubated 
with C. albicans and C. albicans+GBS which were most relevant to infection 
Protein 
code 
Protein name Protein function 
Relative 
abundance 





(VECs + C. 
albicans + 
GBS) / (VECs) 
Q0P5N8 TMSB4X protein  Cytoskeletal 































Q9P0C6 HSPC255  Activates MAPK 0.31 0.339 







Apoptosis, cell cycle 
regulation 
0.331 0.247 
O75676 Ribosomal protein 






Q01546 Keratin, type II 









Protein name Protein function 
Relative 
abundance 





(VECs + C. 
albicans + 
GBS) / (VECs) 
Q6S5L8 SHC-transforming 
protein 4  
Tyrosine kinase binding, 






sorting protein 2  





Induces apoptosis 0.376 0.429 
Q7L3V2 Protein Bop  Induces apoptosis 0.401 0.486 
P02533 Keratin, type I 







protein MyD88  
MyD88, inflammatory 
response, upregulation 











A8K2I0 Keratin 6A  Intermediate filament, 
cytoskeletal protein 
0.424 0.379 
P35080 Profilin-2  Cytoskeletal 




Q5VZL5 Zinc finger MYM-












H0YAT7 Dystonin  Cytoskeletal linker 
protein 
0.465 0.497 






J3KPZ4 Nuclear nucleic 
acid-binding 
protein C1D  
Apoptosis 0.475 0.455 
P13647 Keratin, type II 









Protein name Protein function 
Relative 
abundance 





(VECs + C. 
albicans + 










5.2.2.3 VEC response to dual-species infection 
A total of 299 VEC proteins were downregulated in only the dual-species-infected VECs, 
and 136 were upregulated in only the dual-species-infected cells (see Appendix 7 and 
Appendix 8 for complete lists). When assigned to the five categories described earlier, 
‘biological process’ comprised 14 categories (Figure 5-7A), ‘cellular component’ 
comprised 8 (Figure 5-7B), ‘molecular function’ comprised 7 (Figure 5-7C), ‘protein class’ 
comprised 22 (Figure 5-8) and ‘pathway’ comprised 75 (Figure 5-9). Among the 
‘biological process’ category, the most significantly overrepresented terms comprised 
‘cellular process’ and ‘metabolic process’. This was seen for both up- and downregulated 
proteins, although the latter were most abundant (Figure 5-7A). A similar pattern was 
seen for category ‘cellular component’, for which the most significantly enriched terms 
were ‘cell part’, ‘macromolecular complex’ and ‘organelle’ (Figure 5-7B). Within the 
‘molecular function’ category, downregulated proteins belonging to the terms ‘catalytic 
activity’ or ‘binding’ were the most abundant (Figure 5-7C). 




Figure 5-7 Distribution of VEC proteins grouped into GO categories that were significantly altered in dual-
species infected cells.  
Significantly upregulated proteins, white bars; significantly downregulated proteins, black bars. A) Biological 
process, B) cellular component, C) molecular function. Proteins included across all terms exhibited ≥2-fold 
expression difference relative to uninfected VECs; n=2. 
 
Again, the most altered proteins within the category ‘protein class’ were downregulated 
(Figure 5-8). These proteins were assigned across a number of different terms, the top 
three of which were ‘hydrolase’, ‘transferase’ and ‘oxidoreductase’.  Finally, within the 
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category ‘pathway’, significantly expressed proteins were distributed across numerous 
terms (Figure 5-9). Once again, however, downregulated proteins were the most 
abundant. Of these, proteins associated with the term ‘p53 pathways’ were the most 
altered. For upregulated proteins, the most significant term was ‘integrin signalling 
pathway’.  
 
Figure 5-8 Distribution of VEC proteins grouped into category ‘protein class’ that were significantly altered 
in dual-species infected cells. 
Significantly upregulated proteins, white bars; significantly downregulated proteins, black bars. Proteins 
included across all terms exhibited ≥2-fold expression difference relative to uninfected VECs; n=2. 
 




Figure 5-9 Distribution of VEC proteins grouped into category ‘pathway’ that were significantly altered in 
dual-species infected cells.  
Significantly upregulated proteins, white bars; significantly downregulated proteins, black bars. Proteins 
included across all terms exhibited ≥2-fold expression difference relative to uninfected VECs; n=2. 
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As before, to build on the overview provided by the PAnThER analysis, individual 
proteins were also investigated. Of these selected proteins, those that were significantly 
upregulated are shown in Table 5-6. Among these VEC proteins, the most common 
theme was proteins associated with the actin cytoskeleton and its organisation. Proteins 
were also identified that may have capacity to serve as potential receptors for C. 
albicans and/or GBS. These included ECM proteins, such as laminin and collagen, which 
may act as bridging molecules, or surface-expressed determinants such as CD59. 
Regulatory proteins associated with immune or proinflammatory responses also 
exhibited enhanced expression. These included arginase-1 and four proteins that are 
associated with activation of NF-kappa-B. Arginase-1 has been shown to be upregulated 
in macrophages in response to chitin in the cell wall of C. albicans, preventing the 
induction of nitric oxide and thus reducing the antifungal activity of the macrophages 
(Wagener et al., 2017). In intestinal epithelial cells, excess arginase-2 production was 
linked to a reduction in nitric oxide production in response to E. coli LPS, as well as a 
reduced rate of apoptosis (Talavera et al., 2017). Upregulation of arginase-1 in VECs may 
play a similar role. CD99 antigen is a cell surface protein involved in the migration of 
leukocytes, adhesion of T-cells and death of T-cells by a caspase-independent pathway. 
Although CD99 is primarily expressed on the surface of haematopoetic cells such as 
lymphocytes (Petri and Bixel, 2006), more recently it has also been found to be 
expressed on epithelial cells (Krisanaprakornkit et al., 2013). Upregulation of this protein 
in the dual-species infection may signify increased immune activation in response to GBS 
and C. albicans. 
Table 5-6 VEC proteins which were specifically upregulated in dual-species infections most relevant to 
human infection 
Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) /  
(VECs) 
H7C2F2 CD99 antigen  Cytoskeletal organisation of 
actin 
4.059 
Q86UE4 Protein LYRIC  Activates NF-kappa-B 3.585 




protein of 170 
kDa  
Cytoskeletal organisation of 
microtubules 
3.127 
P05089 Arginase-1  Regulator of immune 
responses 
3.09 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) /  
(VECs) 
P49711 Transcriptional 
repressor CTCF  
MHC class II activator 2.83 
A0A024R2V2 Microtubule-
associated 
protein 4  
Cytoskeletal organisation of 
microtubules 
2.8 
Q14686 Nuclear receptor 
coactivator 6  
Activates NF-kappa-B 2.693 
A0A0R9RWK2 Erb-b2 receptor 
tyrosine kinase 2  
Binds EGF receptor to stabilise 









protein 2  
Cytoskeletal protein 2.547 







M0R0H3 mRNA decay 
activator protein 
ZFP36  
Suppresses TNF-α 2.462 
K7ENT6 Tropomyosin 
alpha-4 chain  
Cytoskeletal organisation of 
actin 
2.42 




protein 9  
Cytoskeletal organisation, 
mediates cell motility, cell-cell 
and cell-matrix interactions 
2.393 
P35222 Catenin beta-1  Transcriptional regulation, 
membrane bound, localises to 
adherens junctions and affects 
integrity of epithelial 
monolayer 
2.319 
V9GYF0 Rho guanine 
nucleotide 
exchange factor 2  
Activates NF-kappa-B 2.276 
G3XAI2 Laminin subunit 
beta-1  
ECM protein 2.251 
P28908 Tumor necrosis 
factor receptor 
superfamily 
member 8  
TNF receptor, NF-kappa-B 
activation 
2.242 
Q06828 Fibromodulin  TGF-β receptor assembly 2.24 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) /  
(VECs) 
containing 
protein 1  
P13645 Keratin, type I 
cytoskeletal 10  
Cytoskeletal protein 2.232 
P11047 Laminin subunit 
gamma-1  
ECM protein 2.226 
A7MBN3 Collagen, type IV, 
alpha 5  
ECM protein 2.222 





MHC class I component, 
involved in antigen 
presentation 
2.191 
Q8N129 Protein canopy 
homolog 4  
TLR4 regulation 2.155 
P13726 Tissue factor  Involved in cytokine receptor 




38, NatC auxiliary 
subunit  
Apoptosis repressor 2.111 
Q86YL7 Podoplanin  Cytoskeletal organisation 2.107 
Q13092 Epidermal type I 
keratin  




















O75712 Gap junction 
beta-3 protein  
Gap junction, membrane 
bound 
2.061 
P81605 Dermcidin  Antimicrobial peptide 2.052 
P25942 Tumor necrosis 
factor receptor 
superfamily 
member 5  
Mediates signalling from 
members of TNF receptor 
superfamily 
2.043 
A0A0S2Z4G4 Tropomyosin 3 Cytoskeletal organisation of 
actin 
2.039 
C9JTA2 Mitotic spindle 
assembly 
Cell cycle progression 2.022 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) /  
(VECs) 
checkpoint 
protein MAD1  
P08572 Collagen alpha-
2(IV) chain  
ECM protein 2.014 
 
Of the downregulated VEC proteins (Table 5-7), eleven proteins were downregulated 
which are involved in cytoskeletal organisation. Seven proteins were involved in 
promotion of apoptosis, suggesting that the microbes may work to promote VEC survival 
and thus evade immune clearance. Likewise, several downregulated proteins are 
associated with the MAPK pathway, which plays a key role in the epithelial immune 
response to C. albicans and GBS. However, there were also proteins for which 
downregulation may be expected to result in the induction of an immune response. For 
example, ubiquitin thioesterase otulin limits proinflammatory cytokine activation and 
negatively regulates NF-kappa-B. Downregulation of a NF-kappa-B repressor correlates 
with the concomitant upregulation of several proteins that promote NF-kappa-B 
activation. 
Table 5-7 VEC proteins which were specifically downregulated in dual-species infections most relevant to 
human infection 
Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) /  
(VECs) 
P14373 Zinc finger protein RFP  Ubiquitination, 
induces apoptosis 
0.01 
O76095 Protein JTB  Cell cycle 
progression, may 
inhibit apoptosis 
induced by TGFB1 
0.273 











A8K710 Sterile alpha motif and 
leucine zipper containing 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 




protein kinase  
MAPK pathway 0.354 





A8K3B6 Tyrosine-protein kinase  Suppresses TCR and 
BCR signalling 
0.367 
P67812 Signal peptidase complex 
























Q00013 55 kDa erythrocyte 




B2R4D5 Actin-related protein 2/3 
complex subunit 3  
Cytoskeletal 






Apoptosis induction 0.406 
Q16539 Mitogen-activated protein 






















F8VZY9 Keratin, type I cytoskeletal 
18  
Cytoskeletal protein 0.429 
O75381 Peroxisomal membrane 





Q96BN8 Ubiquitin thioesterase 
otulin  
Regulates innate 
immune response to 
0.436 
Chapter 5 Host response to GBS-C. albicans interactions 
143 
 
Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 







A8K9G4 FLJ77745  Regulates TNF-α 0.439 
Q9P287 BRCA2 and CDKN1A-





P68366 Tubulin alpha-4A chain  Cytoskeletal protein 0.456 
Q9H4B6 Protein salvador homolog 
1  
Promotes apoptosis 0.459 
A8K669 FLJ78452 Peptide processing 
for MHC class II 
0.46 
P55212 Caspase-6  Caspase, 
overexpression 
leads to apoptosis 
0.46 
B0I1P6 Kidney ankyrin repeat-
containing protein 4  
Cytoskeletal 










A0A024R687 Pleckstrin homology 
domain containing, family 
C (With FERM domain) 
member 1  
Cytoskeletal 
organisation of 
actin, interacts with 
integrin 
0.465 




Q9BTV5 Fibronectin type III and 
SPRY domain-containing 





A0A024R275 Riboflavin kinase  TNF-α pathway 0.47 
Q8TE77 Protein phosphatase 
slingshot homolog 3  
Cytoskeletal 
organisation of actin 
filaments 
0.471 
Q02750 Dual specificity mitogen-
activated protein kinase 
kinase 1  
MAPK pathway 0.476 
A0A0S2Z3H1 Caspase 2 apoptosis-
related cysteine peptidase  
Caspase 0.477 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 











A0A0G2JH58 MHC class I polypeptide-
related sequence B  
MHC class I pathway 0.481 
F5H5D3 Tubulin alpha chain  Cytoskeletal protein 0.482 
P07737 Profilin-1  Cytoskeletal 
organisation of actin 
0.483 
P27449 V-type proton ATPase 16 












for MHC class I 
0.49 
O95999 B-cell 







P05783 Keratin, type I cytoskeletal 
18  
Cytoskeletal protein 0.492 
Q9NZN3 EH domain-containing 




















5.2.3 Real-time RT-PCR studies 
To complement the global analysis approach offered by the proteomics experiments 
(section 5.2.2), additional studies were performed to determine what effects the GBS-C. 
albicans interactions had on the VECs with regards to a proinflammatory cytokine 
response. RNA was harvested from VECs infected with GBS, C. albicans or both, and 
converted to cDNA. Real-time PCR was then performed using primer sets to identify the 
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relative expression levels of genes encoding six cytokines known to be associated with 
GBS or C. albicans disease: IL-1α, IL-1β, IL-8, IL-17, IL-23, and IL-36γ, with GAPDH used as 
the endogenous control (Patras et al., 2015a;Patras and Nizet, 2018;Mikamo et al., 
2004;Doran et al., 2002). Real time RT-PCR was carried out on VEC samples infected with 
NEM316 or COH1. COH1 was used rather than 515 due to the neutrophil chemotaxis 
data, detailed in section 5.2.1, which showed that conditioned media from VECs infected 
with COH1 induced a greater neutrophil response, for which the centre of mass║ and 
FMI║ were comparable to that of the FMLP positive control (Figure 5-2).  
In general, a more dramatic induction of cytokine transcript expression was detected 
with NEM316 than with COH1. Interestingly, a different profile was generated 
dependant on GBS strain. This may correlate with the enhanced cytotoxicity observed 
when VECs were incubated with NEM316 for an extended period (Chapter 3).  
For NEM316 (Figure 5-10A), the transcript levels for IL-8, IL-17 and IL-36γ were 
significantly higher in the dual-species infected cells than the sum of the two 
monospecies infected cells, implying a possible synergistic effect with regards to 
expression of these genes. Transcript levels for IL-1α and IL-23 were comparable for the 
dual-species and C. albicans monospecies samples. No significant difference was seen in 
transcript levels for IL-1β across any of the samples. For COH1 (Figure 5-10B), 
significantly enhanced expression of the IL-8 gene was seen for the dual-species 
infection relative to the combined monospecies levels. Transcript levels for IL-1β, IL-17 
and IL-23 were comparable for dual-species and C. albicans monospecies samples, and 
no significant differences were seen for IL-1α or IL-36γ across any of the samples.  
 




Figure 5-10 Expression ratios of cytokines produced by VECs in response to infection with GBS and/or C. 
albicans.  
VECs were grown to confluence in 75 cm2 tissue culture flasks before incubation with either C. albicans (MOI 
2.5, grey bars) for 4 h or GBS (MOI 5, white bars) for 3 h. Alternatively, VECs were incubated with C. albicans 
for 1 h followed by addition of GBS and incubation for a further 3 h (black bars). Monolayers were 
disassociated, harvested and RNA was extracted using the Qiagen RNeasy Mini kit. Levels of cytokine 
transcripts were determined by real-time RT-PCR. A) VECs incubated with NEM316; n=4, B) VECs incubated 
with COH1; n=3. * indicates P<0.05 relative to VECs incubated with GBS, § indicates P<0.05 relative to VECs 
incubated with C. albicans, as established by one-way ANOVA with Tukey post-test. 
 
    




The data presented in this chapter sought to explore the host response to GBS-C. 
albicans interactions. To do this, the capacity of these microbes to generate a 
chemotactic neutrophil response was investigated, alongside their capacity to modify 
expression of chemotactic or proinflammatory cytokines. To gain a more global 
perspective, changes in proteome profiles of the VECs were examined also. 
 
5.3.1 Neutrophil chemotaxis 
Neutrophil activation was considered for these studies as neutrophils are the most 
abundant immune cell in the vaginal tract (Nandi and Allison, 1993). When neutrophils 
are more activated in terms of motility, they are more likely to eradicate infection 
(Mantovani et al., 2011). Furthermore, there was precedent for bacterial interactions 
with C. albicans to modulate neutrophil behaviour. Peters and Noverr (2013) described a 
C. albicans-S. aureus coinfection that resulted in upregulation of proinflammatory 
cytokines that, in turn, altered the neutrophil response, leading to enhanced virulence 
(Peters and Noverr, 2013). As might be predicted, the data from the studies presented 
here indicated that neutrophils showed more activity when exposed to microbial-
infected conditioned media than VEC-only conditioned media. This confirmed that the 
VECs were not secreting chemokines without microbial stimulation. Moreover, it was 
found that neutrophils were more active and exhibited greater directionality (i.e. 
neutrophils were aware of the location of their target) when cells were infected with 
GBS alone rather than when cells were infected with C. albicans followed by GBS. This 
may indicate that C. albicans physically impairs GBS from mediating its effects, 
effectively masking the presence of GBS. Alternatively, prior incubation with C. albicans 
could initiate a response in the VECs that predominates, even following GBS exposure. It 
is well established that GBS has capacity to induce neutrophil recruitment via toxin β-
H/C, which induces expression of a number of neutrophil chemoattractants. This has 
been demonstrated using HBMEC monolayers in vitro (Doran et al., 2003), and using 
animal models (Doran et al., 2002;Hensler et al., 2005). This infers that the latter 
mechanism may be more likely. Regardless of the mechanism, diminished neutrophil 
recruitment upon coinfection might be expected to promote colonisation of the GU 
tract by these microbes and possibly promote microbial dissemination. However, 
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activation of neutrophils and subsequent infiltration into host tissues does not 
necessarily mean that the immune response will successfully clear an infection and 
indeed, reduced neutrophil recruitment may serve to dampen a symptomatic host 
response to coinfection. This is because it has been implied that neutrophils in the 
vaginal tract may play an aggravating rather than protective role (Fidel et al., 2004), 
leading to an exacerbated inflammatory response and deteriorating pathology (Yano et 
al., 2014;Yano et al., 2012). 
From these studies, no strong chemotactic effect was seen for VECs incubated with C. 
albicans alone. This differs from previous work, in which culture filtrate of C. albicans 
has been found to contain chemoattractants for both neutrophil and macrophage cells 
(Edens et al., 1999). The neutrophil chemoattractant was effective across an intestinal 
epithelial cell line and was found to act via the formyl peptide receptor of neutrophils 
(Edens et al., 1999). This observation was also supported by (Brasch et al., 1992;Cutler, 
1977), who detected the presence of the chemotactic factor and showed that C. albicans 
attracted neutrophils. A further study estimated that the C. albicans neutrophil 
chemoattractant was 1 kDa in size, and not expressed by opaque-phase cells (Geiger et 
al., 2004). Autophagy by VECs, triggered following invasion by C. albicans, is another 
mechanism that has been shown to upregulate release of proinflammatory cytokines, 
leading to neutrophil recruitment (Shroff et al., 2017;Shroff et al., 2018). Such 
differences between our findings and those of these previous studies likely reflect 
variations in the experimental parameters e.g. in vitro vs. in vivo models, and different 
MOI, incubation periods and C. albicans strains. To try and explore the potential for 
strain-specific effects, it could be beneficial to repeat the studies performed here with a 
wider panel of C. albicans strains. 
One of the potential drawbacks to these assays is that centrifugation of the conditioned 
media is unlikely to remove all microbes or microbial by-products, which may then affect 
the outcome of these assays. However, across the parameters tested, neutrophils 
showed less chemotaxis when exposed to conditioned media from dual-species infected 
VECs when compared to monospecies-infected VECs. Since GBS interactions with VECs 
were promoted by the presence of C. albicans, and vice-versa, VECs infected with both 
GBS and C. albicans were exposed to significantly higher numbers of microbes than 
when incubated with the single species. If the neutrophils were responding solely to 
microbes or microbial by-products which had failed to be removed from the 
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supernatant, it could be expected that a much stronger signal would be observed in 
response to the dual-species rather than monospecies conditioned media. As this was 
not the case, it is unlikely that these potential confounding factors would have 
significantly affected the results shown here. Furthermore, centrifugation to remove 
microorganisms is an established method (Hill et al., 1988). 
Further possible limitations of the neutrophil chemotaxis data include sampling bias. 
Neutrophils were excluded from the dataset if they could not be tracked for the full 31 
time points. When neutrophils collide or cross paths, Fiji cannot decipher which 
neutrophil is which so the tracks are cut short. This means that neutrophils which are 
stationary are more likely to be included, while neutrophils which are very active or 
moving quickly are more likely to be excluded. Furthermore, neutrophils which pass 
outside of the field of view cannot be tracked for the full number of time points. 
However, if anything, such effects would likely have underrepresented the chemotactic 
effects of the microbes rather than skewing the data interpretation. A further issue was 
that the stage of the microscope occasionally shifted over the course of the 1 h, 
meaning that tracks had to be manually adjusted to account for this. To do this, 
stationary artefacts on the chemotaxis slide were tracked, and the average movement 
was subtracted from test tracks. However, again, this adjustment should not have 
affected the overall data interpretation.  
 
5.3.2 Proteomics 
Significant differences were seen in the number of modulated VEC proteins across the 
different infection scenarios. GBS NEM316 seemed to have least impact on the VEC 
proteome, while C. albicans was much more stimulatory. Both microbes are known to 
be cytotoxic and microarray profiling has shown a strong response of VECs to GBS at the 
transcriptional level (Patras et al., 2013). The differences observed here may therefore 
reflect temporal variation in the effects mediated by these two microbes and thus a 
different outcome may be observed using a longer incubation period, for example. 
Nonetheless, from these studies it was clear that coinfection by C. albicans and GBS had 
a significant impact on the VEC response, above that seen with the monospecies 
infections. 
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While challenging to predict exactly which of the modulated proteins might significantly 
impact the nature of VEC interactions with C. albicans and GBS, some common themes 
were seen in the functions of the affected proteins in response to the dual-species 
infection. One such theme was organisation of the cytoskeleton. The cytoskeleton is 
known to be a target for both GBS and C. albicans, with induction of cytoskeletal 
rearrangements promoting invasion of epithelial tissues and possible dissemination to 
distant sites (Dalle et al., 2010). Invasion of GBS into A549 and HEp-2 epithelial cells was 
shown to be dependent on actin filaments (Rubens et al., 1992;Valentin-Weigand et al., 
1997;Baron et al., 2004), involved activation of unidentified protein kinase signalling 
pathways, and was dependent on extracellular calcium concentrations (Valentin-
Weigand et al., 1997). C. albicans can invade host cells by two mechanisms: induced 
endocytosis, mediated by hyphae surface proteins Als3 and Ssa1, and active 
penetration, which is less well characterised (Mayer et al., 2013;Sun et al., 2010;Phan et 
al., 2007). Induced endocytosis may occur when fungal cells are non-viable. However, 
active penetration is initiated by fungal cells themselves. Lytic enzymes such as SAPs and 
the physical pressure of hyphae growth are thought to contribute to active penetration, 
although the specific proteins which mediate this are, as of yet, unknown (Wachtler et 
al., 2011;Felk et al., 2002;Naglik et al., 2003;Gow et al., 2002). Both Als3 and Ssa1 bind 
cadherins and are thought to induce endocytosis in a clathrin-dependent mechanism 
(Phan et al., 2007;Sun et al., 2010). However, another study has suggested that induced 
endocytosis may be due to macropinocytosis, where extracellular material is non-
selectively engulfed by membrane ruffles (Dalle et al., 2010). Similar to GBS, induced 
endocytosis by C. albicans filaments is known to be actin-dependent and involves 
reorganisation of the cytoskeleton (Yang et al., 2014). The fact that a number of VEC 
proteins which regulate actin were altered in expression suggests that C. albicans-GBS 
coinfection may enhance the invasive potential of these microbes.  
Moreover, modulation of host cytoskeletal proteins has implications for the integrity of 
the epithelial barrier. Widely studied for E. coli and Salmonella spp., actin modulation 
can enable bacterial disruption of the epithelium, leading to invasion and dissemination 
within the host (Navarro-Garcia et al., 2013;Van Nhieu and Romero, 2017;Zhou et al., 
2001). Further to this, GBS has been described to utilise beta-catenin and integrin 
signalling to enable ascending infection of the vaginal tract (Vornhagen et al., 2018). The 
enhancement of upregulated proteins involved in integrin signalling and beta-catenin 
itself in dual-species-infected VECs could suggest a role for the synergistic relationship 
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between C. albicans and GBS to promote ascending GBS uterine infection and epithelial 
exfoliation, which may be another mechanism by which epithelial integrity is 
compromised by GBS, although this would have to be examined in more detail in further 
studies.  
Another common function amongst the modulated VEC proteins was activation of 
regulator NF-kappa-B. This is interesting, as the epithelial immune response to C. 
albicans is triggered in part following recognition of yeast via NF-kappa-B and MAPK 
responses, leading to downstream activation of cytokines and chemokines (Naglik et al., 
2014). This suggests a possible increase in downstream proinflammatory signalling, 
which would correlate with the real-time RT-PCR cytokine data. NF-kappa-B is activated 
in response to C. albicans in both oral and vaginal epithelial cells. However, different 
downstream signalling pathways appear to be activated, as a different panel of 
cytokines is produced by oral epithelial cells than is produced by vaginal epithelial cells 
(Moyes et al., 2011). GBS also activates NF-kappa-B (Vallejo et al., 2000). GBS interaction 
with TLRs on the surface of host cells leads to activation of NF-kappa-B and subsequent 
downstream signalling, and this was partially dependent on MyD88 expression (Henneke 
et al., 2002). Activation of NF-kappa-B by GBS in endothelial cells has also been shown to 
induce nitrogen oxide synthase (Glibetic et al., 1999). Furthermore, in monocytes GBS 
was shown to activate MAPKs and NF-kappa-B in order to upregulate expression of TNF-
α, a proinflammatory cytokine linked to enhanced pathology of GBS disease such as 
septic shock and increased risk of death (Mancuso et al., 2002). The data presented here 
suggest that dual-species infection may be enhancing VEC proinflammatory response in 
a synergistic manner. 
Both GBS and C. albicans have been described to bind a wide range of host components, 
such as ECM proteins. The data here showed upregulation of ECM proteins laminin and 
collagen. GBS surface proteins which bind these ECM components include laminin-
binding protein Lmb (Tenenbaum et al., 2007), laminin-binding protein BsaB (Jiang and 
Wessels, 2014), and Bsp proteins, which bind both collagen and laminin (Brady et al., 
2010). C. albicans also binds these ECM components (Yan et al., 1998). The Tdh1 adhesin 
of C. albicans has been shown to bind laminin (Villamon et al., 1999), while Als3 has 
been shown to bind collagen, as this ability was conferred upon a S. cerevisiae strain 
heterologously expressing Als3 (Bamford et al., 2015). C. albicans hyphal proteins Ssa1 
and Als3 also specifically target cadherins, components of adherens junctions between 
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host cells (Sun et al., 2010;Phan et al., 2007). As such, upregulation in dual-species 
infected VECs of 2 laminin subunits and 2 collagen proteins, as well as modulation in 
expression of proteins involved in cytoskeletal modulation, is likely to affect the ability 
of GBS and C. albicans to interact with these host cells.  
Several VEC proteins relating to regulation of apoptosis were significantly 
downregulated in dual-species samples. This suggests that C. albicans and GBS may 
promote host cell survival to further microbial persistence. Additionally, as seen for 
other cell types, upregulation of arginase-1 may lead to an inhibition in nitric oxide 
production, decreasing the antifungal activity of VECs, as well as potentially further 
decreasing the likelihood of apoptosis (Wagener et al., 2017;Talavera et al., 2017). 
Moreover, the downregulation in the p53 pathway described by the GO analysis could 
suggest dampening of the host stress response. p53 mediates repair of DNA, arrest of 
the cell-cycle leading to senescence, and apoptosis, indicating an additional mechanism 
by which GBS and C. albicans may work together to promote their survival (Vazquez et 
al., 2008). 
Despite differences in the specific proteins, there was significant overlap in the ontology 
profiles and general functions of the affected proteins obtained from VECs exposed to C. 
albicans alone or both microbes together. This provides further evidence to support the 
notion that the VEC response to C. albicans may predominate and indeed, it seems as if 
the dual-species infection may actually serve to enhance this response.  
 
5.3.3 Proinflammatory cytokine transcription 
Proinflammatory cytokines are well documented as an initial host response to microbial 
infection. IL-1α, IL-1β, IL-17 and IL-23 were significantly increased in expression in a 
murine model of C. albicans vaginal infection when compared against control mice 
(Shroff et al., 2018), while IL-1α, IL-1β, IL-8, IL-23 and IL-36γ expression was induced by 
incubation of VECs with GBS strains A909 or COH1 (Patras et al., 2013). These cytokines 
were therefore the focus of the studies performed here to investigate the potential 
proinflammatory effects of GBS-C. albicans interactions on VECs. 
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In the studies performed here, there was a general trend for the transcription levels of 
all six cytokines by VECs to be higher from dual-species rather than monospecies 
infections. These effects appeared largely to be additive, implying that both C. albicans 
and GBS were inducing transcription of these cytokines independently, and for IL-23, the 
effects seemed to be predominantly driven by C. albicans. However, a synergistic effect 
was seen with IL-8 transcripts when VECs were challenged with either GBS strain. 
Additionally, a synergistic effect was seen for VECs infected with NEM316 and C. 
albicans with regards to transcription levels for IL-17 and IL-36γ.  
IL-8 has been found to have strong chemoattractant activity, which is dose-dependent 
(Doran et al., 2002;Leonard et al., 1991), and facilitates the ability of neutrophils to kill 
some microbial pathogens, such as E. coli, Mycobacterium fortuitum, P. aeruginosa and 
C. albicans (Standiford et al., 1996;Nibbering et al., 1993;Ponglertnapagorn et al., 
1996;Djeu et al., 1990). IL-8 has also been shown to increase expression of adhesion 
proteins on the surface of neutrophils (Detmers et al., 1990), enhance the ability of 
neutrophils to migrate through tissues (Huber et al., 1991), and to induce release of ROS 
and lysosomal enzymes (Peveri et al., 1988). IL-36γ is a member of the IL-1 cytokine 
family. It binds the IL-36 receptor to initiate similar cellular signalling events as IL-1, 
inducing proinflammatory cytokine release from active CD4+ T cells and dendritic cells 
(Vigne et al., 2011). IL-36γ also upregulates expression of MHC class II and CD80/86 to 
induce dendritic cell maturation (Vigne et al., 2011), and is able to induce MAPK and NF-
kappa-B activation, leading to downstream activation of a number of genes, including 
the chemoattractant IL-8 (Towne et al., 2004). The significant induction of IL-36γ and IL-
8 transcription by VECs following dual-species versus monospecies infection implies that 
the dual-species infection could have a much greater proinflammatory effect in vivo, 
with significant neutrophil recruitment. It might have been expected then that the dual-
species conditioned media would have exhibited a greater neutrophil chemotactic effect 
than the conditioned media from the monospecies infections, which was not the case. 
Nonetheless, this may reflect the fact that the transcriptional effects at 4 h post-
infection had yet to be translated into secreted protein levels. Consequently, collecting 
conditioned media from the association assays after a longer time frame might reveal 
different responses from the neutrophil chemotaxis assays. Invasion of host tissues has 
been suggested as the trigger for induction of IL-8, as IL-8 was detected upon entry of a 
range of bacteria into intestinal or cervical epithelial cells (Eckmann et al., 
1993;Eckmann et al., 1995). The elevated transcription of IL-8 by VECs following dual-
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species infection may therefore indicate a higher level of VEC internalisation by C. 
albicans and GBS when incubated together rather than independently. This supports 
data presented in Chapter 3. Candidalysin triggers p38-MAPK/c-Fos, NF-kappa-B, and 
PI3K signalling in oral and vaginal epithelial cells, leading to the expression of 
proinflammatory cytokines, including IL-36, IL-1α, and IL-1β (Verma et al., 
2018;Richardson et al., 2017). It is possible, therefore, that the RT-PCR data are also 
indicative of a higher level of candidalysin production in dual-species infections 
compared to C. albicans alone. If true, this, in turn, could have implications for levels of 
potential tissue disruption with the GU tract following co-colonisation by C. albicans and 
GBS. 
IL-17 may activate secretion of antimicrobial peptides and inflammatory mediators from 
neutrophils to control C. albicans infection (Eyerich et al., 2008) and has been described 
as crucial for C. albicans defence, although the involvement of IL-17 in VVC has little, and 
contrary, evidence (Sparber and LeibundGut-Landmann, 2015). The presence of IL-17 in 
the vaginal tract of mice has also been linked with clearance of GBS, and mice treated 
with recombinant IL-17 had significantly fewer colonising GBS (Patras et al., 2015a). 
Since dual-species infection of VECs with C. albicans/NEM316 resulted in greater IL-17 
transcription than monospecies-infected cells, enhanced clearance of C. albicans and 
GBS from the vaginal tract might be anticipated following coinfection. Again, however, 
the issue of transcription versus translation is important, particularly as Th17 cells are 
known as the predominant source of IL-17. Nonetheless, there is evidence that IL-17 can 
be produced from epithelial cells, albeit from a study focused on the oral cavity 
(Konermann et al., 2013). 
Taken together, these real-time RT-PCR data support prior studies by indicating that 
both GBS and C. albicans have capacity to induce expression of proinflammatory 
cytokines from VECs. Furthermore, there is evidence that coinfection by these microbes 
may elevate this response. Based on the varying cytokine profiles obtained from GBS 
strains NEM316 and COH1, it seems likely that the effects of GBS are strain-specific and 
to fully interpret the impact of these transcriptional responses, it would be important to 
also monitor levels of released protein over time. A useful next step with this work 
would therefore be to investigate a wider range of strains over a longer time period, and 
to additionally monitor levels of cytokine released into the culture medium, for example 
by ELISA or FACS. The innate immune response to GBS is also characterised by cytokines 
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such as TNF-α, IFN-β and IL-12, which are produced by cell types other than epithelial 
cells (Mancuso et al., 1997;Teti et al., 1993;Mancuso et al., 2007). Investigations into the 




Taken together, these data highlight the complexity of the interactions between C. 
albicans, GBS and VECs. Nonetheless there was clear evidence that coinfection of VECs 
by these microbes did modulate the VEC response in a manner that correlates with their 
synergistic partnership. Under the conditions tested, this resulted in an apparent 
enhancement of the effects largely mediated by C. albicans alone, and might be 
predicted to promote microbial association with the epithelium and subsequent 
persistence. Together, these microbes demonstrated a capacity to promote the 
expression of proinflammatory cytokines at the transcriptional level, but chemotactic 
effects on neutrophils appeared to be suppressed.
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Chapter 6 Discussion 
GBS is the leading cause of neonatal sepsis and meningitis in the developed world, and is 
additionally thought to cause significant morbidity and mortality in neonates in the 
developing world (Edmond et al., 2012;Le Doare and Heath, 2013). In many cases, these 
diseases arise as a result of vertical transmission from a colonised mother. GBS can also 
cause infections in the elderly and in animals, particularly cattle and fish (Edwards and 
Baker, 2005;Nair et al., 2005;Evans et al., 2009). C. albicans causes a wide range of 
infections, mostly among immunocompromised individuals, and is often acquired 
nosocomially (Pfaller and Diekema, 2007;Mayer et al., 2013). C. albicans is also the most 
common causative agent of VVC, with particular incidence among pregnant women 
(Sobel, 2007). GBS and C. albicans occupy the same biological niche within the GU tract, 
and there are reports of synergism between C. albicans and related streptococci within 
the oral cavity (Bamford et al., 2009;Hwang et al., 2017;Diaz et al., 2012). Due to the 
disease burden caused by these two opportunistic pathogens, it was considered 
beneficial to investigate whether there was a similar synergism between C. albicans and 
GBS within the GU tract, and what the molecular basis for such an interaction could be. 
Such information could inform the development of future therapeutic interventions. 
These studies were therefore conceived to establish whether GBS facilitates C. albicans 
colonisation of VECs and vice versa, with additional aims of defining the molecular basis 
of any such interactions, and to investigate the effect of GBS-C. albicans interactions on 
the host cells.  
 
6.1 Microbial interactions with VECs 
6.1.1 GBS interactions with VECs 
A key risk factor for neonatal GBS disease is vaginal colonisation of the mother (Baker 
and Barrett, 1974). GBS is known to bind VECs (Sheen et al., 2011), but the abilities of 
the specific GBS strains used here (Table 3-1) to interact with VECs clearly demonstrate 
that this process is strain-specific. Previous studies have inferred that GBS strains with 
CPS III exhibit higher levels of binding to VECs than CPS Ia (Bodaszewska-Lubas et al., 
2013). This appears to be confirmed here, with NEM316 and COH1 (both CPS III) 
adhering to VECs at higher levels than 515 (CPS Ia). Nonetheless, this attribute alone 
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does not seem to dictate disease risk, since CPS types Ia, II, III and V are associated with 
the majority of GBS disease (Zhang et al., 2006;Jiang et al., 2008;Farley, 2001) and CPS 
Ia, III and V predominantly with neonatal disease (Alkuwaity et al., 2012;Weisner et al., 
2004;Zaleznik et al., 2000).  
In addition to expressing CPS III, GBS strain COH1 belongs to CC-17, which is particularly 
associated with neonatal disease and meningitis (Bohnsack et al., 2008;Martins et al., 
2007;Martins et al., 2017;Poyart et al., 2008;Tazi et al., 2010). This has been linked to 
expression of PI-1 and PI-2b. Evidence suggests that PI-1 and PI-2a are expressed in most 
GBS strains, regardless of CPS type, while PI-2b is confined almost exclusively to CC-17 
strains (Dramsi et al., 2012;Springman et al., 2014). Pili are involved in adhesion to host 
surfaces and biofilm formation (Dramsi et al., 2006;Konto-Ghiorghi et al., 2009;Maisey 
et al., 2007), and one study found that GBS isolated from invasive neonatal infections 
more frequently had both PI-1 and PI-2b than did colonising GBS strains from mothers. 
This suggested that, together, these two PI may enhance pathogenicity (Springman et 
al., 2014). Additionally, CC-17 GBS strains bind fibrinogen at higher levels than non-CC-
17 strains (Dramsi et al., 2012), and this has been hypothesised to contribute to the 
elevated pathogenicity observed with these strains (Al Safadi et al., 2011). From these 
studies, it might have been anticipated that COH1 would be more invasive than the 
other GBS strains used and indeed, COH1 supernatant induced a greater level of 
neutrophil chemotaxis than NEM316, regardless of the presence of C. albicans. Since 
neutrophil infiltration has been associated with host tissue damage and pathogen 
dissemination (Yano et al., 2010;Fidel et al., 2004), it is possible that such effects may 
contribute to the enhanced pathogenicity reported for COH1.  
 
6.1.2 GBS interactions with C. albicans and VECs 
All five GBS strains interacted to some degree with C. albicans planktonically. 
Interactions were much less common and involved fewer bacteria for GBS strains 
18RS21, 2603V/R and COH1, but coassociation was clearly seen between C. albicans and 
COH1 in the presence of VECs. This implies a common ability for GBS to interact with C. 
albicans. In all cases, GBS preferentially bound to C. albicans hyphae rather than 
blastospores. This echoes previous work with S. gordonii and S. aureus, both of which 
exhibit a tropism for C. albicans hyphae (Peters et al., 2010;Silverman et al., 2010). 
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Supporting the tropism of GBS for C. albicans hyphae observed during planktonic 
interactions, C. albicans was found to promote GBS in association with VECs only when 
in the filamentous morphology. 
Strains 18RS21 (CPS II) and 2603V/R (CPS V) were only used in the initial studies in 
Chapter 3 and while able to associate with the VECs to high levels, these two strains did 
not aggregate strongly with C. albicans. This is potentially of note, as both of these 
strains belong to CC-19 that, along with CC-1 and -23, are more frequently isolated from 
asymptomatic maternal carriage than from neonatal disease (Jones et al., 2003;Luan et 
al., 2005;Manning et al., 2008). It would be interesting to determine if this was a trend 
seen across other strains belonging to CC-19, as this might support coassociation 
between GBS and C. albicans as a factor that can promote pathogenicity. 
For all three GBS strains tested it was evident that the presence of C. albicans promoted 
numbers of GBS able to associate with VECs. Clearly, coadhesion between GBS and C. 
albicans was one mechanism by which this effect was mediated. Nonetheless, 
proteomics data suggested that the presence of both microbes may also directly 
modulate VECs in a manner that could make them more permissive to infection. For 
example, several AgI/II family proteins are known to bind ECM components such as 
laminin and collagen (Brady et al., 2010;Zhang et al., 2006;Rego et al., 2016b), both of 
which were upregulated in VECs following coinfection. It seems feasible, therefore, that 
C. albicans may serve as a bridging microorganism between GBS and VECs, as well as 
functioning alongside GBS to upregulate VEC receptors. Again, this would correlate with 
the pattern of VEC association seen with GBS upon coinfection, with bacteria bound 
both to C. albicans hyphae but also directly to the VEC monolayer. Coassociation 
between C. albicans and S. gordonii enhances the ability of these microbes to adhere to 
host surfaces and persist (Silverman et al., 2010). Likewise, interaction of C. albicans 
with S. mutans enables formation of multispecies biofilms, leading to a greater burden 
of both species orally (Hwang et al., 2017), while the burden of S. oralis within oral 
biofilms was dramatically increased by coinfection with C. albicans (Diaz et al., 2012). It 
might be anticipated then that association with C. albicans could enhance the burden of 
GBS within the GU tract, and may well represent a strategy that GBS, similar to other 
Streptococcus bacteria, has evolved to promote its colonisation and persistence within 
this ecological niche. 
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Internalisation into VECs by NEM316 and COH1 was promoted by C. albicans but this 
was not seen for strain 515. This correlated with the relative number of hypha-GBS 
interactions observed by confocal microscopy for these strains and suggests that, at 
least in part, the enhanced invasion by NEM316 and COH1 could have been due to 
‘piggybacking’ as C. albicans hyphae penetrated the VECs. It is unclear why the presence 
of C. albicans was apparently inhibitory to 515 internalisation. However, if 515 
preferentially invades via direct binding to VECs rather than C. albicans hyphae, it is 
possible that the extent of hyphal mat formation occluded the host cell receptors 
exploited by 515. Tissue invasion by ‘piggybacking’ on C. albicans hyphae is a mechanism 
utilised by S. aureus and was shown to result in enhanced bacterial dissemination and 
systemic disease (Schlecht et al., 2015b). It is interesting to note then that both NEM316 
and COH1 bear CPS III, the serotype that is particularly associated with invasive disease, 
while 515 belongs to CC-23, one of the CC associated with asymptomatic carriage within 
the GU tract. Again, this might support a potential role for coassociation between GBS 
and C. albicans in contributing to the pathogenic profile of these microbes. Relating to 
this, cytotoxicity levels were significantly higher in VECs exposed to C. albicans and GBS 
than in VECs exposed to monospecies GBS or C. albicans, and may be due to the 
enhancement of GBS invasion by the presence of C. albicans. This was supported by 
proteomics investigations, which showed modulation of a number of VEC proteins 
involved in cell stress and these were detected at the highest levels for coinfections. 
Proteomic analysis of coinfections also demonstrated the modulation in expression of 
no fewer than 8 proteins relating to actin organisation. Given the fact that actin 
filaments coordinate invasion of both GBS and C. albicans into host cells (Rubens et al., 
1992;Baron et al., 2004;Yang et al., 2014), these data suggest a greater invasive 
potential in the presence of both microbes. Again, this correlates well with the 
internalisation data for GBS in the presence of C. albicans. It is not possible to define 
from these studies if the enhanced VEC invasion directly related to the elevated levels of 
biomass for the two species, with both microbes inducing independent pathways, or if a 
synergistic effect was also occurring at the level of VEC signalling. Nonetheless, the fact 
that the modulation of several VEC proteins was unique to the coinfection, may provide 
evidence for the latter. 
One example of VEC responses that were unique to coinfection, and with potential 
implications particularly to GBS disease risk, was upregulation of proteins related to 
integrin signalling. Integrin signalling is utilised by GBS alpha C protein to facilitate 
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internalisation (Bolduc and Madoff, 2007), and has also been linked to S. gordonii AgI/II 
family proteins SspA/B. Specifically, SspA/B promote S. gordonii interactions with HEp-2 
epithelial cells via recognition of β1 integrin (Nobbs et al., 2007). Thus, this VEC response 
correlates with enhanced GBS internalisation upon coinfection, and it would be of 
interest to determine if the Bsp proteins have a specific role in this process. Moreover, 
activation of integrin signalling has been shown to promote ascending GBS infection 
(Vornhagen et al., 2018). Consequently, upregulation of integrin signalling in dual-
species-infected VECs may indicate that coinfection with C. albicans has capacity to 
enhance GBS ascending infection. This has implications for the pathology of GBS 
infections when C. albicans is present. 
 
6.1.3 C. albicans interactions with GBS and VECs 
Interactions between GBS and C. albicans were reciprocal and thus, C. albicans was 
significantly promoted in association with VECs when in the presence of GBS. However, 
C. albicans was promoted to the same level for each of the three GBS strains. Since the 
explicit numbers of GBS that associated with VECs were strain-dependent and thus 
variable, this may indicate an indirect effect(s) rather than as a consequence of direct 
physical interactions between the two microbes. This notion is supported by previous 
work showing promotion of C. albicans association with host cells by oral streptococci. S. 
gordonii promotes filamentation and thus biofilm formation in C. albicans through 
secretion of nutrients and hydrogen peroxide (Bamford et al., 2009;Nasution et al., 
2008). Additionally, the effects on C. albicans of quorum sensing molecule farnesol, 
which negatively regulates hyphae formation, were reversed by co-incubation with S. 
gordonii, and this was due to suppression of farnesol by S. gordonii autoinducer-2 
(Bamford et al., 2009). Likewise, S. oralis can enhance formation of C. albicans hyphae, 
leading to an increase in candidal tissue adherence and invasion (Diaz et al., 2012;Xu et 
al., 2017). Studies using transwell plates or conditioned media gave no evidence of 
secreted components from GBS being able to modulate C. albicans interactions with 
VECs. It cannot be ruled out, however, that in these studies diffusion distances or 
stability of the secreted component(s) were issues, and it may be a combined 
mechanism involving physical proximity and extracellular signals that enables GBS to 
promote C. albicans association with VECs. This could be explored further through use 
of, for example, GBS strains deficient in quorum sensing molecules such as luxS. 
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Alongside physical interactions and extracellular signalling, it is also possible that 
enhanced C. albicans association occurred as a consequence of changes in VEC protein 
expression induced following coinfection. As for GBS, C. albicans may benefit from 
elevated expression of ECM components collagen and laminin, which can be bound by a 
number of candidal receptors, including Als3 (Bamford et al., 2015;Villamon et al., 
1999). Regardless of the precise mechanism(s) involved, it seems quite possible that C. 
albicans and GBS have co-evolved to exploit the presence of the other for colonisation 
and survival within the GU tract. 
 
6.2 Molecular basis of microbial interactions 
6.2.1 Role of AgI/II family proteins 
AgI/II family proteins are expressed on the surface of many species within the 
Streptococcus genus. Among the oral streptococci, these proteins have been shown to 
act as major colonisation determinants, playing a role in binding to host surfaces and to 
members of the resident microbiota (Nobbs et al., 2009). The Bsp proteins of GBS are 
relatively small (<932 amino acid residues) in comparison to AgI/II family proteins of oral 
streptococci (1310-1653 amino acid residues) (Brady et al., 2010). Nonetheless, the data 
presented here, which indicates that BspA and BspC proteins can mediate interactions 
with VECs and C. albicans, add to a growing body of evidence that Bsp proteins may be 
similarly important in facilitating GBS colonisation of the GU tract.  
 
6.2.1.1 Interactions with VECs 
Complementing previous work on BspA by (Rego et al., 2016a),  bspC knockout and 
complemented strains of GBS 515 and COH1 have been used here to demonstrate a role 
for BspC expression in VEC binding and internalisation. Furthermore, anti-Bsp antibodies 
impaired the ability of GBS NEM316 and 515 to interact with VECs, while L. lactis strains 
expressing BspA or BspC were enhanced in both VEC association and invasion compared 
to the L. lactis vector control strain. These data provide strong evidence that BspA and 
BspC, and thus possibly all Bsp family proteins, may facilitate vaginal colonisation by GBS 
through direct interactions with the vaginal mucosa. It was beyond the scope of this 
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project to identify the specific VEC receptor(s) involved. Nonetheless, studies with other 
streptococci do highlight a few potential candidates. As already mentioned, alike to 
other AgI/II family proteins, Bsp proteins may target ECM components. Another 
potential candidate is gp-340. Oral streptococci bind salivary glycoproteins to enable 
colonisation of soft and hard tissues of the oral cavity. AgI/II family proteins, specifically 
their A- and V-domains, mediate this attachment (Brady et al., 1992;Nakai et al., 1993) 
and specifically target gp-340, an innate immunity scavenger receptor protein. This has 
been shown for SpaP of S. mutans, SspA and SspB of S. gordonii, and AspA of S. 
pyogenes, as well as the Bsp proteins of GBS (Rego et al., 2016b;Leito et al., 
2008;Maddocks et al., 2011). Gp-340 serves to aggregate bacteria for clearance when in 
fluid phase, yet can act as a receptor for adhesion when fixed to a host surface (Brady et 
al., 2010). Of note, gp-340 is cell-bound and highly expressed in the vaginal tract, and 
has been described to contribute to VEC interactions with another vaginal pathogen, HIV 
(Stoddard et al., 2007). As such, gp-340 may act as a colonisation determinant in the 
vaginal tract that is targeted by the Bsp proteins of GBS to promote colonisation. Bsp-
mediated binding to gp-340 may also facilitate GBS colonisation of the oropharynx. This 
is particularly relevant to neonatal disease, for which colonisation of the throat is 
considered the route via which neonatal meningitis is initiated (Cheng et al., 2005b). In 
this regard, since the Bsp proteins have been shown to promote GBS internalisation into 
VECs, it would be of interest to determine if similar effects were seen with cells of the 
oropharynx. Similar to AspA, SpaP and SspB (Maddocks et al., 2011;Larson et al., 
2010;Purushotham and Deivanayagam, 2014), the V domain of BspA has been 
implicated in binding gp-340 (Rego et al., 2016b). Thus, if the Bsp/gp-340 interaction 
was found to play a critical role in GBS colonisation and pathogenesis, it may be possible 
to elucidate the precise molecular basis of this interaction and so develop reagents that 
could impede this mechanism.  
 
6.2.1.2 Interactions with C. albicans Als3 
Following on from previous work showing that SspB of S. gordonii specifically associates 
with C. albicans Als3 (Silverman et al., 2010), a direct interaction between Als3 and GBS 
Bsp proteins was confirmed here. Moreover, the interaction between C. albicans 
adhesin Als3 and the GBS adhesins BspA or BspC appeared to play a critical role in the 
synergistic interaction between these two species. GBS showed a significant reduction in 
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coaggregation with C. albicansΔals3 when compared to the WT or complemented 
strains, and this was extended to the L. lactis BspA and BspC expressing strains, the 
interactions of which were virtually ablated with the C. albicansΔals3 strain. Even more 
strikingly, however, GBS was not promoted in VEC association when incubated with C. 
albicansΔals3 and likewise, C. albicans lacking Als3 was not enhanced in the presence of 
GBS. This suggests that Als3 is the sole target for GBS interactions with C. albicans, as 
has been implied for S. gordonii (Silverman et al., 2010), although (Klotz et al., 2007) 
showed that S. gordonii may also bind Als5. By contrast, enhanced VEC association was 
still seen for C. albicans when incubated with the 515ΔbspC strain, although this was by 
significantly lower than with the WT or complemented 515 strains. As such, it seems 
that although Als3 is the sole C. albicans target for GBS, Bsp proteins are not the sole 
GBS target for C. albicans.  
Given the similarity of these data to previous work with S. gordonii, there may be a 
common mechanism for C. albicans Als3 interactions with streptococci. SspB has been 
inferred to bind the N-terminal peptide binding cavity of Als3, which has previously been 
shown to bind ECM proteins via their C-terminus, although the binding portion of SspB is 
as of yet unidentified (Hoyer et al., 2014;Lin et al., 2014;Bamford et al., 2015). In 
particular, S. cerevisiae cells expressing Als3 proteins deficient in N-terminal residues 
166-225, 218-285, 270-305 and 277-286 were unable to form interactions with S. 
gordonii SspB (Bamford et al., 2015). It has been suggested that some SspB proteins 
undergo proteolytic cleavage to release the C-terminus from the peptidoglycan and that 
this then engages the Als3 peptide binding cavity (Hoyer et al., 2014). However, there 
are some significant differences in the C-termini of Bsp proteins compared to those 
AgI/II proteins of the oral streptococci. For example, in S. mutans SpaP, the C1-C2 
portion of the protein is thought to have a role in binding to carbohydrates (Larson et 
al., 2011). However, Bsp proteins lack the C1 subdomain (Rego et al., 2016b). 
Furthermore, the C3 subdomain of Bsp proteins does not contain some of the key amino 
acids involved in metal ion binding that the C3 subdomains of other AgI/II proteins 
possess (Rego et al., 2016b), with the bound metal ions thought to confer increased 
stability and adhesion to ligands (Hall et al., 2014;Nylander et al., 2011;Forsgren et al., 
2010). It is unclear then if such differences preclude a common binding mechanism. 
Future work could include domain mutagenesis studies to establish whether Bsp 
proteins and Als3 interact by a similar mechanism to SspB-Als3, including identifying if, 
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as with SspB, the N-terminal peptide binding domain of Als3 is the target for Bsp 
proteins. 
 
6.2.1.3 Structure-function considerations 
The Bsp proteins of GBS seemingly share a number of functional properties with the 
AgI/II family proteins of other streptococci, such as binding to gp-340 and C. albicans. 
Nonetheless, there are differences at the structural level that, in turn, could lead to 
functional variation (Figure 6-1). Differences in the C-termini of the Bsp and other AgI/II 
proteins have already been described. There are also critical differences relating to the V 
domain, in which the majority of inter- and intraspecies variation among other AgI/II 
family proteins lies (Brady et al., 2010). The V-domain of Bsp proteins has two anti-
parallel β-sheets linked by loops and β-hairpins. This forms a β-sandwich core containing 
a large pocket consisting of negatively charged and hydrophobic residues, which is 
thought to be the region responsible for binding carbohydrates and glycoproteins (Rego 
et al., 2016b). In contrast, S. mutans SpaP V-domain is made up of 16 β-strands formed 
into two sheets, each consisting of eight antiparallel β-strands, and forms a lectin-like 
fold that presents a preformed ligand binding site (Troffer-Charlier et al., 2002). S. 
gordonii SspB possesses a similar V-domain fold, although the binding pocket is 
considerably smaller (Forsgren et al., 2009). Given these structural variations, it seems 
quite feasible that, while sharing some ligands, the Bsp proteins may also engage with 
receptors that differ from those utilised by the oral streptococci. To this end, it is worth 
noting that the V-domains of BspA and AspA, rather than exhibiting variation, share 70% 
sequence identity (Figure 6-1). Going forward, it will be of great interest to investigate if 
the V-domains of these proteins allow GBS and GAS to interact with ligands that directly 
relate to their classification as two of the ‘true’ pathogenic Streptococcus species. This 
could be achieved, for example, by utilising pull-down assays with the Bsp/AspA proteins 
and lysates or ‘surfome’ preparations of specific host cell types. 




Figure 6-1 Domain similarity of AgI/II family proteins.  
GBS BspA; GAS AspA; S. gordonii SspB; S. mutans SpaP. LP, leader peptide; N, N-terminal domain; A, alanine-
rich repeats; V, variable-domain; P, proline-rich repeats; C, C-terminal domain; CW, cell wall anchorage 
region. Amino acid residue numbers are included, alongside the percentage identities of each domain 
relative to BspA. Adapted from (Rego, 2016). 
 
Among the oral streptococci, it is typical for the A- and P-domains of AgI/II family 
proteins to coil around one another to form a ‘stalk’, with the V-domain presented at 
the ‘tip’ of the protein so that the ligand binding domain may protrude away from the 
surface of the bacterial cell (Larson et al., 2010). The Bsp A-domain lacks a heptad motif 
which is critical for this conformation in SpaP, SspB and AspA (Brady et al., 2010;Rego et 
al., 2016b). Nonetheless, it was found that the Bsp A- and P-domains still form a coiled-
coil structure via an alternative mechanism, in which asparagine residues on the A-
domain form hydrogen bonds with oxygen and nitrogen in the P-domain (Rego et al., 
2016b). This conservation of structure implies its importance to adhesin functionality, 
and it has been proposed that the evolution of a stalk-like structure with an adhesive tip 
provides a level of flexibility that allows binding to be maintained under shear forces. As 
within the oral cavity, this would be relevant to microbes colonising the GU tract, further 
supporting a role for the Bsp proteins as colonisation determinants at this site. However, 
Bsp proteins are predicted to be significantly shorter than homologues of the oral 
streptococci i.e. 25-35 nm in length compared to 50 nm for SpaP (Rego et al., 
2016b;Brady et al., 2010;Larson et al., 2010). This may suggest that Bsp proteins do not 
act to facilitate long-distance preliminary contact with host surfaces and indeed, this 
may not be necessary, as this role is likely undertaken by longer adhesins such as pili. 
This could then enable shorter adhesins such as Bsp to strengthen interactions 
subsequent to this.  
6.2.1.4 Bsp variants and expression levels 
There was some indication that different Bsp variants could modulate GBS interactions 
with VECs and C. albicans. NEM316, which carries both bspA and bspB genes bound 
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VECs at a higher level than 515, expressing just BspC. Likewise, L. lactis expressing BspA 
or BspC exhibited different VEC association levels. Of note, GBS strains 2603V/R and 
18RS21, which did not coaggregate strongly with C. albicans, carry bspD. The sequence 
of BspD is identical to BspC, with the exception that it lacks the leader peptide that 
targets the protein to the translocation machinery. As such, these strains may fail to 
express a surface-bound form of BspD. It would be interesting to confirm this in future 
studies and investigate if lack of BspD expression affects the interactions of these strains 
with C. albicans. On a more general level, it will also be important to investigate more 
widely the Bsp expression profile of GBS strains and if this shows any correlation with 
disease profile. This could help inform, for example, if Bsp proteins may represent a 
potential therapeutic target to combat GBS disease. Chuzeville et al. (2015) found that 
of 75 GBS strains which possessed an AgI/II gene similar to bspC, only 40 contained 
signals for transcription or translation, suggesting that many of these proteins may not 
be expressed (Chuzeville et al., 2015). A further 42 GBS strains, additional to NEM316, 
were found to possess genes similar to bspA or bspB. The distribution of AgI/II genes 
among GBS strains differed depending on serotype and CC, with most strains associated 
with neonatal or adult disease possessing an AgI/II gene, while colonising strains did not 
(Chuzeville et al., 2015). Work presented here also inferred that expression of Bsp 
proteins may be growth-phase or temperature-dependent. Again, a more 
comprehensive analysis of this aspect using GBS reporter strains would be beneficial, as 
it could help identify the circumstances under which Bsp proteins play a critical role. This 
is particularly pertinent given the adhesin redundancy seen in GBS.  
 
6.3 Effects of C. albicans-GBS interactions on host immune responses 
Neutrophils are the predominant immune cell in the vaginal tract and levels of 
infiltration can significantly influence both microbial clearance and host tissue 
inflammation. It is of interest, therefore, that in these studies conditioned media from 
VEC coinfection appeared to be less chemotactic than from GBS monospecies infection. 
This is particularly striking, when considering that the microbial burden of coinfections 
was approximately 5- and 4-fold higher for GBS and C. albicans respectively. No strong 
chemotactic effects were seen for conditioned media from C. albicans monospecies 
infections. Thus, these data may indicate that upon coinfection, the C. albicans response 
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predominates, dampening the neutrophil response to GBS. Of note, similar effects were 
largely seen for induction of VEC cytokine gene transcription, with the major exception 
being IL-8 transcripts, the levels of which were significantly elevated upon coinfection. It 
must be acknowledged, however, that discrepancies exist within these data. IL-8 is a 
major neutrophil chemoattractant. Furthermore, C. albicans proteins SAP2 and SAP6 
have been shown to trigger neutrophil chemotaxis by induction of IL-8 and MIP-2 from 
VECs (Gabrielli et al., 2016), and candidalysin has been shown to stimulate neutrophil 
migration to sites of infection (Richardson et al., 2017). Transcription of cytokine genes 
may not directly relate to subsequent protein expression levels. Thus exploring levels of 
cytokines released from VECs will be an important next step for these studies. It cannot 
be ruled out, however, that C. albicans effects on VECs are modulated by the presence 
of GBS and that this, in turn, leads to the differences from previous studies using C. 
albicans alone. Clearly then, much more research needs to be undertaken in this area 
but if coinfection does have a dampening effect on neutrophil recruitment, this could 
have a significant impact on C. albicans and GBS colonisation and pathogenesis within 
the GU tract. Neutrophil infiltration in response to C. albicans has been described as 
detrimental to the host, magnifying infection rather than providing a defensive role 
(Fidel et al., 2004), and subsequent inflammation within the GU tract does not correlate 
with neutralisation of C. albicans (Yano et al., 2012;Yano et al., 2014). Likewise, it has 
been suggested that GBS stimulation of neutrophils enhances inflammation and host 
damage rather than serving a protective role (Doran et al., 2002;Hensler et al., 2005). 
Reduced neutrophil recruitment upon coinfection might therefore minimise host tissue 
damage and inflammation, thereby promoting carriage within the GU tract. 
Related to this were the effects of coinfection on major VEC signalling pathways 
involving MAPKs, as detected from the proteomics studies. These signalling pathways 
are important in terms of pathogenesis as they are involved in the initial recognition of 
microbes and signal to promote microbial clearance through such mediators as 
proinflammatory cytokines. MAPKs are activated specifically in response to C. albicans 
hyphae rather than blastospores (Moyes et al., 2010;Moyes et al., 2011), while GBS 
activates MAPKs following recognition by TLRs, and the resulting signalling cascade 
generates proinflammatory cytokines and induces ROS from resident and attracted 
immune cells (Henneke et al., 2002). Proteins relating to the MAPK pathways were, in 
general, significantly downregulated upon coinfection of VECs. For the C. albicans 
monospecies response, two MAPK-related proteins were upregulated and one 
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downregulated, while proteins only modulated upon coinfection showed 
downregulation of seven proteins involved in the MAPK pathway (and upregulation of 
none). This is particularly important given the promotion of microbial burden in contact 
with VECs for dual-species infections, which might be expected to enhance MAPK 
signalling. Again, these data imply that coinfection of VECs may dampen their 
proinflammatory response to the microbial challenge. It would be interesting to 
investigate whether this is a common mechanism, by repeating the proteomics studies 
with GBS strains 515 and COH1. 
Taken together, these data suggest that C. albicans and GBS may operate synergistically 
to dampen the host proinflammatory response and so enhance their colonisation and 
persistence within the GU tract.  
 
6.4 Therapeutic considerations 
This work implicates Als3 and Bsp proteins as adhesins that likely contribute to 
coinfection of the vaginal epithelium by C. albicans and GBS. Going forward, 
identification of the precise interactions at the molecular scale of GBS or C. albicans 
adhesins with each other or with host receptors that contribute to GU tract colonisation 
could lead to development of novel anti-adhesive strategies to combat disease risk. 
There are a number of benefits to therapeutics that function by blocking adhesive 
interactions rather than by microbicidal mechanisms, as seen with more traditional 
drugs. Firstly, this approach would not exert a selective pressure that could contribute 
to the development of antimicrobial resistance. Moreover, anti-adhesive therapeutics 
are less likely to have side effects, and the resultant release of microbes from host 
surfaces would enhance the chances of microbial killing by immune cells (Ofek et al., 
2003;Cozens and Read, 2012;Ternent et al., 2015). Such proof-of-concept has already 
been demonstrated for the AgI/II protein SpaP of S. mutans. A synthetic peptide that 
blocked the adhesive functions of SpaP successfully inhibited oral cavity colonisation by 
S. mutans (Kelly and Younson, 2000). 
There is currently no effective GBS vaccine, and there have been numerous issues in 
developing a vaccine which would immunogenically cover the most common capsular 
serotypes associated with disease. This work implies that a vaccine targeting C. albicans 
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may also significantly reduce the burden and pathogenicity of GBS. There is a promising 
vaccine directed against recombinant Als3 which has passed phase 1 trials (Schmidt et 
al., 2012). This was developed to combat the synergistic partnership between C. albicans 
and S. aureus, which leads to an increase in C. albicans pathogenicity and devastating 
systemic S. aureus disease, often in immunocompromised individuals (Schlecht et al., 
2015b). Studies with this vaccine have shown that vaccinated mice challenged with C. 
albicans orally, vaginally or intravenously were protected from disease. Additionally, 
mice were protected from systemic S. aureus infection (Schmidt et al., 2012). Phase 1 
human clinical trials showed high levels of seroconversion, with production of IgG and 
IgA1 antibodies against Als3, as well as inducing production of IFN-γ and IL-17 (Schmidt 
et al., 2012). When this vaccine was investigated in a mouse model of VVC, anti-Als3 IgG 
serum and IgA vaginal antibodies were induced, resulting in a vast reduction in vaginal 
fungal burden (Ibrahim et al., 2013). As demonstrated for S. aureus, convergent 
immunity conferred by this Als3-based vaccine may therefore have the additional effect 
of reducing GU tract colonisation by GBS and thus risk of vertical transmission to initiate 
neonatal disease. 
 
6.5 Additional future work 
6.5.1 Alternative models of vaginal colonisation 
The work detailed here describes, for the first time, a synergistic interaction between C. 
albicans and GBS that has potential to modulate interactions with VECs. Nonetheless, 
only early stage interactions could be explored, as extending the incubation period was 
associated with an increase in cytotoxicity and concomitant reduction in the integrity of 
the VEC monolayer. Furthermore, although the VK2/E6E7 cell line is widely used to 
examine vaginal tract interactions of microorganisms, and is largely comparable to 
native tissue, the original paper on VK2/E6E7 cell line generation notes that there is a 
slight difference in cytokeratin expression among these cells (Fichorova et al., 1997). 
Some of our microscopy studies using the nuclei stain DAPI also showed that certain 
‘giant’ VECs possessed more than one nucleus (data not shown), which may have been 
due to the HPV E6 and E7 proteins promoting replication without successful cytokinesis. 
This VK2/E6E7 model is therefore appropriate for proof-of-principle studies, but more 
clinically-relevant options should be explored to take understanding of the GBS/C. 
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albicans interactions with vaginal epithelium further. One option would be to expand 
these studies using an in vitro reconstituted vaginal epithelial model such as that offered 
by Skin Ethics Laboratories. This incorporates cell differentiation and stratification and 
thus is more comparable to in vivo vaginal epithelium. Again, however, this would have 
limitations relating to time frame due to cytotoxicity, and this model also lacks other 
important host factors such as resident immune cells. Ultimately, it would be beneficial 
to validate the current findings using an in vivo model of vaginal colonisation. Murine 
models have been established for GBS (Patras et al., 2013) or C. albicans (Rahman et al., 
2012) alone, which could likely be adapted for a coinfection scenario. The murine 
vaginal tract is similar to humans in that it is either persistently or sporadically colonised 
with GBS (Yow et al., 1980;Patras et al., 2013), but does differ with regards to a number 
of parameters, including pH, resident microbiota, oestrus cycle length and host response 
(Patras et al., 2013). Nevertheless, in vivo studies would provide important information 
about the contribution of GBS and C. albicans coinfection to colonisation over a longer 
time frame, and to the interplay of these microbes with the host immune response. 
Such models would also allow the possibility of coinfection modifying the invasive 
potential of these microbes and thus dissemination and systemic disease risk to be 
explored in greater detail. 
 
6.5.2 Effects of other resident vaginal microorganisms 
Lactobacilli are the dominant colonising commensal bacteria in the vaginal tract (Boris 
and Barbes, 2000). An inverse relationship has been reported between the presence of 
lactobacilli and GBS in the vaginal tract, suggesting that GBS colonisation requires 
dysbiosis (Ronnqvist et al., 2006;Kubota et al., 2002). Lactobacilli have been shown to 
outcompete GBS, preventing GBS proliferation and adhesion to host surfaces (Ruiz et al., 
2012). In addition, vaginal challenge of mice with lactobacilli prior to inoculation with 
GBS protects the host from GBS-mediated infection by altering the immune response 
generated (De Gregorio et al., 2016). For C. albicans, the relationship with lactobacilli is 
less clear. Ronnqvist et al. (2006) and Demirezen (2002) found that vaginal burden of 
yeasts correlated with that of lactobacilli, although neither of these studies identified 
the yeast species, and lactobacilli were detected in over 89% of women identified as 
having VVC (Osset et al., 2001;Ronnqvist et al., 2006;Demirezen, 2002). By contrast, 
studies investigating lactobacilli as potential probiotics found that Lactobacillus jensenii 
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and Lactobacillus johnsonii showed high inhibition of C. albicans in broth culture (Gil et 
al., 2010), and that 8 out of 15 Lactobacillus strains tested significantly inhibited C. 
albicans association with VECs and provided a fungistatic effect in liquid culture (Osset 
et al., 2001). A further study found that Lactobacillus reuteri alone or in combination 
with Lactobacillus rhamnosus was able to significantly reduce the burden of C. albicans 
associating with VECs and induced greater levels of proinflammatory cytokines 
(Martinez et al., 2009). Such variations may reflect species- or strain-dependent 
differences.  
Since at least certain lactobacilli seemingly have the capacity to modulate interactions of 
GBS or C. albicans with VECs, it would be of interest to investigate how GBS/C. albicans 
coinfection affects this dynamic. For example, if coinfection can cause dysbiosis due to 
inhibition of lactobacilli, or if the presence of lactobacilli can counteract the enhanced 
VEC association seen upon coinfection. This could be examined by adding lactobacilli to 
the VEC association assay, would help to gain further insight into GBS-C. albicans 
interactions in the natural GU tract environment. 
 
6.5.3 Expansion of host response studies 
Due to the limitations of the VEC model, this work focused on proinflammatory 
cytokines that are produced by epithelial cells. However, another important 
consideration with regards to the host response is those cytokines that are largely 
released by immune cells as part of the initial innate immune response. As mentioned, 
such data could be obtained from an in vivo coinfection model. As there were GBS 
strain-specific differences in terms of which cytokine genes were expressed, use of a 
wider panel of strains could also help to determine what the common GBS-C. albicans 
response is, and whether there are any correlations with GBS capsular serotype or CC. 
Transwell studies could be utilised to further explore whether infiltration of neutrophils 
is induced by C. albicans-GBS, and if this serves as a precursor to clearance of infection.  
6.5.4 Intermicrobial responses 
It is well documented that interactions between microorganisms can alter their 
respective proteomes. For example, in a multispecies biofilm with S. gordonii and F. 
nucleatum, P. gingivalis significantly decreased expression of proteins involved in cell 
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envelope formation and cell shape, while proteins involved in protein synthesis were 
upregulated (Kuboniwa et al., 2009). A further study into the interaction of S. gordonii 
with F. nucleatum or P. gingivalis showed that S. gordonii reacted to the interactions in a 
species-specific manner, i.e. different proteins were up- or downregulated depending on 
the binding partner (Hendrickson et al., 2012). When investigating the transcriptomics of 
an interspecies C. albicans-S. gordonii biofilm, (Dutton et al., 2016) found that genes 
involved in hyphae formation were upregulated, and thus C. albicans pathogenesis was 
promoted by S. gordonii. S. gordonii was less affected by the co-incubation (Dutton et 
al., 2016). It would be interesting therefore to explore whether similar responses were 
also seen upon C. albicans-GBS interaction, as this could provide further insight into the 
pathogenic potential of these microbes upon coinfection. 
Additionally, it would be beneficial to expand the proteomics data to investigate the 
effects of coassociation on the microbial protein profile. To achieve this, a baseline 
profile of expression could be generated in blank K-SFM medium, and then compared 
against that of the microbe in the presence of VECs as a monospecies or dual-species 
infection. This could provide insight into whether synergism between C. albicans and 
GBS involves only modulation of the host environment, or also involves modulation of 
microbial protein expression to enable coassociation.  
 
6.6 Conclusions 
These studies show a synergism between C. albicans and GBS, leading to promotion of 
both species in association with VECs, both at the level of attachment and 
internalisation. The molecular basis for the C. albicans-GBS interaction was found to be 
dependent on candidal adhesin Als3 and involved, at least in part, direct binding by GBS 
Bsp proteins. Furthermore, Bsp proteins were identified as putative colonisation 
determinants for GBS within the GU tract by mediating direct interactions with vaginal 
epithelial cells. Identification of the importance of Als3 and Bsp surface adhesins, but 
particularly Als3, in mediating C. albicans-GBS interactions could have implications for 
future therapeutic interventions. For example, there is an anti-Als3 vaccine currently in 
clinical trials which could also serve to prevent GBS disease as a result of convergent 
immunity. There is data to suggest that GBS/C. albicans coinfection may dampen 
neutrophil recruitment, whilst modulating VEC proteins in a manner that could further 
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suppress the host proinflammatory response and promote microbial adhesion and 
internalisation. Taken together, such effects could promote colonisation of the vaginal 
mucosa by both C. albicans and GBS, and this, in turn, could enhance risk of disease by 
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Appendix A: Proteomics 
VEC proteins altered in expression in the GBS-only sample 
Appendix 1 Overview of proteins that were upregulated only in the GBS-infected VECs 
relative to the VEC-only control. 
Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ GBS) / (VECs) 
Q86V85 Integral 
membrane 
protein GPR180  
G protein-coupled receptor 100 
Q96P63 Serpin B12  Enzyme binding 2.871 
P19013 Keratin, type II 
cytoskeletal 4  
Keratin, expressed by 
epithelia, paired with 
keratin 13 
2.67 
A1A4E9 Keratin 13  Keratin, expressed by 
epithelia, paired with 
keratin 4 
2.489 
B4DL32 Keratin, type II 
cytoskeletal 5 
Cytoskeletal organisation 
of actin, inhibits actin 
polymerisation 
2.475 
Q4KMP7 TBC1 domain 
family member  




O60711 Leupaxin  Regulates cell adhesion 2.204 
A0A087WUM0 SYNJ2BP-COX16 
readthrough  
Read-through transcription 2.186 





protease 7  
De-sumolation 2.064 
 
Appendix 2 Overview of proteins that were downregulated only in the GBS-infected VECs 
relative to the VEC-only control. 







kinase ATR  













Q8WWQ0 PH-interacting protein  Cytoskeletal 
organisation 
0.37 
Q53EY2 ElaC homolog 1 variant  RNA transport 0.377 
B3KQT6 Tetraspanin-13  Signal transduction, 
membrane protein 
0.405  
M1VKI3 Tyrosine-protein kinase 
receptor  




P78527 DNA-dependent protein kinase 




O60318 Germinal-center associated 
nuclear protein  
DNA replication 0.427 
A8K2P6 Zinc finger protein 503  Possible transcriptional 
repressor 
0.43 
A0A0S2Z2Z6 Annexin  Vesicle fusion 0.445 
P51636 Caveolin-2  Scaffolding protein 0.45 
O75643 U5 small nuclear 
ribonucleoprotein 200 kDa 
helicase  
RNA helicase 0.452 
P52701 DNA mismatch repair protein 
Msh6  
Mismatch repair 0.453 
Q9Y2X0 Mediator of RNA polymerase II 









Q9HB20 Pleckstrin homology domain-
containing family A member 3  
Intracellular trafficking 0.468 
Q13137 Calcium-binding and coiled-coil 
domain-containing protein 2  





A8K359 Excision repair cross-
complementing rodent repair 
deficiency  
DNA helicase 0.496 
E9PLM6 Midkine  Growth factor 0.499 





VEC proteins altered in expression in the C. albicans-only sample 
Appendix 3 Overview of proteins that were upregulated only in the C. albicans-infected 
VECs relative to the VEC-only control. 
Protein code Protein name Protein function 
Relative 
abundance 
(VECs + C. 
albicans) / 
(VECs) 




Enzyme, glycolytic process 2.59 
I3L3D5 Profilin  Cytoskeletal organisation of 
actin 
2.441 
Q9HAT2 Sialate O-acetylesterase  Enzyme, metabolic process 2.434 
Q9BZQ6 ER degradation-enhancing 
alpha-mannosidase-like 




P20749 B-cell lymphoma 3 protein  Activation of NF-kappa-B 2.378 





A0A024R4Y2 HCG39762  Possible transmembrane 
transport 
2.331 
A0A0G2JMZ8 Occludin  Formation of tight junctions, 
membrane protein 
2.247 
A8K3H9 v-rel reticuloendotheliosis 
viral oncogene homolog B 
NF-kappa-B subunit 2.221 




convertase 2  
Processing of hormones 2.165 
A0A0M4UT83 Glutathione S-transferase 
P  
Enzyme 2.161 
Q9H488 GDP-fucose protein O-
fucosyltransferase 1  
Glycosyltransferase 2.15 
P27701 CD82 antigen  Associates with CD4 or CD8 
and delivers costimulatory 




reductase B3  
Enzyme 2.127 
P02452 Collagen alpha-1(I) chain  Collagen 2.116 
Q4ZGM8 Hemoglobin alpha-2 
globin mutant  
Haemoglobin 2.113 










Protein code Protein name Protein function 
Relative 
abundance 
(VECs + C. 
albicans) / 
(VECs) 
Q96HE7 ERO1-like protein alpha  Enzyme 2.065 
E7EX59 Propionyl-CoA carboxylase 
beta chain, mitochondrial  
Enzyme 2.06 
Q59EQ5 Cysteine and glycine-rich 
protein 1 variant  
Metal ion binding 2.053 
H0Y6T8 Ras-related protein Rab-
18  
GTPase 2.053 
P23284 Peptidyl-prolyl cis-trans 
isomerase B  
Enzyme, protein folding 2.047 
A0A1W2PRS1 Lysosome membrane 
protein 2  
Lysosome membrane protein 2.035 




Appendix 4 Overview of proteins that were downregulated only in the C. albicans-
infected VECs relative to the VEC-only control. 
Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans) / 
(VECs) 
Q86Z14 Beta-klotho  Transcriptional repressor 0.146 
Q15329 Transcription factor E2F5  Transcription factor, cell 
proliferation 
0.319 
D6RH31 Nephronectin  Possible calcium binding 
protein 
0.344 
Q8TF42 Ubiquitin-associated and 
SH3 domain-containing 
protein B  
Promotes localisation of 
activated EGFR to 
membrane 
0.346 
Q8TDG2 Actin-related protein T1  Spermatid formation 0.353 
A0A024QZD9 Zinc finger protein 668  Nucleic acid binding 0.368 
Q9P0M6 Core histone macro-H2A.2  Histone, transcriptional 
regulation 
0.374 
A0A024R9Z8 Aryl hydrocarbon receptor  Transcription factor 0.394 
Q3KQV9 UDP-N-acetylhexosamine 
pyrophosphorylase-like 
protein 1  
Metabolism 0.396 
Q99808 Equilibrative nucleoside 




Q8IZX4 Transcription initiation 
factor TFIID subunit 1-like  
Meiosis 0.405 






Protein code Protein name Protein function 
Relative 
abundance (VECs 




lysine-36 and H4 lysine-20 
specific  
Histone methylation 0.417 
Q15904 V-type proton ATPase 
subunit S1  
ER membrane trafficking 0.417 
Q8WY91 THAP domain-containing 
protein 4  
Possible DNA binding 
protein 
0.451 
Q6P0N6 DST protein  Cytoskeletal linker 
protein 
0.454 
O75808 Calpain-15  Transcription factor 0.46 
B2C310 Glutathione S-transferase 
pi  
Enzyme, transferase 0.463 
A0A024R5D2 Multiple endocrine 
neoplasia I  
Transcriptional regulation 0.466 
O94906 Pre-mRNA-processing 
factor 6  
Processing of pre-mRNAs 0.472 
Q14684 Ribosomal RNA processing 
protein 1 homolog B  
Induces apoptosis in 
response to DNA damage 
0.473 
B2RB17 F-box protein 5  Regulates cell cycle 0.478 
A0A024RDT9 Fibronectin type III 
domain containing 3A  
Spermatogenesis 0.481 
Q53GA4 Pleckstrin homology-like 
domain family A member 
2  
Uncharacterised 0.483 
P54278 Mismatch repair 
endonuclease PMS2  
DNA mismatch repair 0.484 
A0A0S2Z570 RXRB  Retinoic acid receptor 0.484 
B2RAF2 cDNA, FLJ94875  Uncharacterised 0.485 
O75182 Paired amphipathic helix 
protein Sin3b  
Transcriptional repressor 0.487 
Q8TEC9 cDNA FLJ23639 fis  RNA helicase 0.49 
A0A024R377 KIAA0863 protein  Uncharacterised 0.49 
P08779 Keratin, type I cytoskeletal 
16  
Keratin 0.493 
Q13835 Plakophilin-1  Cytoskeletal linker 
protein 
0.493 
Q549H9 cAMP-dependent protein 














VEC proteins altered in expression in the C. albicans and C. albicans+GBS samples 
Appendix 5 Overview of proteins that were upregulated in the C. albicans-infected VECs 
and C. albicans+GBS-infected VECs relative to the VEC-only control. 
Protein code Protein name Protein function 
Relative 
abundance 















Q71F56 Mediator of RNA 
polymerase II 
transcription 
subunit 13-like  









Hormone 9.83 12.45 
Q1RMG2 Adenosylhomocy
steinase  
Methylation control 7.408 7.724 
H0YL33 Annexin Ion transport 6.407 3.609 











P02787 Serotransferrin  Iron transport, 
membrane protein 
5.582 5.758 
B4E1B2 cDNA FLJ53691, 
highly similar to 
Serotransferrin  
Iron transport 5.286 5.657 
I3WAC9 Insulin Hormone 5.275 5.449 
Q9BX10 GTP-binding 
protein 2 
GTP-binding protein 4.987 5.628 
P10645 Chromogranin-A  Antimicrobial peptide 4.833 5.083 
B2R892 cDNA, FLJ93793, 




Enzyme 4.789 4.018 




Protein code Protein name Protein function 
Relative 
abundance 









U3PXP0 Alpha globin 
chain  






A0A161I202 Lactoferrin Antimicrobial peptide, 
iron binding 
4.235 4.912 
A0A087WXL3 DNA polymerase 
theta 
DNA Polymerase 4.026 4.578 
Q96IZ5 RNA-binding 
protein 41 
RNA binding 3.891 4.611 
A0A024R3E3 Apolipoprotein 
A-I  
Apolipoprotein 3.859 4.191 







Q6ZN40 Tropomyosin 1 
(Alpha)  
Actin binding protein 3.76 4.754 
Q14403 Gamma-G globin Haemoglobin 3.652 3.443 
B4DPP6 cDNA FLJ54371, 
highly similar to 
Serum albumin 





Hormone control 3.337 4.154 
B2R7D2 cDNA, FLJ93389, 





phosphatase 1   
Enzyme 3.272 2.602 
B2R5M3 cDNA, FLJ92530, 
highly similar to 
Homo sapiens 
chromogranin B 
(secretogranin 1)  
 Uncharacterised 3.214 3.696 




Cilia biogenesis 3.193 3.371 
Q01650 Large neutral 
amino acids 




Protein code Protein name Protein function 
Relative 
abundance 










subunit 1  
A0A0B4J1S4 Selenoprotein F  Protein folding 3.126 3.869 
P53985 Monocarboxylat



















ATPase, cell adhesion, 
membrane protein 
2.935 3.061 
A0A024R5W6 Tropomyosin 1 
(Alpha)  












B4DE27 cDNA FLJ58765, 









ATPase, ion transport 2.823 3.162 
A1E282 Beta-actin  Actin 2.803 2.384 













Uncharacterised 2.786 2.413 
O15061 Synemin Muscle support 2.753 3.977 




Protein code Protein name Protein function 
Relative 
abundance 









A0A024R5M9 Nuclear mitotic 
apparatus 




B2R6W9 cDNA, FLJ93157, 
highly similar to 
Homo sapiens 
SH3KBP1 binding 
protein 1  





Translation initiator 2.683 5.259 






binding protein Li 
97n  
Regulates NF-kappa-B 2.681 3.219 
A0A1K0GXZ1 Globin C1  Ion binding 2.649 2.43 
















Component of the 
proteosome 
2.623 2.685 
A0A024R5R0 KIAA0256 gene 
product 
Uncharacterised 2.621 4.323 
Q15758 Neutral amino 
acid transporter 
B(0)  




Uncharacterised 2.614 2.781 
Q96AE7 Tetratricopeptid













Protein code Protein name Protein function 
Relative 
abundance 
















Processes hormones 2.577 2.643 
P08123 Collagen alpha-
2(I) chain 
Collagen 2.553 2.296 
Q6N030 Uncharacterized 
protein  












Nucleotide binding 2.507 2.561 
P62633 Cellular nucleic 
acid-binding 
protein 



















Li 8  
Calcium ion binding 2.43 2.845 





Uncharacterised 2.425 2.692 
V9HWA9 Epididymis 
secretory sperm 










Enzyme 2.392 2.18 






Protein code Protein name Protein function 
Relative 
abundance 









U3KQE2 Calpain small 






Q5U0D2 Transgelin  Actin binding protein 2.377 2.221 
P62847 40S ribosomal 
protein S24  
Ribosomal component 2.367 5.66 
A8K0V5 cDNA FLJ77004, 





glucosaminyl) 4  
Enzyme 2.363 2.379 
A0A024R3R5 Lamin B receptor Nuclear membrane 
integrity 
2.352 5.03 
Q6IAW5 CALU protein  Protein folding 2.35 2.845 
A0A024R884 Calponin ECM protein 2.339 2.827 






D6RAN1 PDZ and LIM 
domain protein 7 
Actin binding protein 2.336 2.26 
Q13438 Protein OS-9  Protein degredation 2.329 3.115 
B4DWN9 cDNA FLJ55258, 






family F member 
1 
Limited information 2.326 2.622 











  2.323 2.009 










Protein code Protein name Protein function 
Relative 
abundance 
























Regulates apoptosis 2.266 2.472 
Q14473 Uncharacterized 
protein 












Endothelial receptor 2.247 2.14 
Q8NI22 Thrombomodulin  ER-Golgi transport 2.247 2.832 
B4DW33 cDNA FLJ54187, 






















ATP binding 2.221 2.862 
B2RAH2 Sodium/hydroge
n exchanger  
Membrane 
transporter, expressed 
in kidney and intestine 
2.221 2.302 








Protein code Protein name Protein function 
Relative 
abundance 














P13521 Secretogranin-2  Chemotactic protein 2.208 2.337 
Q9H3Z4 DnaJ homolog 
subfamily C 
member 5  
Chaperone 2.2 2.386 














Microtubule binding 2.186 2.881 
Q8WWX9 Selenoprotein M Metabolism 2.186 2.084 
A0A1S5UZH5 Mitochondrial 
thioredoxin 
Redox reactions 2.185 2.119 












Histone binding 2.163 2.444 
V9HWB4 Epididymis 
secretory sperm 
binding protein Li 
89n  
Protein folding 2.162 2.658 
A0A0F7G8J1 Plasminogen Degrades blood clots 2.16 2.133 
Q8NI35 InaD-like protein  May regulate protein 
targeting, cell polarity 













Protein code Protein name Protein function 
Relative 
abundance 










M member 1  
H7BZJ3 Protein disulfide-
isomerase A3 
Protein folding 2.129 2.513 
P00352 Retinal 
dehydrogenase 1  
Enzyme 2.128 2.13 
E9PN89 Heat shock 
cognate 71 kDa 
protein 
Protein folding 2.12 3.91 
Q9UBS4 DnaJ homolog 
subfamily B 
member 11  
Protein folding 2.116 2.584 










A0A024R206 Ring finger 
protein 126 
Ubiquitination 2.099 3.212 
Q9Y639 Neuroplastin  Cell adhesion, 




B4DL55 Laminin beta-3 
chain  
Laminin 2.084 2.395 
P62979 Ubiquitin-40S 
ribosomal 








Enzyme 2.066 2.232 
P05362 Intercellular 
adhesion 








Lysosomal protein 2.054 2.386 
Q7Z406 Myosin-14  Cytokinesis 2.053 2.348 









Protein code Protein name Protein function 
Relative 
abundance 











Enzyme 2.043 2.143 
H0YMT9 Annexin  Ion transport 2.031 2.391 
K7EKQ2 Hsp90 co-




















folding of TLRs 
2.021 2.249 
Q8IXB1 DnaJ homolog 
subfamily C 




Q14696 LDLR chaperone 
MESD  




Metal ion binding 2.002 2.176 
Appendix 6 Overview of proteins that were downregulated in the C. albicans-infected 
VECs and C. albicans+GBS-infected VECs relative to the VEC-only control. 
Protein code Protein name Protein function 
Relative 
abundance 











Intracellular transport 0.01 0.01 
A0A0A0MT16 ATP-binding 
cassette sub-
family A member 
13  
ATP binding 0.01 0.01 
A0A024QZE6 Chromosome 16 
open reading 
frame 58 
Membrane protein 0.01 0.01 
A8K5Y2 cDNA FLJ77228, 
highly similar to 
Homo sapiens 
amphiphysin 




Protein code Protein name Protein function 
Relative 
abundance 













Intracellular transport 0.07 0.109 
P01036 Cystatin-S  Protease inhibitor 0.079 0.161 
A4D198 Similar to 
mKIAA0038 
protein  
RNA binding 0.087 0.143 
Q9UHN6 Cell surface 
hyaluronidase  
Enzyme 0.093 0.068 
Q0P5N8 TMSB4X protein  Cytoskeletal 





receptor 1  
Fatty acid receptor 0.116 0.161 





protein 1  
Glucosyltransferase 0.125 0.23 
B7Z9D5 cDNA FLJ50387  rRNA processing 0.141 0.134 
J3KP58 CAP-Gly domain-
containing linker 









Enzyme 0.148 0.401 
Q92736 Ryanodine 













Uncharacterised 0.162 0.091 
E9PLG2 26S proteasome 
regulatory 
subunit 6A  
Proteosome 0.169 0.095 
Q13232 Nucleoside 
diphosphate 










Protein code Protein name Protein function 
Relative 
abundance 
















Uncharacterised 0.189 0.172 
Q08AJ9 Histone H2A  Histone 0.193 0.366 
Q9H6N6 Putative 
uncharacterized 
protein MYH16  




DNA mismatch repair 0.208 0.201 
A0A090N8E9 Enhancer of 













protein 3  
Uncharacterised 0.219 0.183 
Q9HD33 39S ribosomal 
protein L47, 
mitochondrial  
Ribosomal protein 0.239 0.156 
A0A1U9X819 MRPS18B  Mitochondrial 
ribosome protein 
0.256 0.145 
B7Z7L8 cDNA FLJ50425, 




Pseudogene 0.258 0.348 
B4DSG5 Tax1-binding 





Q68CZ1 Protein fantom  Embryonic 
development, may be 






member 6  









Protein code Protein name Protein function 
Relative 
abundance 











A8K883 cDNA FLJ77590, 





Uncharacterised 0.269 0.268 
B2R8G6 Peptidylprolyl 
isomerase  
Protein folding 0.273 0.315 
Q8N0Z6 Tetratricopeptid
e repeat protein 
5  
DNA binding 0.275 0.258 
B7ZKN5 UTX protein  Regulation of gene 
expression 
0.29 0.188 
B2R636 cDNA, FLJ92762, 
highly similar to 
Homo sapiens 
ubiquitin specific 
protease 1  
DNA repair 0.294 0.401 
D3DQ70 SERPINE1 mRNA 
binding protein 1  
mRNA stability 0.308 0.267 
Q9P0C6 HSPC255 Activates MAPK 0.31 0.339 
A8K8V8 cDNA FLJ76444  Chaperone 0.312 0.383 
Q15438 Cytohesin-1  Membrane transport, 
membrane protein 
0.313 0.276 
Q96EB3 EEF1A1 protein  Translation 0.316 0.416 
Q7Z6V5 tRNA-specific 
adenosine 
deaminase 2  
tRNA modification 0.33 0.153 





Apoptosis, cell cycle 
regulation 
0.331 0.247 
Q14690 Protein RRP5 
homolog  
Involved in the 
biogenesis of rRNA. 
0.335 0.245 
Q14469 Transcription 












Protein code Protein name Protein function 
Relative 
abundance 























A8K800 cDNA FLJ76924, 




Ribosome assembly 0.361 0.407 
A1JUI8 Chaperonin 
subunit 6A  
Chaperone 0.362 0.346 





factor 65 kDa 






protein 4  
Tyrosine kinase 
binding, may have a 









A0A024R509 Arylsulfatase A Enzyme 0.367 0.333 
B2R5U4 Suppressor of 


















regulates DNA repair 
0.378 0.262 
A0A1W2PP10 Vacuolar protein 
sorting-
associated 
protein 35  




Protein code Protein name Protein function 
Relative 
abundance 









B4DIS6 cDNA FLJ56443, 




ATP binding, helicase 
activity  
0.38 0.379 
A8K4P8 cDNA FLJ75337  Uncharacterised 0.381 0.48 
Q9H6R4 Nucleolar protein 
6  
rRNA processing 0.382 0.448 
A0A087WZ30 ATP-dependent 
DNA helicase Q4  
DNA helicase 0.383 0.438 
Q59EJ3 Heat shock 
70kDa protein 1A 
variant  
Protein folding 0.386 0.457 
A0A126LAX6 U30  Virion assembly 0.388 0.3 





protein 3  
Intracellular transport 0.394 0.279 
Q14593 Zinc finger 




Q7L3V2 Protein Bop  Induces apoptosis 0.401 0.486 
Q9UQR0 Sex comb on 
midleg-like 




P02533 Keratin, type I 





protein 2  
Possible role in 
tumorigenesis 
0.406 0.298 

















A8KAK5 cDNA FLJ77399, 




Activates transcription 0.416 0.499 
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Protein code Protein name Protein function 
Relative 
abundance 













protein 54  
Uncharacterised 0.416 0.312 
O75063 Glycosaminoglyc
an xylosylkinase 
Kinase activity 0.416 0.331 

















































protein 1  
Intracellular transport 0.428 0.312 
Q53RE8 Ankyrin repeat 
domain-
containing 
protein 39  
Uncharacterised 0.43 0.395 
Q53HE6 HSPC163 protein 
variant  




Protein code Protein name Protein function 
Relative 
abundance 












Enzyme 0.434 0.296 
P35080 Profilin-2  Cytoskeletal 




Q5VZL5 Zinc finger MYM-












protein 7  
Uncharacterised 0.44 0.445 
Q9NXF1 Testis-expressed 
protein 10  
rRNA processing 0.441 0.418 





Enzyme 0.443 0.295 
Q92618 Zinc finger 




B4DJM5 cDNA FLJ61294, 
highly similar to 
Keratin, type I 
cytoskeletal 17  




protein 7  
Intracellular transport 0.446 0.291 
A0A024RAP4 Polymerase (DNA 
directed) kappa  
DNA repair 0.448 0.248 
B3KN76 cDNA FLJ13834 
fis, clone 
THYRO1000684, 








Protein code Protein name Protein function 
Relative 
abundance 










e repeat protein 
14  




subunit 14C  






tRNA modification 0.451 0.422 
H7BY64 Uncharacterized 
protein  
Uncharacterised 0.453 0.35 
Q7L8W6 Diphthine-
ammonia ligase  
Enzyme 0.454 0.318 
B3KQ21 cDNA FLJ32640, 




protein 6  




Enzyme 0.456 0.388 
O15260 Surfeit locus 
protein 4  
Golgi organisation 0.459 0.266 
P10244 Myb-related 












Q2KHT3 Protein CLEC16A  Autophagy 0.462 0.407 
O14949 Cytochrome b-c1 
complex subunit 
8  
Respiratory chain 0.463 0.452 





e isoform MB  




Protein code Protein name Protein function 
Relative 
abundance 



















n D  
RNA binding 0.468 0.32 
Q15013 MAD2L1-binding 
protein  
Cell cycle regulation 0.468 0.186 
A0A024RAQ3 Dihydrofolate 
reductase  








protein PKNOX1  
DNA binding 0.47 0.471 
P08243 Asparagine 
synthetase 
Enzyme 0.473 0.37 
O60518 Ran-binding 













component 2  
Mitochondrial protein 0.475 0.349 
J3KPZ4 Nuclear nucleic 
acid-binding 
protein C1D  
Apoptosis 0.475 0.455 
Q9NRX1 RNA-binding 
protein PNO1  
RNA binding 0.479 0.364 
P13647 Keratin, type II 




A8K9U2 cDNA FLJ77474, 




containing 6  
  0.481 0.448 
Q9Y2X9 Zinc finger 







Protein code Protein name Protein function 
Relative 
abundance 























Q8WVD5 RING finger 
protein 141  
Spermatogenesis 0.485 0.462 
Q9H4L4 Sentrin-specific 





Q15746 Myosin light 
chain kinase, 
smooth muscle  




Uncharacterised 0.49 0.449 
Q96EK4 THAP domain-
containing 






synthase 2  
Antiviral response 0.491 0.427 
O43572 A-kinase anchor 
protein 10, 
mitochondrial  















VEC proteins altered in expression in only the dual-species sample 
Appendix 7 Overview of proteins that were upregulated in only the C. albicans+GBS-
infected VECs relative to the VEC-only control. 
Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
Q8ND30 Liprin-beta-2  Cytoskeletal organisation 12.448 
B2R932 cDNA, FLJ94187, 
highly similar to 
Homo sapiens CD99 
antigen 
Uncharacterised 6.259 
Q9C0B0 RING finger protein 
unkempt homolog 
Translational regulation 4.368 
H7C2F2 CD99 antigen  Cytoskeletal organisation 4.059 
B3KX23 cDNA FLJ44516 fis, 
highly similar to 
Homo sapiens DEAD 
(Asp-Glu-Ala-Asp) 
box polypeptide 42  
Nucleic acid binding 3.802 
Q86UE4 Protein LYRIC Activates NF-kappa-B 3.585 








RNA processing 3.26 





H0Y4V9 La-related protein 
4B 
Translational regulation 3.218 
H0Y2V6 Centrosomal protein 




P05089 Arginase-1 Regulator of immune 
responses 
3.09 
B4DW52 cDNA FLJ55253, 
highly similar to 
Actin 
Uncharacterised 2.964 
Q86UP2 Kinectin  Intracellular trafficking 2.908 
F8W7C6 60S ribosomal 
protein L10  
Ribosome subunit 2.859 
Q96TA2 ATP-dependent zinc 
metalloprotease 
YME1L1  
Protein degradation 2.848 
P49711 Transcriptional 
repressor CTCF  
MHC-II activator 2.83 
A0A024R2V2 Microtubule-






Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans +
GBS) / (VECs)
A0A1U9X8Y8 DNA-directed RNA 
polymerase subunit  
RNA polymerase 2.798 
G3V3T3 Apoptotic chromatin 
condensation 
inducer in the 
nucleus  
Chromatin condensation 2.727 
B4DN86 cDNA FLJ56047, 








Chromatin condensation 2.715 
Q14686 Nuclear receptor 
coactivator 6  
Activates NF-kappa-B 2.693 
A0A024R926 Chromosome 1 
open reading frame 
21 
Uncharacterised 2.649 
Q8IUH3 RNA-binding protein 
45  
RNA binding 2.641 
A0A024QZU8 Ras responsive 
element binding 
protein 1 
Transcriptional regulation 2.609 
A0A0R9RWK2 Erb-b2 receptor 
tyrosine kinase 2  
Binds EGF receptor to 
stabilise ligand binding 
2.607 




B9VJ68 Toll-like receptor 5 TLR5 2.592 
E9PR17 CD59 glycoprotein  Inhibits complement-
mediated cell lysis 
2.585 
B4E2S3 cDNA FLJ56561  RNA binding 2.562 
H7BZB9 Microtubule-
associated protein 2 
Cytoskeletal protein 2.547 








Autophagy regulation 2.518 




Intracellular trafficking 2.511 




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
M0R0H3 mRNA decay 
activator protein 
ZFP36  
Suppresses TNF-a 2.462 
A0A024R046 High mobility group 
nucleosomal binding 
domain 4 
Chromatin expansion 2.456 
P07305 Histone H1.0  Histone 2.441 
V9HW88 Calreticulin Transcriptional regulation 2.434 
A0A1B0GVU9 Glutamine-tRNA 
ligase 
tRNA aminoacylation 2.428 
B3KY59 cDNA FLJ46903 fis, 
clone 
MESAN2003661, 









G3V203 60S ribosomal 
protein L18  
Ribosome subunit 2.414 
A8MZ36 Envoplakin-like 
protein  
Cytoskeletal organisation 2.41 
B4DJQ5 cDNA FLJ59211, 
highly similar to 
Glucosidase 2 
subunit beta 





RNA processing 2.401 
P16035 Metalloproteinase 




A3R0T8 Histone 1, H1e  Histone 2.394 
A8K4E0 cDNA FLJ78122 Uncharacterised 2.393 
Q13443 Disintegrin and 
metalloproteinase 
domain-containing 
protein 9  
Cytoskeletal organisation, 
mediates cell motility, 
cell-cell and cell-matrix 
interactions 
2.393 
A0A0J9YXJ0 CUGBP Elav-like 
family member 2  
RNA processing 2.379 
P14625 Endoplasmin  Protein processing, Toll-










Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
hydroxylase), alpha 
polypeptide I variant  
Q96GD7 CSDA protein  Transcriptional regulation 2.359 
Q53H37 Calmodulin-like skin 
protein variant  
Uncharacterised 2.356 
P35712 Transcription factor 
SOX-6 
Transcriptional regulation 2.349 
P09629 Homeobox protein 
Hox-B7  
Transcription factor 
involved in cell 
proliferation 
2.336 
Q86YZ3 Hornerin Keratinisation, 




isomerase A5  
Protein folding 2.324 
P35222 Catenin beta-1  Transcriptional 
regulation, membrane 
bound, localises to 
adherens junctions and 







Q9NUD5 Zinc finger CCHC 
domain-containing 
protein 3  
RNA binding 2.299 
Q6UXH1 Cysteine-rich with 
EGF-like domain 
protein 2  
  2.299 
O43818 U3 small nucleolar 
RNA-interacting 
protein 2  
RNA processing 2.295 
H0Y5B0 Band 4.1-like 
protein 2  
Cytoskeletal organisation 2.285 
Q59G46 Thioredoxin-like 1 
variant 
Cell redox homeostasis 2.283 
V9GYF0 Rho guanine 
nucleotide exchange 
factor 2  
Activates NF-kappa-B 2.276 









subunit 4  




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
Q9Y3E1 Hepatoma-derived 
growth factor-
related protein 3  
DNA synthesis 2.261 
O15516 Circadian locomoter 
output cycles 
protein kaput  
Circadian clock 2.257 
G3XAI2 Laminin subunit 
beta-1  
ECM protein 2.251 
F8W031 Uncharacterized 
protein  
Uncharacterised  2.25 




TNF receptor, NF-kappa-B 
activation 
2.242 
Q06828 Fibromodulin  TGF-b receptor assembly 2.24 
I3L0Y6 NmrA-like family 
domain-containing 




P13645 Keratin, type I 
cytoskeletal 10  
Cytoskeletal protein 2.232 
P11047 Laminin subunit 
gamma-1  
ECM protein 2.226 
A7MBN3 Collagen, type IV, 
alpha 5 
ECM protein 2.222 
A8K3Y5 cDNA FLJ78186  Uncharacterised 2.217 
H7BY36 RNA-binding protein 
EWS 
RNA processing 2.215 









Citric acid cycle enzyme 2.199 
A0A024R8S5 Protein disulfide-
isomerase  
Protein processing 2.196 
B4E0X1 Beta-2-
microglobulin  
MHC class I component, 
involved in antigen 
presentation 
2.191 
G3V3F7 X-linked retinitis 
pigmentosa GTPase 
regulator-




protein 29  




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 







Q8N129 Protein canopy 
homolog 4 
TLR4 regulation 2.155 
A0A0S2Z4Z6 Serine/arginine 
repetitive matrix 1 
isoform 2 
RNA processing 2.151 
K7EN83 EPS8-like 1  EGF receptor-like 2.144 
A0A0G2JN70 Leukocyte receptor 
cluster member 8  
Uncharacterised 2.124 
Q9NYF3 Protein FAM53C  Transcriptional regulation 2.117 






Staufen homolog 1  
RNA transport 2.113 





38, NatC auxiliary 
subunit  
Apoptosis repressor 2.111 




RNA binding 2.105 
Q6ZSJ8 Uncharacterized 
protein C1orf122  
Uncharacterised 2.101 
Q13092 Epidermal type I 
keratin  
Cytoskeletal protein 2.095 
P14316 Interferon 
regulatory factor 2 
MHC class I repression, 
cell cycle regulation 
2.091 
P36954 DNA-directed RNA 
polymerase II 
subunit RPB9 


















Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 









Tight junction assembly 2.072 
E7EQY1 Protein FAM136A  Uncharacterised 2.067 
B7Z5R7 cDNA FLJ61355, 







O75712 Gap junction beta-3 
protein  




splicing factor 8 
RNA binding 2.059 
Q02447 Transcription factor 
Sp3  
Transcriptional regulation 2.057 
Q02880 DNA topoisomerase 
2-beta  
Topoisomerase 2.053 




Protein folding 2.051 
A8KAJ3 cDNA FLJ77823, 




matrix protein 1 
EGF receptor-like 2.047 
A0A087WZM
2 
Ribonuclease T2   RNA binding 2.044 
P25942 Tumor necrosis 
factor receptor 
superfamily 
member 5  
Mediates signalling from 
members of TNF receptor 
superfamily 
2.043 
A0A0S2Z4G4 Tropomyosin 3 Cytoskeletal organisation 
of actin 
2.039 
A8K6R0 cDNA FLJ75726, 
highly similar to 
Homo sapiens basic 
leucine zipper 
nuclear factor 1 
Intracellular transport 2.036 
B3KVV6 cDNA FLJ41607 fis, 
highly similar to 
Homo sapiens 
alpha-2-





Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 









Protein folding 2.03 
P25398 40S ribosomal 
protein S12  
Ribosome subunit 2.029 
A0A024QZ72 PR domain 
containing 2, with 
ZNF domain 
Transcriptional regulation 2.024 




Cell cycle progression 2.022 
A0A024R968 Calcium-
transporting ATPase  
ATP hydrolysis, calcium 
transport 
2.021 
O95218 Zinc finger Ran-
binding domain-
containing protein 2  
RNA processing 2.02 




Ion channel 2.016 
P08572 Collagen alpha-2(IV) 
chain  
ECM protein 2.014 
 
Appendix 8 Overview of proteins that were downregulated in only the C. albicans+GBS-
infected VECs relative to the VEC-only control. 
Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
B1PS43 Myosin heavy chain 
11 smooth muscle 
isoform 
Uncharacterised 0.01 





B2R533 cDNA, FLJ92320, 
highly similar to 
Homo sapiens 
glutathione S-





Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
Q9Y679 Ancient ubiquitous 
protein 1  
Protein degradation 0.243 
O76095 Protein JTB Cell cycle progression, 
may inhibit apoptosis 
induced by TGFB1 
0.273 
P36542 ATP synthase 
subunit gamma 














phosphate lyase 1 
Fatty acid enzyme, 





Actin binding 0.296 
A0A140VJX5 Testicular tissue 
protein Li 202 
Uncharacterised 0.297 
T2C6S4 WWC family 
member 3  
Uncharacterised 0.306 





Q8NI62 Ribosomal protein 
S2 
Ribosomal formation 0.315 
P49411 Elongation factor 
Tu, mitochondrial  







P36952 Serpin B5  Tumour supressor 0.328 
P82650 28S ribosomal 
protein S22, 
mitochondrial  
Mitochondrial ribosome 0.33 
O60287 Nucleolar pre-
ribosomal-




Tumour supressor 0.338 
D3YTI2 Low molecular 
weight 
phosphotyrosine 
protein phosphatase  
Uncharacterised 0.339 




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 




B2RAH7 cDNA, FLJ94921, 
highly similar to 
Homo sapiens prolyl 
endopeptidase 
Uncharacterised 0.344 
X6RAY8 39S ribosomal 
protein L4, 
mitochondrial  
Mitochondrial ribosome 0.347 
O75964 ATP synthase 
subunit g, 
mitochondrial  
ATP Synthase 0.348 
F5H4M0 Vacuolar protein 
sorting-associated 
protein 37B  
Uncharacterised 0.349 
Q8TBM8 DnaJ homolog 
subfamily B member 
14  
Protein trafficking 0.349 
A8K710 Sterile alpha motif 










erase 2  










Fatty acid enzyme 0.356 
H7C1N3 BET1 homolog  Golgi-to-ER transport 0.356 
Q8WZ82 Esterase OVCA2  Uncharacterised 0.359 
P16152 Carbonyl reductase 
[NADPH] 
Reductase 0.361 
O00762  E2 C Ubiquitin-conjugating 
enzyme 
0.361 
Q86TI0 TBC1 domain family 




P49406 39S ribosomal 
protein L19, 
mitochondrial  
Mitochondrial ribosome 0.363 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans +
GBS) / (VECs)













Fatty acid enzyme 0.364 
Q9H1A3 Methyltransferase-













Epithelial cell polarity 0.368 
Q5VWZ2 Lysophospholipase-
like protein 1 
Protein depalmitoylation 0.372 
X6R2S6 Signal peptidase 
complex subunit 1  
Peptide processing 0.373 
B4DZK0 Cysteine protease Protein trafficking 0.374 
Q969T4 Ubiquitin-
conjugating enzyme 







Respiratory enzyme 0.375 
Q53F60 Carbonyl reductase 





Catalytic enzyme 0.378 









Non-glycolytic enzyme 0.381 
Q9HAB8 Phosphopantothena
te--cysteine ligase 
Catalytic enzyme 0.383 
B4DH89 cDNA FLJ55560, 
highly similar to 
Retinal 
dehydrogenase 2  




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
Q16763 Ubiquitin-
conjugating enzyme 
E2 S  
Ubiquitination 0.383 
Q5BKZ8 HSPA12B protein  Heat stress response, cell 
senescence 
0.383 
B3KM58 cDNA FLJ10358 fis, 




Catalytic enzyme 0.384 





protein kinase  









Protein modification 0.387 
A8K7T4 cDNA FLJ75774, 
highly similar to 
Homo sapiens 
lectin, mannose-
binding 2  





enzyme, involved in 










B3KY29 Poly [ADP-ribose] 
polymerase  
Cell cycle progression 0.396 








Catalytic enzyme 0.397 
A8K7F6 cDNA FLJ78244, 







Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
translation initiation 
factor 4A 






















associated protein 7  
Uncharacterised 0.405 
A0A024QZN9 Voltage-dependent 
anion channel 2 
Apoptosis induction 0.406 
E9KL44 Epididymis tissue 
sperm binding 
protein Li 14m 
Mitochondrial enzyme 0.406 
B3KRI8 cDNA FLJ34373 fis, 
highly similar to 
Dual specificity 
protein kinase CLK3 
Protein kinase 0.406 








thioesterase 2  
Fatty acid enzyme 0.407 
B7WPL0 Synembryn-B  Uncharacterised 0.407 
Q16539 Mitogen-activated 
protein kinase 14 




Q53ET9 Ariadne homolog 2 
variant 
Protein degradation 0.409 
Q9H2W6 39S ribosomal 
protein L46, 
mitochondrial  
Mitochondrial ribosome 0.409 






AMP salvage 0.41 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans +
GBS) / (VECs)
Q96K37 Solute carrier family 
35 member E1  
Uncharacterised 0.411 







O75884 Putative hydrolase 
RBBP9  
Uncharacterised 0.414 
P42574 Caspase-3  Activation of caspases 
responsible for apoptosis 
0.415 
Q53GP2 Thioredoxin-like 4B 
variant  























B2RE46 cDNA, FLJ96923, 
highly similar to 
Homo sapiens 
ribophorin II  
N-linked glycosylation 0.42 
A0A024R718 Pre-B-cell colony 
enhancing factor 1 






B4DDK9 cDNA FLJ55952, 







Catalytic enzyme 0.421 
Q96BX8 MOB kinase 
activator 3A  
Uncharacterised 0.421 








Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
B2R9H3 cDNA, FLJ94391, 
highly similar to 
Homo sapiens 
serine (or cysteine) 
proteinase inhibitor, 
clade B (ovalbumin), 




Glycoprotein transport 0.423 
Q59ET0 Glucan, branching 
enzyme 1 variant 
Glycogen branching 0.423 
Q9NRL2 Bromodomain 
adjacent to zinc 
finger domain 
protein 1A 
Chromatin remodelling 0.423 
B3KQQ9 cDNA PSEC0048 fis, 
highly similar to 
Serine protease 23  
Uncharacterised 0.423 
Q96GX2 Putative ataxin-7-
like protein 3B  
Ubiquitination 0.425 
Q9BS40 Latexin  Inflammatory response 0.426 
Q6ZWE6 Pleckstrin homology 
domain-containing 
family M member 3  
Uncharacterised 0.427 
V9HWH1 Epididymis luminal 
protein 57 
Protease inhibitor 0.428 
F8VZY9 Keratin, type I 
cytoskeletal 18  
Cytoskeletal protein 0.429 
Q9Y217 Myotubularin-
related protein 6 
Phosphatase, regulates 
CD4 T cell proliferation 
0.429 
Q9NYK5 39S ribosomal 
protein L39, 
mitochondrial  
Mitochondrial ribosome 0.429 
A0A024QYR3 Transmembrane 9 
superfamily 
member 




Q5JPI9 EEF1A lysine 
methyltransferase 2 




Catalytic enzyme 0.431 
B2R7T6 cDNA, FLJ93596, 
highly similar to 
Homo sapiens 




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 












Mitochondrial enzyme 0.432 
B4DQE1 Annexin Uncharacterised 0.433 
Q8IY81 pre-rRNA processing 
protein FTSJ3 




Catalytic enzyme 0.433 
J3KQY1 39S ribosomal 
protein L22, 
mitochondrial  
Mitochondrial ribosome 0.433 




Links integrins to the 
actin cytoskeleton 
0.434 
Q53GF9 Full-length cDNA 5-
PRIME end of clone 
CS0DF013YM24 of 




Q96K80 Zinc finger CCCH 
domain-containing 







Catalytic enzyme 0.435 
P52895 Aldo-keto reductase 






Protein degradation 0.435 
Q8WVY7 Ubiquitin-like 
domain-containing 
CTD phosphatase 1 
Phosphatase 0.436 
Q96BN8 Ubiquitin 
thioesterase otulin  
Regulates innate immune 
response to limit 
proinflammatory 
signalling, negative 











Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 




tRNA hydroxylase 0.436 
Q9NQZ5 StAR-related lipid 
transfer protein 7, 
mitochondrial  
Uncharacterised 0.436 
B3KSH8 cDNA FLJ36241 fis, 







B3KVH4 cDNA FLJ16549 fis, 








A8K9G4 FLJ77745 Regulates TNF-a 0.439 
A0A024R782 Phosphoglycerate 
mutase  
Glycolytic process 0.439 
Q9H668 CST complex subunit 
STN1  
Regulates DNA replication 0.439 






B4DI08 cDNA FLJ60091, 
highly similar to 
Hypoxia-inducible 
factor 1 alpha 
inhibitor 




Mitochondrial enzyme 0.442 
A0A0A0MQW
3 









Calcium transporter 0.443 
Q01954 Zinc finger protein 
basonuclin-1 
Cell differentiation 0.444 
B2R739 cDNA, FLJ93269, 
highly similar to 




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 








Q9BV61 TRAP1 protein  Mitochondrial chaperone 0.447 





B5BUI8 Dual specificity 




Decarboxylase factor 0.447 
P21266 Glutathione S-
transferase Mu 3 
Glutathione transferase 0.448 
Q9Y570 Protein phosphatase 
methylesterase 1 
Protein demethylation 0.448 
A0A024RA66 Cell division cycle 2-
like 5 
(Cholinesterase-





A0A024RDJ1 DC2 protein Uncharacterised 0.448 
Q15819 Ubiquitin-
conjugating enzyme 










Non-glycolytic enzyme 0.45 
Q6PIW8 COG4 protein Golgi protein 0.45 
Q9H992 E3 ubiquitin-protein 
ligase MARCH7 
Ubiquitin ligase 0.451 
D3DPA6 WD repeat, sterile 






Glycolysis enzyme 0.454 




Q6N0B1 Succinate-CoA ligase 
subunit beta 




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 














Catalytic enzyme 0.455 
P68366 Tubulin alpha-4A 
chain  
Cytoskeletal protein 0.456 
V9HW91 Epididymis 
secretory sperm 
binding protein Li 8a 
Uncharacterised 0.456 
Q9UK99 F-box only protein 3  Protein degradation 0.457 





























Mitochondrial enzyme 0.459 
Q15797 Mothers against 
decapentaplegic 
homolog 1  
Receptor kinase 0.459 
Q9H4B6 Protein salvador 
homolog 1  




Glycogen phosphorylase 0.46 
A8K669 FLJ78452 Peptide processing for 
MHC class II 
0.46 
P55212 Caspase-6 Caspase, overexpression 





Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 





48 kDa subunit 
Glycosyltransferase 0.46 
Q9NUQ7 Ufm1-specific 









A0A0A0MSS8 Aldo-keto reductase 
family 1 member C3  
Catalytic enzyme 0.462 






A0A024RC24 Impact homolog  Stress response 0.463 
P11216 Glycogen 
phosphorylase, 
brain form  
Glycogen phosphorylase 0.464 
B2R7G6 cDNA, FLJ93437, 












O00483 Cytochrome c 
oxidase subunit 
NDUFA4  





e 1  
Glycosyltransferase 0.464 
Q6ICB0 Desumoylating 
isopeptidase 1  
Protease 0.464 













Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
glycosyltransferase 
subunit 1  
A0A024R687 Pleckstrin homology 
domain containing, 
family C (With FERM 
domain) member 1 
Cytoskeletal organisation 
of actin, interacts with 
integrin 
0.465 
O00154 Cytosolic acyl 
coenzyme A 
thioester hydrolase 











Q6IAQ2 SDHC protein  Mitochondrial enzyme 0.466 
Q9BTV5 Fibronectin type III 
and SPRY domain-






phosphatase 1  
Phosphatase 0.467 
Q53EP0 Fibronectin type III 
domain-containing 
protein 3B  
Uncharacterised 0.467 
P0CG31 Putative zinc finger 
protein 286B  
Uncharacterised 0.468 
P12429 Annexin A3 Inhibitor of 
phospholipase 
0.469 
B2RE94 EEF1A lysine 





rRNA processing 0.47 




A0A024R275 Riboflavin kinase TNF-α pathway 0.47 
Q8TE77 Protein phosphatase 
Slingshot homolog 3 
Cytoskeletal organisation 
of actin filaments 
0.471 
B8ZZC8 Methyltransferase-
like protein 5  
Uncharacterised 0.471 
Q9UIL1 Short coiled-coil 
protein  
Golgi-to-ER transport 0.471 






Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 




MAPK pathway 0.476 
Q9P0T4 Zinc finger protein 
581 
Uncharacterised 0.476 
B4DV48 cDNA FLJ55526, 
highly similar to 
Complement C2  
Uncharacterised  0.476 




P30043 Flavin reductase 
(NADPH)  
Reductase 0.477 
Q9BYE7 Polycomb group 
RING finger protein 
6  
Transcriptional repressor 0.477 
A0A0S2Z3H1 Caspase 2 
apoptosis-related 





Catalytic enzyme 0.478 
A0A0S2Z542 Mitogen-activated 
protein kinase 




Q13951 Core-binding factor 
subunit beta 
DNA binding 0.479 
J3QL71 Secernin-2  Uncharacterised 0.479 
A0A024RAN2 Calpastatin Membrane fusion 0.48 
Q06124 Tyrosine-protein 
phosphatase non-
receptor type 11 








Ribosomal formation 0.48 
B4DP80 NAD(P)H-hydrate 
epimerase 
Catalytic enzyme 0.48 
A0A087WZT3 BolA-like protein 2 Iron maturation 0.48 
Q9UNL2 Translocon-
associated protein 
subunit gamma  
Protein transport 0.48 
Q9NVP2 Histone chaperone 
ASF1B 




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
P04275 von Willebrand 
factor 
Von Willebrand Factor 0.48 
I3L3Q4 Glyoxalase domain-





AKT kinase, regulates NF-
kappa-B 
0.481 
A0A0G2JH58 MHC class I 
polypeptide-related 
sequence B  
MHC class I pathway 0.481 








activating protein 1 
GTPase 0.483 
P27449 V-type proton 
ATPase 16 kDa 






binding protein Li 
128m 
Fatty acid enzyme 0.484 










Cell adhesion receptor 0.485 
A0A024R3Z6 Basic leucine zipper 












protein 1  
Uncharacterised 0.486 
A0A024R398 Ankyrin repeat 
domain 49 
NF-kappa-B pathway 0.486 
A0A140VJT8 Testicular tissue 
protein Li 164 
RNase inhibitor 0.487 
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Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans +
GBS) / (VECs)
Q14512 Fibroblast growth 
factor-binding 
protein 1  






Transcription factor, DNA 
repair 
0.487 
B4DZS0 DNA fragmentation 





Catalytic enzyme 0.488 






Q9NP77 RNA polymerase II 
subunit A C-terminal 
domain 
phosphatase SSU72  
RNA polymerase 0.489 
A8K2P7 cDNA FLJ77652, 
highly similar to 
Homo sapiens 
START domain 





Antigen processing for 













B4DKM0 cDNA FLJ51883, 
highly similar to 
Mitochondrial 39S 
ribosomal protein L3 
Mitochondrial ribosome 0.49 
J3KQ32 Obg-like ATPase 1 ATP Hydrolase 0.491 
B4DQY2 MICOS complex 




B2R7E8 cDNA, FLJ93412, 







Q92547 DNA topoisomerase 
2-binding protein 1




Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
P05783 Keratin, type I 
cytoskeletal 18  
Cytoskeletal keratin 0.492 
Q59ER5 WD repeat-
containing protein 1 
isoform 1 variant 
Uncharacterised 0.492 














protein 17  
Modulates TNF-α and NF-
kappa-B activation 
0.493 










protein 4  
Uncharacterised 0.493 






Catalytic enzyme 0.495 
P27144 Adenylate kinase 4, 
mitochondrial 
Catalytic enzyme 0.495 
H7BYJ1 E3 ubiquitin-protein 
ligase RNF34  




E9PJ55 T-complex protein 
11-like protein 1  
Uncharacterised 0.495 
P55263 Adenosine kinase Adenosine kinase 0.496 























Protein code Protein name Protein function 
Relative 
abundance (VECs 
+ C. albicans + 
GBS) / (VECs) 
domain-containing 
protein 1 
B3KW34 Protein YIPF  Golgi-to-ER transport 0.497 




Regulates ATPase activity 0.497 
O00148 ATP-dependent RNA 
helicase DDX39A 
RNA helicase 0.499 
P61081 NEDD8-conjugating 
enzyme Ubc12 
Catalytic enzyme 0.499 
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MOLECULAR PATHOGENESIS 
Coassociation between Group B Streptococcus and 
Candida albicans Promotes Interactions with 
Vaginal Epithelium
Grace R. Pidwill,a Sara Rego,a* Howard F. Jenkinson,a Richard J. Lamont,b Angela H. Nobbsa 
aUniversity of Bristol Dental School, Bristol, United Kingdom 
bDepartment of Oral Immunology and Infectious Diseases, University of Louisville, 
Louisville, Kentucky, USA 
ABSTRACT Group B Streptococcus (GBS) is a leading cause of neonatal sepsis, pneumonia, and meningitis 
worldwide. In the majority of cases, GBS is transmitted vertically from mother to neonate, making 
maternal vaginal colonization a key risk factor for neonatal disease. The fungus Candida albicans is an 
opportunistic pathogen of the female genitourinary tract and the causative agent of vaginal thrush. 
Carriage of C. albicans has been shown to be an independent risk factor for vaginal colonization by GBS. 
However, the nature of interactions between these two microbes is poorly understood. This study 
provides evidence of a reciprocal, synergistic interplay between GBS and C. albicans that may serve to 
promote their cocolonization of the vaginal mucosa. GBS strains NEM316 (serotype III) and 515 (serotype 
Ia) are shown to physically interact with C. albicans, with the bacteria exhibiting tropism for candidal 
hyphal filaments. This interaction enhances association levels of both microbes with the vaginal epithelial 
cell line VK2/E6E7. The ability of GBS to coassociate with C. albicans is dependent upon expression of the 
hypha-specific adhesin Als3. In turn, expression of GBS antigen I/II family adhesins (Bsp polypeptides) 
facilitates this coassociation and confers upon surrogate Lactococcus lactis the capacity to exhibit 
enhanced interactions with C. albicans on vaginal epithelium. As genitourinary tract colonization is an 
essential first step in the pathogenesis of GBS and C. albicans, the coassociation mechanism reported here 
may have important implications for the risk of disease involving both of these pathogens. 
KEYWORDS Candida albicans, Streptococcus agalactiae, adhesins, cocolonization, polymicrobial 
interactions, vaginal epithelium 
treptococcus agalactiae (group B Streptococcus [GBS]) is a leading cause of invasive disease (sepsis, 
pneumonia, and meningitis) in neonates and is responsible for life-threatening infections in elderly 
and immunocompromised individuals (1–3). GBS is an opportunistic pathogen of the female genitourinary 
(GU) tract, with a carriage rate in Western countries of approximately 30% (2). The primary route of 
transmission to neonates is from the mother during or preceding birth, with estimated transmission rates 
of up to 50% (2). Among neonates that are colonized, about 1% develop severe GBS disease, resulting in 
significant infant morbidity or mortality (2, 4). 
A variety of proteins that may promote colonization of host mucosae have been identified on the 
surface of GBS. These include pili (5), alpha C protein (6), BibA (7), serine-rich repeat proteins (Srr1/2) (5, 
8), FbsA (9), Lmb (10), and the recently characterized antigen I/II (AgI/II) family proteins, designated BspA 
to -D (11, 12). Many of these surface proteins have been shown to target receptors expressed directly on 
the cervical or vaginal epithelia, while others bind extracellular matrix (ECM) proteins, such as collagen, 
fibrinogen, fibronectin, or laminin (5, 8–10). An additional colonization strategy for GBS, but one that 
remains poorly understood, is via interactions with other members of the vaginal microbiota. It is widely 
accepted that a “healthy” vaginal microbiota is dominated (ca. 70%) by the genus Lactobacillus, but Gram-
positive bacteria (e.g., streptococci and staphylococci), Gram-negative bacteria (e.g., Escherichia coli), and 
S
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yeasts (e.g., Candida albicans) are also frequently isolated (13). Of particular relevance to GBS colonization 
is a growing body of evidence indicating an association with the fungus C. albicans. In both developed and 
developing countries, vaginal carriage of C. albicans has been shown to be an independent risk factor for 
vaginal colonization by GBS (14–18). 
C. albicans accounts for the fourth highest rate of systemic nosocomial infection in the United States
(19), and as an opportunistic pathogen of the oropharynx and the female GU tract, it is the predominant 
cause of both oral and vaginal thrush. Key risk factors for C. albicans infection are immunosuppression, use 
of oral contraceptives, hormone therapy, antibiotics, diabetes, and pregnancy (20). A number of 
colonization determinants have been implicated in promoting candidal adhesion to and invasion of 
mucosae. These include proteins that are expressed on the surfaces of both morphological forms 
(blastospore and hypha) of C. albicans, such as Als1, Eap1, Eno1, Pra1, and Tdh1 (21–25). Other major 
candidal adhesins, including Hwp1, Als3, and Ssa1, are expressed exclusively on the filamentous hyphae 
(22, 26, 27). Similar to the case with GBS, epithelial receptor molecules (e.g., CEACAMs and cadherins) and 
ECM proteins (e.g., fibronectin and laminin) have been identified as targets of these C. albicans adhesins 
(25, 27–29). 
Synergistic polymicrobial interactions have already been described for C. albicans and a number of 
Gram-positive bacteria. For example, the oral bacterium Streptococcus gordonii produces nutrient by-
products that are stimulatory to C. albicans, enhancing the length of hyphal filaments (30). In turn, S. 
gordonii benefits from the reduced oxygen environment generated by C. albicans metabolism (31). 
Physical coadhesion of these two microbes also serves to promote retention of C. albicans within the oral 
cavity; the molecular basis of this was identified as recognition of the C. albicans adhesin Als3 by the S. 
gordonii AgI/II family protein SspB (32). Similar interactions have been reported for Streptococcus mutans 
and C. albicans, for which the S. mutans glucosyltransferase GtfB has been shown to bind mannans on the 
candidal cell surface, promoting robust cross-kingdom biofilm formation within the oral cavity of rats (33). 
In addition to niche colonization, interkingdom interactions may modulate disease progression. 
Streptococcus oralis and C. albicans synergize within the oropharynx to promote breakdown of epithelial 
tight junctions, resulting in enhanced systemic dissemination of C. albicans (34, 35). Likewise, 
Staphylococcus aureus has a high affinity for binding C. albicans hyphae and can “piggyback” on these 
filamentous forms as they infiltrate host cells to gain access to deeper tissues (36). Again, staphylococcal 
recognition of the C. albicans hyphal protein Als3 is critical for this coadhesion (37). 
We recently characterized an AgI/II family polypeptide of GBS designated BspA. Alongside binding to 
the salivary pellicle and vaginal epithelium, BspA was shown to promote coaggregation of GBS strain 
NEM316 with C. albicans under planktonic conditions (12). The present study therefore aimed to build on 
these initial observations, determine in more detail the interkingdom interactions between GBS and C. 
albicans, and investigate the potential of these interactions to modulate the colonization or pathogenic 
capabilities of these two microbes within the GU tract. 
RESULTS
Planktonic interactions of GBS and C. albicans. The first step in exploring the interactions of GBS and C. 
albicans was to confirm their capacity to coaggregate under planktonic conditions. The following two 
strains of GBS that represent two of the most common capsular serotypes associated with neonatal 
disease were tested: GBS strain 515 (capsular serotype Ia) and strain NEM316 (capsular serotype III) (Table 
1). C. albicans was fluorescently labeled with calcofluor white, while GBS strains were labeled with 
fluorescein isothiocyanate (FITC). Suspensions were then incubated together for 1 h before visualization by 
fluorescence microscopy. Both GBS strains were able to coaggregate with C. albicans, indicating that these 
interactions are not restricted to a single capsular serotype (Fig. 1). Furthermore, as reported previously 
(12), GBS strain NEM316 exhibited a tropism for C. albicans hyphae rather than blastospores. This binding 
pattern was also apparent with GBS strain 515, although higher levels of association were seen overall 
with strain NEM316 (Fig. 1). Taken together, these data confirmed that GBS can undergo planktonic 




TABLE1 Microbial strains and plasmids used in this study 
Strain or plasmid Unique ID Relevant genotype Reference or source 
Strains 
C. albicans 
SC5314 UB1843 Wild type Neil Gow, University of Aberdeen 
 UB1941 Δals3 39 
 UB1940 Δals3 pUL.als3 39 
S. cerevisiae 
BY4742 UB2156 pBC542-ALS3sm 40 
S. agalactiae 
NEM316 UB1931 Wild type Shaynoor Dramsi, Institut Pasteur 
515 UB2410 Wild type Victor Nizet, University of 
California, San Diego 
515 UB2873 ΔbspC This study 
L. lactis 
NZ9800 UB2635 pMSP 12 
 UB2658 pMSP.bspA 12 
 UB2659 pMSP.bspC This study 
Plasmids  
     pMSP7517 
 
E. coli-Enterococcus shuttle vector 
containing Enterococcus faecalis prgB 
under the control of the nisA 
promoter; erythromycin resistance 
54 
pMSP.bspC  pMSP7517-derived plasmid containing 
bspC from GBS 515 in place of prgB 
 
pR326  Chloramphenicol resistance 58 




GBS-C. albicans interactions with VECs. Since GBS and C. albicans are able to coaggregate, we 
hypothesized that such interactions can influence the capacity of these microbes to associate with vaginal 
epithelium. To this end, an in vitro assay was developed using the vaginal epithelial cell (VEC) line 
VK2/E6E7. In the first instance, epithelial cell monolayers were exposed either to GBS alone for 1 h or to C. 
albicans for 1 h to initiate hypha formation followed by GBS for a further 1 h. Associated GBS organisms 
were then enumerated by viable counts (CFU) from epithelial cell lysates. While GBS strain NEM316 
showed a higher level of association (1.51 x105 CFU/ monolayer) than that of strain 515 (7.57 x104 
CFU/monolayer) (Fig. 2), both strains exhibited a strong affinity for the VEC monolayers. However, 
significantly larger numbers of bacteria were recovered for both strains in the presence of C. albicans. 
Numbers of GBS cells recovered from the epithelium were 1.9-fold higher for strain NEM316 and 2.1-fold 
higher for strain 515 than those from their respective monospecies samples (Fig. 2). These augmented 
effects were verified by confocal microscopy, although a slightly longer incubation period (5 h) was needed 
to obtain bacterial cell numbers that were of sufficient abundance to be clearly visible (Fig. 3). For 
monospecies samples, both GBS strains were evenly distributed across the VECs, but numbers of GBS cells 
per field of view were higher for strain NEM316 than for strain 515 (Fig. 3, columns 1 and 2). In the 
presence of C. albicans, an increase in the number of GBS cells associated with the VECs was apparent for 
both strains (Fig. 3, columns 3 and 4) compared to those for the monospecies equivalents. This was 
verified by quantification of GBS biovolume (Fig. 4A). In the presence of C. albicans, GBS biovolume levels 
were 4.6-fold and 2.8-fold higher for strains NEM316 and 515, respectively, than for their monospecies 
equivalents (Fig. 4A). Many GBS cells could be seen interacting with C. albicans hyphae, which formed 




visible increase in the number of GBS cells interacting with the epithelium in areas that were not seemingly 
colonized by C. albicans (Fig. 3, red arrows). This pattern was seen for both GBS strains. Augmentation of 
the GBS association with VECs after 5 h by C. albicans was further supported by enumeration of GBS cells 




FIG 1 Fluorescence micrographs of planktonic interactions between C. albicans and GBS. C. albicans 
SC5314 was grown in YNBPTG for 2 h at 37°C and 220 rpm before addition of GBS strain NEM316 (A) or 
GBS strain 515 (B) and incubation for a further 1 h. GBS was labeled with FITC (green), and C. albicans was 
labeled with calcofluor white (blue). Bars, 20 µm. 
 
 
FIG 2 Effects of C. albicans SC5314 on association of GBS with VECs. VEC monolayers were incubated with 
GBS suspensions (MOI 2.5) for 1 h (open bars) or with C. albicans (MOI 2.5) for 1 h followed by GBS for a 
further 1 h (black bars). Monolayers were then lysed, and associated GBS cells were enumerated by serial 
dilution onto THY agar supplemented with 50 g/ml nystatin. *, P <0.05 compared to monospecies controls, 





FIG 3 Representative confocal micrographs of C. albicans-GBS association with VECs. VEC monolayers were 
incubated with GBS alone for 5 h (columns 1 and 2) or with C. albicans for 1 h followed by GBS for a further 
5 h (columns 3 and 4). Cells were then fixed, stained, and mounted onto glass slides. GBS was labeled using 
an Alexa Fluor 488-conjugated antibody (green), C. albicans was labeled with calcofluor white (blue), and 
VECs were labeled with phalloidin-TRITC (red). GBS strains NEM316 (top panels) and 515 (bottom panels) 
were tested. Columns 2 and 4 are duplicates of columns 1 and 3, respectively, in which the red filter (i.e., 
the VECs) has been removed (VK2/E6E7 off). Bars, 100 µm. White arrows indicate areas where GBS binds 






FIG 4 Effects of C. albicans on association of GBS with VECs following 5 h of incubation. (A) Quantification 
of GBS cells from the confocal micrographs illustrated in Fig. 3. Images were processed using Volocity 
software, and Imaris software was used to calculate GBS biovolumes (in cubic micrometers). (B) 
Quantification of GBS cells by viable counts. VEC monolayers were incubated with GBS suspensions for 5 h 
(open bars) or with C. albicans for 1 h followed by GBS for a further 5 h (black bars). Monolayers were then 
lysed, and associated GBS cells were enumerated by serial dilution onto THY agar supplemented with 50 
g/ml nystatin. **, P<0.01 compared to monospecies controls, as determined by unpaired Student’s t test 
(n=4). 
To investigate the potential for a reciprocal relationship between GBS and C. albicans, the effects of 
GBS on the C. albicans association with vaginal epithelium were then explored using the same in vitro 
assay. For both strains tested, the presence of GBS resulted in a 4-fold elevation in the levels of C. albicans 
recovered from the VEC monolayers compared to those of C. albicans alone (Fig. 5). These data imply that 
a synergistic relationship exists between C. albicans and GBS and that each microbe can enhance 
association of the other with the vaginal epithelium. 
Role of diffusible signals in GBS-C. albicans interactions. One potential mechanism for the enhanced 
recovery of both GBS and C. albicans cocultured with vaginal epithelium might be that each microbe 
releases some form of diffusible, chemical signal that either stimulates growth of the other or promotes its 
capacity to associate with VECs. To explore the first possibility, growth levels of GBS and C. albicans in 
singleand dual-species suspensions were compared. These studies were performed under conditions 
similar to those of the in vitro cell culture assay, using keratinocyte serumfree medium (K-SFM) and 
incubation periods of 1 to 2 h. No significant differences in numbers of CFU were seen for either species 
(Fig. 6A and B), regardless of whether they were grown under mono- or dual-species conditions. This 




FIG 5 Effects of GBS on association of C. albicans SC5314 (Ca WT) with VECs. VEC monolayers were 
incubated with C. albicans cells for 1 h to allow production of hyphae. GBS suspensions were then added 
for a further 1 h before monolayers were lysed. Associated C. albicans cells were enumerated by serial 
dilution onto SAB agar supplemented with 5 g/ml erythromycin. *, P<0.05 compared to the monospecies 
control, as determined by unpaired Student’s t test with Bonferroni correction (n=3). 
To determine if diffusible signals were modulating microbial interactions with the vaginal epithelium, 
GBS was incubated with VEC monolayers in K-SFM or in spent medium harvested from C. albicans grown in 
K-SFM for 1 h in the presence or absence of VECs. After 1 h of incubation with VEC monolayers, associated
GBS cells were enumerated by viable counts from epithelial cell lysates. No significant differences in
numbers (CFU per monolayer) of GBS cells recovered were observed across the different conditions (Fig. 
7A).
For the reciprocal study, C. albicans was incubated on VEC monolayers for 1 h, and then suspensions of 
GBS or K-SFM alone were placed in transwell inserts above the VECs. Viable counts of C. albicans were 
determined after a further 1 h of incubation. Again, no significant differences in C. albicans association 
levels with VECs were seen in the presence or absence of GBS (Fig. 7B). 
One final possibility explored was that GBS or C. albicans modulated the permissiveness of VECs to 
association with the other microbe via an active but contactdependent mechanism. This was investigated 
by repeating the association assays with paraformaldehyde-fixed VECs. Fixation reduced the numbers of 
GBS cells recovered from the cell lysates overall. Nonetheless, the presence of C. albicans again resulted in 
elevated association levels of GBS (Fig. 7C), and the reciprocal effect was seen for levels of C. albicans 
recovered in the presence of GBS (Fig. 7D). Taken together, these data imply that neither intermicrobial 
diffusible signals nor active modulation of the VEC receptor profile is required for enhanced coassociation 
of GBS or C. albicans with the vaginal epithelium. 
Role of Bsp protein in GBS-C. albicans interactions. Oral streptococci have been shown to promote the 
colonization and retention of C. albicans within the oral cavity, and this is mediated in large part by 
coadhesion between the microbes (31). Having demonstrated similar coadhesion between GBS and C. 
albicans, the next step was to determine the molecular basis for this physical interaction and its 
contribution to the synergistic effects seen with vaginal epithelium. 
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FIG 6 Growth of C. albicans or GBS in mono- or dual-species suspension culture. K-SFM broth cultures were 
inoculated with C. albicans SC5314 (Ca WT) at 37°C and 220 rpm for 1 h before addition of GBS and 
incubation for a further 1 h (black bars). Alternatively, broth cultures were inoculated with C. albicans or 
GBS alone and incubated for 2 h or 1 h, respectively (open bars). The numbers of C. albicans CFU per 
milliliter were then determined by viable counts on SAB agar supplemented with 5 g/ml erythromycin (A), 
while numbers of GBS CFU per milliliter were determined by viable counts on THY agar supplemented with 
50 g/ml nystatin (B). NS, P >0.05 compared to the monospecies control, as determined by unpaired 
Student’s t test (n=3). 
We recently showed that the AgI/II family protein BspA of GBS strain NEM316 promotes coaggregation 
with C. albicans under planktonic conditions (12). We therefore wanted to build on this observation and 
determine if the Bsp adhesin family is important in GBS-augmenting interactions of C. albicans with VECs. 
In the first instance, a ΔbspC knockout mutant was generated in GBS strain 515, which carries only a single 
copy of the bspC gene (a homologue of bspA). This strain displayed only a modest (ca. 15%) reduction in 
association with VECs compared to that of parent strain 515 (Fig. 8A). However, it was reported previously 
that streptococci can compensate for loss of AgI/II family proteins by upregulation of alternative adhesins 
(38). To further explore the role of Bsp adhesins, inhibition studies were therefore performed using 
specific antisera. Anti-Bsp sera reduced the association of wild-type GBS strains NEM316 and 515 with 
VECs by 46% and 63%, respectively, compared to that with preimmune control serum (Fig. 8B). Together 
these data support previous evidence that Bsp adhesins have the capacity to promote GBS interactions 
with vaginal epithelium (12), but they indicate that there are additional determinants utilized by GBS for 
this purpose. 
In the presence of C. albicans, a more significant difference was seen between the parent strain 515 and 
the ΔbspC knockout strain. C. albicans significantly promoted recovery of both GBS strains from the 
epithelium compared to that with their respective monospecies samples. However, numbers of bacteria 
recovered were approximately 30% lower for mutant strain 515 ΔbspC than for parent strain 515 (Fig. 8A). 
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These data imply that BspC plays a role in mediating GBS coassociation with C. albicans. However, 
additional adhesins must be involved and may compensate for the lack of BspC in strain 515 ΔbspC. 
FIG 7 Role of contact-independent mechanisms or fixation in modulating interactions of C. albicans or GBS 
with VECs. (A) C. albicans SC5314 (Ca WT) was grown on VEC monolayers, or planktonically in K-SFM 
medium, for 1 h before spent media were collected and filter sterilized. GBS cells were incubated in these 
spent media on VECs for 1 h before the monolayers were lysed and associated GBS cells enumerated by 
serial dilution onto THY agar. NS, P>0.05 compared to the blank K-SFM control, as determined by unpaired 
Student’s t test (n=3). (B) C. albicans was grown on VEC monolayers for 1 h before GBS suspensions or K-
SFM alone was placed into transwell baskets suspended above. After a further 1 h of incubation, C. 
albicans was enumerated by serial dilution onto SAB agar. (C and D) VEC monolayers were fixed with 2% 
paraformaldehyde and then incubated with GBS suspensions (MOI 2.5) for 1 h (open bars) or with C. 
albicans (MOI 2.5) for 1 h followed by GBS for a further 1 h (black bars). Monolayers were then lysed, and 
numbers of GBS CFU per milliliter were determined by viable counts on THY agar supplemented with 50 
g/ml nystatin (C), while numbers of C. albicans CFU per milliliter were determined by viable counts on SAB 
agar supplemented with 5 g/ml erythromycin (D). NS, P>0.05; **, P <0.01 compared to monospecies 
controls, as determined by unpaired Student’s t test with Bonferroni correction (n =4 [A and B] or 3 [C and 
D]). 
Given this apparent adhesin redundancy, surrogate Lactococcus lactis strains expressing BspA or BspC 
were then employed in coassociation assays. This allowed the functional properties associated with the 
individual AgI/II family proteins to be explored in greater detail. For monospecies L. lactis samples, once 
again, only a modest increase in numbers of bacteria recovered from VECs was seen for L. lactis strains 
expressing BspA or BspC compared to the numbers with the empty vector control strain (Fig. 9). However, 
for dual-species samples, recoveries of L. lactis strains expressing BspA and BspC were promoted 1.8-fold 
and 3-fold, respectively, by C. albicans (Fig. 9), while vector-only L. lactis control recovery was increased 




GBS association with vaginal epithelium directly, but they likely play a greater role by promoting 
association via C. albicans. 
 
 
FIG 8 Effects of C. albicans or Bsp antisera on the association of GBS wild-type and isogenic mutant strains 
with VECs. (A) VEC monolayers were incubated with GBS wild-type (WT) strain 515 or mutant ΔbspC cell 
suspensions (MOI 2.5) for 1 h (open bars) or with C. albicans SC5314 (MOI 2.5) for 1 h followed by addition 
of strain 515 suspensions for a further 1 h (black bars). Monolayers were then lysed and associated GBS 
cells enumerated by serial dilution onto THY agar supplemented with 50 g/ml nystatin. **, significance 
relative to monospecies controls; Ω, significance relative to wild-type monospecies control; §, significance 
relative to the wild type in the presence of C. albicans. (B) GBS cell suspensions were preincubated with 
preimmune (open bars) or anti-Bsp (black bars) sera before incubation with VEC monolayers (MOI 2.5) for 
1 h and enumeration from cell lysates by viable counts. **, significance relative to preimmune controls. 
Significance indicates that the P value was <0.01 as determined by unpaired Student’s t test with 
Bonferroni correction (n=3). 
Role of Als3 protein in GBS-C. albicans interactions. A possible receptor for the Bsp proteins of GBS was 
the candidal glycoprotein Als3, since this adhesin is hypha specific (22) and has been shown to bind the 
AgI/II family protein SspB of S. gordonii to mediate interkingdom interactions (32). A C. albicans strain with 
both alleles of the als3 gene deleted (39) and a corresponding complemented strain (Δals3als3) were used 
to determine if Als3 is involved in interactions between GBS and C. albicans. This was first investigated 
under planktonic conditions, and levels of coaggregation were determined semiquantitatively according to 
numbers of GBS cells associated with individual hyphae. Both GBS strains exhibited strong interactions 




recorded as binding 6 to 20 bacteria or 20 bacteria (Fig. 10). In contrast, the majority of C. albicans Δals3 
hyphae were either devoid of bacterial cells or bound only 1 to 5 GBS cells (Fig. 10). Thus, the expression of 
Als3 on candidal hyphae is required to mediate strong physical interactions with GBS under planktonic 
conditions. 
The various C. albicans strains were then used to determine if Als3-mediated interactions were required to 
modulate GBS association with VECs. Interestingly, numbers of C. albicans Δals3 cells associated with VECs 
were not significantly different from those recovered for wild-type SC5314 or the C. albicans Δals3als3 
strain. This contrasts with observations made by others (39) in studies of oral epithelium and implies that 
Als3 may exhibit tissue-specific tropism. Unlike the phenomenon observed with wildtype C. albicans, there 
was no enhanced association of GBS with C. albicans Δals3 in the presence of VECs, and numbers of GBS 
cells recovered were comparable to those from monospecies samples (Fig. 11). In contrast, 
complementation of the Δals3 mutation in the C. albicans Δals3als3 strain restored the capacity of C. 
albicans to significantly promote GBS association with vaginal epithelium relative to that of GBS 
monospecies samples (Fig. 11). 
 
 
FIG 9 Effects of C. albicans on association of L. lactis Bsp surrogate expression strains with VECs. VEC 
monolayers were incubated with suspensions of the L. lactis pMSP vector control, pMSP.bspA, or 
pMSP.bspC (MOI 2.5) for 1 h (open bars) or with C. albicans SC5314 (MOI 2.5) for 1 h followed by addition 
of L. lactis suspensions for a further 1 h (black bars). Monolayers were then lysed, and associated L. lactis 
cells were enumerated by serial dilution onto GM17 agar supplemented with 50 g/ml nystatin. **, 
significance relative to monospecies controls; Ω, significance relative to the pMSP empty vector control; §, 
significance relative to the pMSP empty vector control in the presence of C. albicans. Significance indicates 
that the P value was <0.01 as determined by unpaired Student’s t test with Bonferroni correction (n=4). 
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FIG 10 Role of Als3 in planktonic interactions between C. albicans and GBS. (A) Fluorescence micrographs 
of planktonic interactions between the C. albicans Δals3 strain (left panels) or the Δals3als3 
complemented strain (right panels) and GBS strain NEM316 (top panels) or 515 (bottom panels). C. 
albicans was grown in YNBPTG for 2 h at 37°C and 220 rpm before addition of GBS and incubation for a 
further 1 h. GBS was labeled with FITC (green), and C. albicans was labeled with calcofluor white (blue). 
Bars, 20 m. Note that interactions of GBS strains with wild-type C. albicans SC5314 are shown in Fig. 1. (B) 
Semiquantitation of C. albicans hyphae with 0, 1 to 5, 6 to 20, or 20 interacting GBS cells, based on 
approximately 40 randomly selected images for each experimental group. *, P<0.05; NS, P>0.05 (as 





FIG 11 Role of Als3 in synergistic effects of C. albicans on association of GBS with VECs. VEC monolayers 
were incubated with GBS suspensions for 1 h (open bars) or with C. albicans SC5314 (wild type [WT]) (black 
bars), Δals3 (gray bars), or Δals3als3 (striped bars) for 1 h followed by GBS for a further 1 h. Monolayers 
were lysed, and then associated GBS cells were enumerated by serial dilution onto THY agar supplemented 
with 50 g/ml nystatin. **, P<0.01; NS, P>0.05 (as determined by unpaired Student’s t test with Bonferroni 
correction) (n=4). 
A similar scenario was seen for reciprocal studies to determine the role of Als3 in GBS modulation of C. 
albicans interactions with VECs. Numbers of C. albicans Δals3 cells recovered from epithelial monolayers 
were comparable for monospecies samples and dual-species samples incorporating either of the two GBS 
strains (Fig. 12). In contrast, both GBS strains enhanced the recovery of C. albicans Δals3als3 2.5-fold (Fig. 
12) relative to that of the monospecies control. These effects were similar to those seen previously with C. 
albicans wild-type strain SC5314 (Fig. 5). Thus, Als3 expression by C. albicans is required for both GBS and 
C. albicans to modulate coassociation with vaginal epithelium. 
Finally, studies were performed to investigate if Bsp polypeptides of GBS can bind directly to Als3 of C. 
albicans. Again, to avoid potential issues with adhesin redundancy, surrogate expression strains were 
utilized. A strain of Saccharomyces cerevisiae that expresses the small allele of C. albicans Als3 on its cell 
surface was previously generated (40). This S. cerevisiae (Als3) strain was fluorescently labeled with FITC, 
while L. lactis strains expressing BspA, BspC, or an empty vector control were labeled with tetramethyl 
rhodamine isocyanate (TRITC). Suspensions were then incubated together for 1 h before visualization by 
fluorescence microscopy. No interactions were seen between S. cerevisiae (Als3) and the L. lactis control 
(Fig. 13A). In contrast, coaggregation could clearly be seen with S. cerevisiae (Als3) and L. lactis strains 
expressing either BspA (Fig. 13B) or BspC (Fig. 13C). Thus, GBS polypeptides BspA and BspC are direct 





FIG 12 Role of Als3 in synergistic effects of GBS on association of C. albicans with VECs. VEC monolayers 
were incubated with C. albicans SC5314 (wild type [WT]) (open bars), Δals3 (black bars), or Δals3als3 
(striped bars) for 1 h followed by GBS for a further 1 h. Monolayers were lysed, and associated C. albicans 
cells were enumerated by serial dilution onto SAB agar supplemented with 5 mg/ml erythromycin. **, P 
<0.01; NS, P>0.05 (as determined by unpaired Student’s t test with Bonferroni correction) (n=4). 
 
FIG 13 Fluorescence micrographs of planktonic interactions between S. cerevisiae Als3 and L. lactis Bsp 
surrogate expression strains. S. cerevisiae (Als3) was grown in YNBPTG for 3 h at 30°C and 220 rpm before 
addition of L. lactis(pMSP) (control) (A), L. lactis(pMSP.bspA) (B), or L. lactis(pMSP.bspC) (C) and incubation 
for a further 1 h. L. lactis was labeled with TRITC (red), and S. cerevisiae was labeled with FITC (green). 
Bars, 20 µm. 
 
DISCUSSION 
Intermicrobial interactions occur at most sites of colonization within the human body, and according to 




instances, these interactions have antagonistic outcomes, such as those between C. albicans and 
Pseudomonas aeruginosa. Other 
partnerships are seemingly synergistic in nature, such as the interactions between C. albicans and S. 
gordonii, S. oralis, S. mutans, and S. aureus (32, 35, 37, 42). Several studies have reported the 
cooccurrence of GBS and C. albicans within the GU tract (14–18), and we recently provided evidence for 
coaggregation of these two microbes (12). The aim of this study was therefore to further define the 
interkingdom interactions of these two microbes and their capacity to modulate GU tract colonization, an 
essential step in the pathogenesis of both microorganisms. 
Using the VEC line VK2/E6E7 as a model system, this study provides evidence that a reciprocal, 
synergistic relationship exists between GBS and C. albicans and may serve to promote their cocolonization 
of the vaginal mucosa. Specifically, when the organisms were incubated together, numbers of both 
microbes associated with the epithelial monolayers were found to be significantly larger than the numbers 
recovered from equivalent monospecies samples. Confocal microscopy revealed extensive hyphal “mats” 
of candidal cells overlaying the epithelial monolayers to which GBS cells were attached. This implies that 
direct physical contact (i.e., coadhesion) between GBS and 
C. albicans is a key mechanism that contributes to their synergistic interplay. Thus, GBS may bind directly 
to epithelium or to adherent C. albicans cells, and vice versa. 
To identify the mechanistic basis of coadhesion between GBS and C. albicans, our studies focused on 
the hypha-specific adhesins of C. albicans, and specifically the adhesin Als3, since a distinct tropism for 
candidal hyphae was observed for both GBS strains tested. Use of Als3 knockout and complemented 
strains of C. albicans confirmed that recognition of this glycoprotein by GBS is required for effective 
coaggregation of these two microbes under planktonic conditions and for coassociation with vaginal 
epithelium. This correlates well with the interactions of C. albicans and streptococci within the oral cavity 
reported to date (32, 34) and thus may imply that Als3 recognition represents a common mechanism for C. 
albicans engagement by members of the Streptococcus genus. The addition of GBS to the list of microbes 
that utilize Als3 as a receptor, alongside other streptococci, S. aureus, and Rothia dentocariosa (32, 37, 43), 
also adds support to the notion that Als3 plays a major role in the capacity of C. albicans to mediate a 
diverse range of polymicrobial interactions. 
In addressing the GBS side of this synergistic partnership, this study provides evidence for the role of 
GBS AgI/II family (Bsp) adhesins in this process. Previous work implicated BspA in facilitating coaggregation 
of GBS strain NEM316 with C. albicans under planktonic conditions (12). These data are supported here 
and were developed to include the adhesin BspC, implying that these capabilities may represent functions 
that are shared across the Bsp adhesin family. Moreover, loss of BspC impaired GBS coassociation with C. 
albicans, while expression of BspC by L. lactis enabled C. albicans to promote association of this surrogate 
host with VEC monolayers. This extends our current understanding of the properties of the adhesin family 
and implies that Bsp adhesins are determinants of GBS that facilitate coassociation with C. albicans on 
vaginal epithelium. Moreover, coaggregation of surrogate hosts expressing Als3 and Bsp adhesins adds 
support to the hypothesis that direct binding between Bsp polypeptides of GBS and Als3 of C. albicans is a 
mechanism that underpins, at least in part, the synergy in epithelial cell interactions between these two 
microbes. Interestingly, while deletion of bspC did not ablate the coassociation of GBS and C. albicans, 
deletion of both als3 alleles effectively prevented the interaction. This indicates a role for additional GBS 
determinants in mediating the interkingdom relationship and implies that these determinants may also 
target the candidal receptor Als3. This supports the evidence that Als3 has the capacity to bind multiple, 
diverse ligands (44). 
Based on primary sequence, the AgI/II family polypeptides of GBS can be divided into four homologues: 
BspA and -B, which share 90% sequence identity, and BspC and -D, which share 99% sequence identity 
(12). The highest level of variation between BspA/B and BspC/D is seen within the N-terminal alanine-rich 
and proline-rich domains. In contrast, the V domain shares 96 to 100% sequence identity across all four 
Bsp homologues (12). The V domain has been identified as the functional region of a number of AgI/II 
family polypeptides (45–47), including BspA, in which it was shown to promote binding of GBS NEM316 to 
the scavenger receptor agglutinin glycoprotein340 (12). If the V domain is also responsible for GBS 




BspC display comparable functional properties. Delineating the precise domains within Bsp that are 
required for engagement with candidal Als3 will be the focus of future studies. 
It is clear that direct physical contact between C. albicans and GBS plays a significant role in their 
coassociation with VECs. We also considered the possibility that intermicrobial signals played a role in the 
processes described here. However, no evidence was found for diffusible molecules released by either C. 
albicans or GBS having the capacity to significantly modulate microbial interactions with vaginal 
epithelium. Nonetheless, provision of additional intermicrobial binding sites may not be the only 
mechanism involved in the synergy with VECs. For example, in dual-species images, there were patches of 
epithelium that were heavily colonized by GBS while seemingly devoid of C. albicans (Fig. 3). Fixation of 
VECs did not inhibit coassociation of GBS and C. albicans, implying that these effects are not dependent 
upon modulation of epithelial cell biology (e.g., receptor availability). Nonetheless, it remains possible that 
GBS engagement with C. albicans alters the GBS receptor profile such that the bacteria are subsequently 
more permissive to interactions with VECs. The large impact of als3 gene deletion on the GBS-C. albicans-
VEC coassociation raises the prospect that Als3 may mediate such effects. Future studies will explore these 
possible explanations. 
To conclude, this study identifies a synergistic interplay between GBS and C. albicans that enhances the 
capacity of both microorganisms to associate with vaginal epithelial cells. Molecular determinants critical 
to this coassociation mechanism were identified as Bsp adhesins of GBS and Als3 of C. albicans. GU tract 
colonization is an essential first step in the pathogenesis of some diseases, such as vaginal thrush, and is a 
significant risk factor for neonatal GBS disease due to vertical transmission. Coassociation of GBS and C. 
albicans may therefore have important implications for disease risk for both of these opportunistic 
pathogens. This coassociation also raises the intriguing possibility of utilizing a convergent immunity 
approach to develop novel intervention strategies, as has been explored for C. albicans and S. aureus (48). 
There is currently no vaccine against GBS disease. Furthermore, while use of intrapartum antibiotic 
prophylaxis (IAP) has been successful in decreasing the incidence of early-onset neonatal GBS disease in 
some countries, the logistics of IAP make it an unrealistic control strategy for rural and developing 
countries, and IAP has had no impact on the rate of late-onset GBS infection (49, 50). The data presented 
here imply that better control of vaginal colonization by C. albicans may restrict or reduce GBS 
colonization, which in turn would reduce the risk of GBS transmission. Hence, vaccines against C. albicans, 
such as the promising rAls3 vaccine that has completed phase 1 clinical trials (51), may concomitantly help 
to reduce the burden of neonatal GBS disease. 
MATERIALS AND METHODS 
Microbial strains and culture conditions. The microbial strains used in this study are listed in Table 1. 
GBS strains were cultured in Todd-Hewitt broth with 0.5% yeast extract (THY) or on THY agar plates at 37°C 
and 5% CO2. L. lactis was cultured in GM17 broth (M17 broth supplemented with 0.5% glucose) or on 
GM17 agar plates at 30°C in a candle jar. Escherichia coli was cultured aerobically in Luria-Bertani (LB) 
broth or on LB agar plates at 37°C. Media were supplemented with 5 g/ml erythromycin or with 50 g/ml (E. 
coli) or 5 g/ml (GBS) chloramphenicol, as appropriate. Heterologous protein expression in L. lactis was 
induced from nisin-inducible plasmids by the addition of 10 ng/ml nisin. Cells from GBS and L. lactis broth 
cultures were harvested by centrifugation at 5,000 g for 7 min. 
C. albicans was cultured in YPD medium (1% yeast extract, 2% mycological peptone, 2% glucose) at 
37°C with shaking (220 rpm) or maintained on Sabouraud dextrose (SAB) agar plates incubated aerobically 
at 37°C. C. albicans cells were harvested from broth cultures by centrifugation at 5,000  g for 5 min. S. 
cerevisiae was cultured in complete supplement medium (CSM) without uracil (ForMedium), 
supplemented with 0.67% yeast nitrogen base (YNB; Difco) and 2% glucose, at 30°C with shaking. 
Generation of GBS knockout and L. lactis surrogate expression strains. A ΔbspC mutant was generated 
in GBS strain 515 by in-frame allelic replacement with a chloramphenicol resistance gene cassette by 
homologous recombination, using a previously described method (52). Briefly, a knockout construct was 
generated by amplifying flanking regions directly upstream and downstream of the bspC gene from GBS 
strain 515 genomic DNA by using primer pairs bspC.F1/bspC.R1 and bspC.F2/bspC.R2, respectively (Table 
2). A cat cassette was amplified from the chloramphenicol resistance plasmid pR326 by use of primers 
cat.F and cat.R (Table 2). Upstream and downstream bspC and cat amplicons were then combined by 




via XbaI and BamHI sites and propagated in E. coli Stellar cells (Clontech) prior to isolation and 
electroporation into GBS 515. 
An L. lactis strain expressing BspA had been generated previously (12), and a similar methodology was 
employed here to generate an L. lactis strain expressing BspC. In brief, the bspC gene was amplified from 
GBS strain 515 genomic DNA by use of primers pMSP.bspC.F and pMSP.bspC.R (Table 2). The resultant 
amplicon was then cloned into the nisin-inducible expression vector pMSP7517 (54) via NcoI and XhoI 
sites, generating plasmid pMSP.bspC. This construct was transformed directly into electrocompetent L. 
lactis NZ9800 as described previously (12). Transformants were confirmed by plasmid isolation and PCR, 
while expression of BspC in L. lactis was verified by dot immunoblotting. 
 
TABLE2 Primers used in this study 









aRestriction endonuclease sites are underlined. 
Tissue culture. Experiments were conducted using VK2/E6E7 cells (ATCC CRL-2616), an immortalized 
human VEC line with a protein profile similar to that of the natural tissue (55, 56). VECs were cultured in K-
SFM (Gibco) supplemented with 0.4 mM CaCl2, 0.05 mg/ml bovine pituitary extract, and 0.1 ng/ml 
epidermal growth factor. Upon reaching 70 to 80% confluence, cells were disassociated by use of TrypLE 
Express trypsin replacement reagent (Gibco) before being harvested and resuspended in K-SFM. 
Appropriate volumes of cells were seeded in fresh flasks or in assay plates, as required. 
Visualization of dual-species planktonic interactions. Cells from 16-h cultures of C. albicans were 
harvested, washed in YNBPT (1 YNB, 20 mM Na2HPO4, 0.02% tryptone, adjusted to pH 7), and suspended 
to an optical density at 600 nm (OD600) of 1.0 (equivalent to 106 cells/ml) in YNBPT. This suspension was 
diluted 1:10 in YNBPTG (YNBPT supplemented with 0.4% glucose) and incubated at 37°C and 220 rpm for 2 
h (2-ml final volume). These growth conditions have previously been shown to induce candidal hypha 
formation (57). 
GBS cells were harvested from 16-h cultures, washed in YNBPT, suspended in 1.5 mM fluorescein 
isothiocyanate (FITC) dissolved in carbonate buffer (100 mM NaCl, 50 mM Na2CO3), and incubated for 30 
min with gentle agitation. GBS cells were harvested and washed three times in carbonate buffer, and the 
pellet was suspended and adjusted to an OD600 of 0.5 (equivalent to 5 x107 cells/ml) in YNBPTG. GBS 
suspension (1 ml) was added to that of C. albicans and incubated at 37°C for a further 1 h with shaking. 
Calcofluor white (0.00001% in distilled water [dH2O]) was added before visualization of 10-l samples by 
fluorescence microscopy. 
For quantification assays, approximately 40 images of randomly selected hyphae were taken for each 
experimental group. Hyphal interactions were counted and placed into one of the following four groups, 
similar to a method reported previously (32): 0 interacting bacteria, 1 to 5 bacteria, 6 to 20 bacteria, and 
20 bacteria per hypha. 
In a variation of this assay, S. cerevisiae cells were harvested from a 16-h overnight broth culture in 
CSM broth, washed once in YNBPT (5 ml), and stained with 1.5 mM FITC for 30 min with gentle agitation. S. 
cerevisiae cells were harvested and washed three times in carbonate buffer. The pellet was suspended and 
adjusted to an OD600 of 1.0 (equivalent to 106 cells/ml) in YNBPTG before 1:5 dilution in YNBPTG (final 
volume, 2 ml). This suspension was incubated at 30°C and 220 rpm for 3 h. L. lactis cells were harvested 
from a 16-h overnight broth culture and washed once in YNBPT before suspension in 2 ml TRITC (0.1 
mg/ml in carbonate buffer) and incubation for 30 min with gentle agitation. L. lactis cells were harvested, 
washed three times in carbonate buffer, and adjusted to an OD600 of 0.5 in YNBPTG (equivalent to 5 x107 
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cells/ml). The adjusted L. lactis suspension (1 ml) was added to S. cerevisiae and incubated for a further 1 h 
at 30°C and 220 rpm before visualization of 10-l samples by fluorescence microscopy. 
Microbial growth in dual-species broth cultures. Cells from an overnight (16 h) C. albicans suspension 
culture were harvested and washed once in phosphate-buffered saline (PBS). The pellet was suspended 
and adjusted to an OD600 of 1.0 in K-SFM before being diluted 1:10 in K-SFM (2-ml final volume) and 
incubated at 37°C and 220 rpm for 2 h. Cells from overnight GBS broth cultures were harvested, washed 
once in PBS, and suspended in K-SFM to an OD600 of 0.5. GBS suspension (1 ml) was added to the C. 
albicans suspension, and the mixture was incubated at 37°C for a further 1 h. Planktonic suspensions were 
vortex mixed for 15 s before being serially 10-fold diluted in THY broth. Numbers of microorganisms were 
detected by viable counts (CFU) on either THY agar plates (GBS) supplemented with 50 g/ml nystatin to 
inhibit C. albicans growth or SAB agar plates (C. albicans) supplemented with 5 g/ml erythromycin to 
inhibit GBS growth. 
Epithelial association assay. Epithelial association assays were conducted as described previously (5), 
with a few modifications. VECs were seeded into a 24-well plate at 2 x105 cells/well and incubated at 37°C 
and 5% CO2 until confluent (48 to 72 h). C. albicans cells were diluted in K-SFM to obtain approximately 5 
x105 cells/ml, while GBS or L. lactis cells were diluted in K-SFM to obtain approximately 5 x105 cells/ml. 
Wells containing VEC monolayers were washed once with PBS, and approximately 5 x105 bacteria or C. 
albicans cells (1 ml; multiplicity of infection [MOI] 2.5) were then added to each well. Bacterial suspensions 
were incubated at 37°C and 5% CO2 for 1 h, while C. albicans suspensions were incubated for 2 h. For dual-
species assays, C. albicans suspensions were incubated for 1 h before the medium was replaced by GBS or 
L. lactis and incubated for a further 1 h. For all assays, wells were then washed three times with PBS before 
incubation for 15 min with TrypLE, followed by two ice-cold water incubations, lasting 20 min each, to lyse 
the VECs. Lysates were serially diluted onto THY (GBS), GM17 (L. lactis), or SAB (C. albicans) agar plates and
viable counts determined as described above. It was confirmed both visually and by monitoring levels of
lactate dehydrogenase (LDH) released into the culture supernatants that epithelial monolayers remained
intact and viable over the periods of the mono- or dual-species association assays. 
In a variation of this assay, VEC monolayers were fixed in 2% paraformaldehyde overnight prior to 
incubation with cell suspensions of C. albicans and/or GBS. Alternatively, GBS suspensions were prepared 
as described above and preincubated at room temperature with 10 g/ml rabbit preimmune or anti-Bsp 
sera (Eurogentec) for 30 min prior to incubation at 37°C for 1 h with VEC monolayers. 
Spent medium studies. VECs were seeded in a 24-well plate and grown to confluence. C. albicans was 
prepared as described above and then incubated with the VECs or grown planktonically in K-SFM medium 
for 1 h. The C. albicans medium was then collected and sterilized by filtration through a 0.2-m filter. GBS 
suspensions, prepared as described above, were adjusted to an OD600 of 1.0 in K-SFM before being diluted 
1:200 in either fresh K-SFM, K-SFM from C. albicans planktonic growth, or K-SFM from C. albicans growth 
on VK2/E6E7 monolayers. Aliquots (1 ml) were added to VEC monolayers and incubated for 1 h. VECs were 
disassociated and lysed as described above, and numbers of GBS CFU were determined by serial dilution 
and viable counts on THY agar plates. 
Transwell studies. VECs were seeded in a 24-well plate and grown to confluence. C. albicans cells were 
prepared as described above and then incubated with VEC monolayers for 1 h before the medium was 
replaced with 1 ml K-SFM. Transwell inserts with high-density, 0.4-m pores (Sarstedt) were placed into 
wells. GBS suspensions in K-SFM (OD600 1.0) were diluted 1:100 in K-SFM. Aliquots (0.5 ml) were added to 
the transwell inserts, and the plates were incubated for a further 1 h. The inserts were removed, remaining 
VECs were disassociated and lysed as described above, and numbers of C. albicans CFU were determined 
by serial dilution and viable counts on SAB agar plates. 
Confocal microscopy. For visualization by confocal microscopy, VEC monolayers were grown on 19-mm 
glass coverslips in a 12-well plate until confluent. The epithelial association assay was then carried out as 
described above, except that the time was extended by 4 h. Calcofluor white (1 l) was added to stain the 
chitin in the C. albicans cell wall, and the coverslips were then fixed in 2% paraformaldehyde. Triton X-100 
(0.3%) was used to permeabilize the epithelial cells before blocking in 2% bovine serum albumin (BSA). 
Bacteria were stained with a mouse anti-GBS antibody (1.B.501; Santa Cruz Biotechnology) followed by an 
Alexa Fluor 488-conjugated goat anti-mouse antibody (Fisher), both of which were used at a dilution of 
1:200. The F-actin of the epithelial cells was stained with phalloidin-TRITC (Sigma). Coverslips were then 




AOBS confocal laser scanning microscope (CLSM) attached to a Leica DM I6000 inverted epifluorescence 
microscope. Images were processed using Volocity software, and Imaris v7.5 software (Bitplane AG, Zurich, 
Switzerland) was used to calculate biovolumes (in cubic micrometers). 
Statistical analyses. All assays were performed in triplicate unless otherwise stated. Data were 
analyzed using unpaired Student’s t tests with Bonferroni correction, as appropriate. 
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